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Abstract 
 
The novel hormone kisspeptin has been identified to play a pivotal role in the regulation of 
the hypothalamo-pituitary-gonadal axis. Previous studies from our laboratory have 
demonstrated that a bolus administration of kisspeptin-54 can acutely stimulate 
gonadotrophin release in healthy men and women. However, no previous studies have 
examined the effects of kisspeptin-54 to women with infertility. In this study I have examined 
the effects of acute and chronic administration of kisspeptin-54 on women with infertility due 
to hypothalamic amenorrhoea. This study has identified that acute administration of 
kisspeptin to women with hypothalamic amenorrhoea results in stimulation of reproductive 
hormones, but chronic administration for two weeks of twice daily injections of kisspeptin-54 
at a dose of 6.4 nmol/kg, results in tachyphylaxis. I have conducted further studies to 
examine the time course of desensitisation of the kisspeptin receptor. I have also determined 
that a dosing regime of twice weekly administration of kisspeptin-54 results in sustained 
stimulation of gonadotrophin release. I have performed the first study of kisspeptin-10 
administration to men and women. These results demonstrate that kisspeptin-10 stimulates 
gonadotrophin release in men as well as women during the preovulatory phase of the 
menstrual cycle; but fails to stimulate gonadotrophin release in women during the follicular 
phase. This reveals a sexual dimorphism in response to the kisspeptin-10. These findings 
have important ramifications for the potential use of kisspeptin-54 and kisspeptin-10 as a 
therapeutic agent in disorders of reproduction. 
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Chapter 1  
 
General Introduction 
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1.1 The hypothalamo-pituitary-gonadal axis 
 
The regulation of reproductive function is controlled by the hypothalamo pituitary gonadal 
(HPG) axis. A pulsatile secretion of gonadotrophin releasing hormone (GnRH), a ten amino 
acid peptide (Figure 1), synthesized in hypothalamic neurons situated in the preoptic area 
(POA) and anterior hypothalamus, stimulates gonadotrophs via GnRH receptors in the 
anterior pituitary gland to release luteinizing hormone (LH) and follicle stimulating hormone 
(FSH) into the circulation (Figure 2) (Gore 2002). The secretion of LH also demonstrates a 
pulsatile pattern and reflects the pulsatile secretion of GnRH (Dierschke et al. 1970). LH and 
FSH in turn act on the gonads to activate gametogenesis and sex steroid production. Sex 
steroids and gonadotrophins inhibit further GnRH secretion, in a negative feedback system. 
A failure at any point in the HPG axis or metabolic stress and extremes in energy reserves 
may result in disordered reproductive function and infertility (Neill J.D 2006).  
One in seven couples in the United Kingdom suffers with infertility (HEFA Fertility Facts and 
Figures 2008). The resulting impact on physical, psychological and social functioning can 
be dramatic. Current therapies for infertility are associated with limitations both in 
terms of side effects and drug delivery. Improving our understanding of the 
physiology of the HPG axis may lead to the development of novel therapies for 
infertility.  
 
Figure 1. The amino acid sequence of GnRH decapeptide. 
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
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Figure 2. The hypothalamic pituitary gonadal (HPG) axis (Conn & Ulloa-Aguirre 2010). 
The HPG axis is controlled in a classical endocrine feedback loop. Gonadotrophin releasing 
hormone (GnRH) is synthesised and secreted by specialised neurons located in the preoptic 
and arcuate nucleus of the hypothalamus. GnRH neurons have projections to the median 
eminence (ME) where GnRH is released into the hypophyseal-portal capillary circulation to 
act on gonadotrope cells of the adenohypophysis (AH). This stimulates the release of 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), which in turn act on the 
gonads to activate gametogenesis and sex steroid production. The pulsatile release of 
GnRH, LH, and FSH are positively or negatively regulated by several hypothalamic 
neurotransmitters and sex steroids. 
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In the male, LH binds to LH receptors on the Leydig cells of the testis resulting in the 
stimulation of the synthesis and secretion of androgens, primarily testosterone. Testosterone 
stimulates spermatogenesis and the development of secondary sexual characteristics. In the 
female, LH stimulates secretion of testosterone from the theca cells of the ovary; this is 
converted into oestrogens by neighbouring granulosa cells. Follicle stimulating hormone 
(FSH) stimulates folliculogenesis. A mid-cycle surge of LH in the pre-ovulatory phase of the 
menstrual cycle induces ovulation (Levi-Setti et al. 2004). Although generally LH release is 
suppressed by negative feedback from ovarian steroids, during the pre-ovulatory phase the 
high levels of oestradiol secreted from the developing ovarian follicle and progesterone 
result in positive feedback and stimulate LH release. Following ovulation the corpus luteum 
forms in the follicle, which secretes progesterone and oestradiol. Throughout the menstrual 
cycle the changing levels of LH and FSH (figure 3) act in a synergistic manner to promote 
follicular development, oestradiol synthesis, follicular rupture and ovulation (Levi-Setti et al. 
2004)  
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Figure 3. The human female menstrual cycle (Aitken et al. 2008). 
The follicular phase of the menstrual cycle begins on the first day of menstrual bleeding. A 
decrease in levels of oestrogen and progesterone results in the breakdown and shedding of 
the endometrium. Follicle stimulating hormone (FSH) levels increase, stimulating the 
development of several oocyte follicles. FSH levels subsequently decrease and only one or 
two follicles continue to develop. The developing follicles release oestrogen, which initiates 
thickening of the endometrium. The second phase of the menstrual cycle is the ovulatory 
phase which begins at approximately day 13, levels of LH and FSH increase dramatically; 
levels of oestrogen also peak at this time and levels of progesterone begin to increase. The 
high levels of LH stimulate ovulation. During the luteal phase, levels of LH and FSH 
decrease and the ruptured follicle forms the corpus luteum, which produces progesterone. 
The corpus luteum degenerates without fertilisation and the decreased levels of 
progesterone and oestrogen, initiates a new menstrual cycle. 
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GnRH displays structural conservation across species and all mammals, except the guinea 
pig, have an identical decapeptide sequence (Gore 2002). In the guinea pig GnRH sequence, 
tyrosine replaces histidine at position 2 and valine replaces leucine present at position 7 
(Gore 2002). The secretion of GnRH from hypothalamic neurons varies throughout human 
development. Pulsatile secretion of GnRH is noted in early gestation and continues until six 
months of age in boys and two years in girls. Re-emergence of GnRH secretion does not 
occur until puberty is approached, when pulsatile secretion of GnRH occurs first during sleep 
followed by the addition of daytime pulses. Thus the pulse interval and amplitude of GnRH 
pulses varies throughout development and also during the female menstrual cycle (Neill J.D 
2006). LH release stimulated by GnRH is lower in the luteal phase of the menstrual cycle 
compared with the follicular phase. Pulse interval is 110 minutes in the early follicular, 70 
minutes in the mid-follicular and 65 minutes in periovulatory phase. This is more frequent 
than the luteal phase pulses, which are 100, 200 and 300 minutes in the early, middle and 
late luteal phase (Gore 2002). Due to other factors such as the action of inhibin, the 
secretion of FSH, unlike that of LH, does not strictly reflect that of pulsatile GnRH secretion 
(Clarke, Moore, & Veldhuis 2002;Clarke et al. 1986). The pulsatile secretion of GnRH is 
necessary for normal reproductive function. Continuous chronic administration of GnRH 
causes downregulation of the GnRH receptor, resulting in a failure to stimulate pituitary LH 
and FSH release (Belchetz et al. 1978). Thus GnRH has a pivotal role in regulating 
reproduction and disordered secretion of GnRH can result in a failure of normal reproductive 
function.  
GnRH neurons have projections to the median eminence where GnRH is released into the 
hypophyseal-portal capillary circulation (Gore 2002). The onset of puberty and normal 
reproductive function throughout adulthood is dependent on the pulstatile release of GnRH 
from the anterior hypothalamic region acting on the anterior pituitary gland to stimulate 
gonadotrophin release (Belchetz et al. 1978). This “pulse generator” appears to be contained 
either in the GnRH neuronal network or in the GnRH neurone. In vitro studies have 
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demonstrated that the hypothalamic neuronal cell line GT1-7 secretes GnRH in a 
spontaneous pulsatile fashion (Wetsel et al. 1992). In addition GnRH neurones release 
GnRH in a pulsatile manner without hypothalamic inputs (Funabashi et al. 2000;Terasawa et 
al. 1999). In vivo a number of excitatory and inhibitory factors influence GnRH secretion; 
these include noradrenaline, neuropeptide Y (NPY), glutamate, gamma-aminobutyric acid 
(GABA) and endogenous opioids, nitric oxide, cyclic adenosine monophosphate (cAMP), 
and adenosine triphosphate (ATP) may modify GnRH release without synaptic input (Evans 
1999;Terasawa 2001) (Table 1). The precise mechanisms controlling the pulsatile release of 
GnRH are not fully established. Sex steroid feedback, stress and nutrition also have a role in 
the regulation of the hypothalamo pituitary gonadal axis. Recently kisspeptin has been 
identified as a key player in the regulation of GnRH secretion and reproduction.  
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Table 1. Neurotransmitters acting on Gonadotrophin releasing hormone (GnRH) 
neurons. 
A number of neurotransmitters have either inhibitory, stimulatory or both inhibitory and 
stimulatory actions on GnRH neurones.  
Inhibitory  Stimulatory  
Acetycholine Acetycholine 
Cholecystokinin Angiotensin II 
CRF Cholecystokinin 
Dopamine Delta sleep inducing peptide 
GABA Dopamine 
Opioids Endothelin 
Oxytocin Galanin 
Serotonin Glutamate 
Vasopressin Histamine 
 Leptin 
 Neuropeptide Y 
 Neurotensin 
 Norepinephrine 
 Oxytocin 
 Serotonin 
 Substance P 
 VIP 
 Vasopressin 
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1.2 Kisspeptin 
In 2003 the kisspeptins and their receptor GPR54 (KISS1R) were identified to play a pivotal 
role in the regulation of reproduction and puberty (de Roux N. et al. 2003;Seminara et al. 
2003). In humans the kisspeptins are the neuropeptide products of the KISS1 gene, and are 
the ligands for the G-protein-coupled receptor KISS1R (GPR54) (Kotani et al. 2001; Lee et al. 
1999;Muir et al. 2001; Ohtaki et al. 2001). The KISS1 gene encodes a 145 precursor amino 
acid peptide which undergoes proteolytic processing to produce shorter peptides. The 
kisspeptins are named according to amino acid number, kisspeptin-10, 13, 14 and 54; and 
all share a common C-terminal decapeptide necessary for receptor binding (Kotani et al. 
2001) (Figure 4). The kisspeptin peptide hormones all have an arginine-phenylalanine 
residue present at the carboxy terminal (Clements et al. 2001; Kotani et al. 2001), and thus 
belong to the RF family of peptides.  
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Figure 4. The amino acid structure of the kisspeptins. 
The kisspeptin hormones all have a common carboxy-terminal decapeptide sequence 
highlighted in grey. This sequence is necessary for biological activity. 
Kisspeptin-54 
GTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF-NH2 
Kisspeptin-14 
DLPNYNWNSFGLRF-NH2 
Kisspeptin-13 
LPNYNWNSFGLRF-NH2 
Kisspeptin-10 
YNWNSFGLRF-NH2 
 
Kisspeptin 10 is highly conserved between humans and mice, with only one amino acid 
replacement; tyrosine to phenylalanine (Stafford et al. 2002). The KISS1 gene was initially 
defined as a metastasis suppressor gene (Lee & Welch 1997) and thus kisspeptin was 
originally termed metastin. In vivo studies have demonstrated that KiSS-1 suppresses 
metastasis in human melanoma cells and breast carcinomas (Lee & Welch 1997). 
Kisspeptin-54 has also been shown to inhibit pulmonary metastasis in a murine melanoma 
model (Ohtaki et al. 2001). Kisspeptin inhibits the chemotaxis, motility and growth of Chinese 
Hamster Ovary (CHO) cells with KISS1R, but not that of mock transfectants, thus its actions 
appear to be mediated via the KISS1R (Ohtaki et al. 2001). The kisspeptin/GPR54 system 
may have a role in cancer progression (Dhar et al. 2004; Masui et al. 2004;Shirasaki et al. 
2001), GPR54 is over-expressed in various forms of malignant tissue compared with normal 
tissue (Muir et al. 2001; Ohtaki et al. 2001). Plasma kisspeptin levels have been shown to be 
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elevated in women with placental malignancies such as gestational trophoblastic neoplasia 
(Dhillo et al. 2006). The precise mechanisms by which KiSS-1 expression or GPR54 
activation influence metastasis are not yet fully understood. 
Data from rodents, sheep, primates and humans has demonstrated KISS1 mRNA to be 
expressed both centrally in the anteroventral periventricular nucleus (AVPV) or preoptic area 
and the arcuate or infundibular nucleus; as well as peripheral expression in a number of 
organs including the placenta, gonads, pancreas and liver (Adachi et al. 2007; Estrada et al. 
2006; Gottsch et al. 2004; Kauffman et al. 2007; Kotani et al. 2001; Lee et al. 1999; Muir et 
al. 2001; Navarro et al. 2004; Ohtaki et al. 2001;Rometo et al. 2007; Shahab et al. 2005; 
Smith et al. 2007). 
The kisspeptin/GPR54 system has an essential role in the reproductive development of 
humans (de Roux N. et al. 2003; Seminara et al. 2003). Inactivating mutations in the GPR54 
gene result in hypogonadotrophic hypogonadism and a failure to undergo puberty in humans 
and mice (de Roux N. et al. 2003; Funes et al. 2003; Seminara et al. 2003). GPR54 null 
mice have anatomically normal GnRH neurons with normal levels of hypothalamic GnRH. 
However, they display phenotypical features of hypogonadotrophic hypogonadism and do 
not go through puberty, they are phenotypically normal in all other respects (de Roux N. et al. 
2003; Funes et al. 2003; Seminara et al. 2003). Administration of GnRH to GPR54 null mice 
stimulates pituitary gonadotrophin release (Funes et al. 2003; Seminara et al. 2003). In 
contrast administration of kisspeptin to GPR54 null mice at a dose equivalent to stimulating 
gonadotrophin release in wild type mice, does not result in gonadotrophin release (Messager 
et al. 2005). Humans with inactivating mutations in the GPR54 gene have clinical features of 
hypogonadotrophic hypogonadism (Cerrato et al. 2006; de Roux N. et al. 2003; Lanfranco et 
al. 2005; Pallais et al. 2006; Seminara et al. 2003; Semple et al. 2005; Tenenbaum-Rakover 
et al. 2007). They do not display any features associated with abnormal GnRH neuron 
migration (such as anosmia), and apart from reduced gonadotrophin release, have normal 
anterior pituitary function (Seminara et al. 2003). Treatment of patients with GPR54 
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inactivating mutations with GnRH or gonadotrophins has allowed some of these patients to 
undergo gametogenesis, successful placental function during gestation and lactation 
(Lanfranco et al. 2005; Pallais et al. 2006; Tenenbaum-Rakover et al. 2007). Thus these 
findings suggest that inactivating mutations of the GPR54 gene result in disordered GnRH 
secretion and subsequently hypogonadotrophic hypogonadism, but that the GPR54 may not 
be vital to maintain pregnancy. 
Precocious puberty can be stimulated with administration of kisspeptin to immature 
prepubertal female rats, as demonstrated by signs of premature vaginal opening, increased 
uterine weight and stimulation of ovulation (Matsui et al. 2004; Navarro et al. 2004). 
Kisspeptin can also induce pulsatile LH secretion in juvenile rhesus monkeys, these results 
appear to be secondary to GnRH stimulation, as the utilisation of GnRH antagonists 
abolished the effects of kisspeptin (Plant, Ramaswamy, & Dipietro 2006). In humans an 
activating mutation of GPR54 has been reported to result in central precocious puberty 
(Teles et al. 2008). The substitution of proline for arginine at amino acid 386 resulted in 
extended activation of GPR54 receptor with kisspeptin administration (Teles et al. 2008). 
Three further KISS1R mutations, P74S and H90D (Silveira et al. 2010), and Pro196His 
(Luan et al. 2007); and a kisspeptin variant Pro110Thr (Luan et al. 2007; Luan et al. 2007); 
have been identified in idiopathic central precocious puberty. Thus the kisspeptin / GPR54 
system has an essential role in pubertal regulation. 
 
1.3 The kisspeptin receptor and kisspeptin signaling 
The kisspeptin receptor also known as the GPR54 (abbreviated to KISS1R in humans) is a 
G protein coupled receptor (GPCR). The KISS1R shares 45% amino acid similarity to the 
galanin receptor (Lee et al. 1999), despite this homology galanin is not a ligand for the 
KISS1R.  
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Binding kisspeptin to its receptor stimulates phospholipase C which in turn activates second 
messenger systems inositol 1,4,5-trisphosphate and diaclyglycerol resulting in increased 
intracellular calcium (Kotani et al. 2001; Muir et al. 2001; Stafford et al. 2002). The minimum 
sequence length of kisspeptin required for activation is the ten amino acid sequence at the C 
terminal (Kotani et al. 2001). Although in vitro studies have demonstrated similar biological 
activity of the kisspeptins (Kotani et al. 2001); in vivo studies suggest that kisspeptin 54 (KP-
54) has a higher potency (Thompson et al. 2006).  
In humans there is widespread distribution of the kisspeptin receptor. Highest levels are 
expressed in the placenta, but the receptor is distributed throughout the body in a number or 
organs, the central nervous system and peripheral vasculature; these include the cerebral 
cortex, thalamus, medulla, cerebellum pituitary, pancreas, spinal cord, heart, muscle, kidney, 
liver, aorta, coronary arteries and umbilical vein (Clements et al. 2001; Kotani et al. 2001; 
Mead et al. 2007; Muir et al. 2001; Ohtaki et al. 2001). 
G protein coupled receptors exhibit receptor desensitisation (Lefkowitz 1998; Ritter & Hall 
2009). Acutely desensitisation occurs via loss of signaling to secondary messenger systems 
due to persistent ligand binding and subsequently receptor internalisation. Degradation 
rather than recycling of these receptors results in chronic desensitisation (Ferguson 2001). 
Recently it has been shown that the sequence variant R368P which clinically results in 
precocious puberty (Teles et al. 2008), reduces the rate of desensitisation of the kisspeptin 
receptor by decreasing the degradation of the receptor resulting in prolonged 
responsiveness to kisspeptin (Bianco et al. 2011). Degradation of the kisspeptin receptor 
appears to be via proteasomes rather than the more common pathway of GPCR degradation 
which is via lysosomes (Bianco et al. 2011). 
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1.4 Kisspeptin administration results in stimulation of reproductive hormone 
release  
Kisspeptin administration either via central or peripheral routes stimulates the HPG axis in a 
number of animal models including rodents, sheep, pigs, primates and humans (Arreguin-
Arevalo et al. 2007; Caraty et al. 2007; Dhillo et al. 2005; Dhillo et al. 2007; Gottsch et al. 
2004; Irwig et al. 2004; Lents et al. 2008; Matsui et al. 2004; Messager et al. 2005; Navarro 
et al. 2004; Plant, Ramaswamy, & Dipietro 2006; Ramaswamy et al. 2007; Seminara et al. 
2006; Thompson et al. 2004). Evidence suggests this effect appears to be predominantly 
mediated via the release of GnRH (Gottsch et al. 2004; Irwig et al. 2004; Matsui et al. 2004; 
Messager et al. 2005). The use of GnRH antagonists inhibits kisspeptin stimulated increases 
in gonadotrophins (Gottsch et al. 2004; Irwig et al. 2004; Matsui et al. 2004; Shahab et al. 
2005). Intracerebroventricular administration of kisspeptin to sheep results in an increase in 
cerebrospinal fluid GnRH (Messager et al. 2005). Administration of GnRH to humans and 
mice with GPR54 mutations results in pituitary release of gonadotrophins suggesting that the 
kisspeptin/GPR54 system acts upstream of GnRH neurons (Seminara et al. 2003). GPR54 
expression has been co-localized to GnRH neurons in rodents (Irwig et al. 2004; Messager 
et al. 2005) and kisspeptin axons project to GnRH neurons (Clarkson & Herbison 2006). 
Intracerebroventricular administration of kisspeptin to mice results in increased expression of 
neuronal markers of activation in GnRH neurons (Irwig et al. 2004). In addition the use of a 
kisspeptin antagonist at the GPR54 receptor inhibits activation of GnRH neurons and inhibits 
the release of GnRH and subsequently gonadotrophin release (Roseweir et al. 2009). 
Kisspeptin is released into the stalk median eminence in a pulsatile fashion with a pattern 
that demonstrates high concordance with the release of GnRH (Keen et al. 2008). 
Sex steroids exert both a negative and positive feedback on GnRH secretion. However the 
precise mechanisms that regulate these effects are unknown. GnRH neurons do not express 
oestrogen alpha or androgen receptors (Clarkson & Herbison 2006). In contrast the majority 
of Kiss1 neurons in the hypothalamus of rodents do express oestrogen alpha receptors 
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(Smith et al. 2005; Smith et al. 2005) and also express androgen receptors (Smith et al. 
2005). Thus kisspeptin neurons may relay sex steroid signals to GnRH neurons. In rodents 
low circulating sex steroids result in an increase in Kiss1 mRNA expression in the arcuate 
nucleus but a decrease in Kiss1 mRNA expression in the anteroventral periventricular 
nucleus (Smith et al. 2005a; Smith et al. 2005b). This configuration of kisspeptin expression 
is reversed with replacement of sex steroids. Thus this rodent model suggests that 
kisspeptin neurons in the arcuate nucleus may be involved in negative feedback regulation 
of HPG axis and those in the AVPV with positive feedback regulation of GnRH secretion 
(Smith et al. 2005a; Smith et al. 2005b). Studies from other species show that 
gonadectomised animals with subsequently low sex steroid levels exhibit increased Kiss1 
expression in the arcuate or infundibular nucleus and increased gonadotrophin levels due to 
the removal of negative feedback of sex steroids on the HPG axis (Kauffman et al. 2007; 
Shibata et al. 2007; Smith et al. 2005a; Smith et al. 2005b). Elevated levels of 
gonadotrophins are not found in gonadectomised GPR54 null mice, even though Kiss1 gene 
expression is increased in their arcuate nuclei, suggesting that the kisspeptin GPR54 system 
is pivotal in the negative feedback stimulation of sex steroids on the HPG axis (Dungan et al. 
2007). 
The use of a kisspeptin antagonist has been demonstrated to inhibit the post castration rise 
in LH in male mice, which occurs due to removal of negative feedback of sex steroids on the 
HPG axis. Thus kisspeptin appears to be pivotal in relaying signals between sex steroids 
and GnRH neuron modulation (Roseweir et al. 2009b). 
 
1.5 Kisspeptin and ovulation  
In females positive feedback of oestrogen and progesterone on GnRH secretion triggers the 
LH surge required for ovulation. Data from rodents suggests that the AVPV is integral in this 
preovulatory GnRH/LH rise (Herbison 2008; Smith et al. 2006). Rodent models have 
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demonstrated sexual differentiation in the expression of Kiss1, with an increased expression 
of Kiss1 mRNA and kisspeptin in the AVPV of females (Adachi et al. 2007; Clarkson & 
Herbison 2006; Kauffman et al. 2007). In female mice there are an increased number of 
kisspeptin fibre projections to GnRH neurons compared to male mice (Clarkson & Herbison 
2006). Evidence suggests that kisspeptin neurons in the AVPV may be involved in the 
regulation of ovulation. In female rats the injection of a specific kisspeptin monoclonal 
antibody into the preoptic area close to GnRH neuron cell bodies, results in elimination of the 
preovulatory LH surge and inhibits oestrous cyclicity (Kinoshita et al. 2005). Differential 
hypothalamic expression of KISS-1 is noted during proestrous or experimentally evoked LH 
surge in female rats; with increased expression of kiss1 and elevated c-fos expression noted 
in the anteroventral periventricular nucleus in direct contrast to expression in the arcuate 
nucleus (Smith et al. 2006). In females oestrogen administration results in an increased 
expression of kiss1 mRNA in the AVPV (Adachi et al. 2007; Smith et al. 2005a; Smith et al. 
2006). In addition the majority of kisspeptin neurons in the AVPV express oestrogen receptor 
alpha, which is proposed to mediate the positive feedback of oestrogen (Glidewell-Kenney et 
al. 2007; Smith et al. 2005a; Smith et al. 2005b; Wintermantel et al. 2006). Using dual label 
immunofluorescence techniques Kiss1 neurons appear to have axonal projections to GnRH 
neurons, with an increase in the number of kisspeptin neuron fibres juxtaposing GnRH 
neuron cell bodies occurring prior to puberty in the rostral preoptic area of the mouse 
hypothalamus. However, the absolute numbers of GnRH neurons receiving kisspeptin 
neuron synaptic connections have not been clarified and inputs to GnRH neuron dendrites 
has not been established (Clarkson & Herbison 2006). Confirmation of synapse apposition is 
required with other methods such as electron microscopy. Similar findings have been 
reported in experiments on female mice, with the identification that kisspeptin neurons in the 
rostal periventricular area of the third ventricle express oestrogen receptor alpha and 
progesterone receptors and that these kisspeptin neurons are activated during the GnRH/LH 
surge (Clarkson et al. 2008). 
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Importantly, wild type mice which are ovariectomised and supplemented with oestrogen and 
progesterone are able to generate LH surges, however GPR54 null and Kiss-1 null mice 
which underwent the same procedure were unable to mount a LH surge and did not display 
GnRH neuron activation (Clarkson et al. 2008). This highlights the essential role of the 
kisspeptin/GPR54 system in linking sex steroid signals and GnRH neuron activation required 
for ovulation. However, a previous study has reported that GPR54 null mice are able to 
mount an oestrogen induced LH surge, with simultaneous c-Fos induction in GnRH neurons 
(Dungan et al. 2007).These two studies differed both in the methods used to generate 
GPR54 knockout mice and in the experimental protocols used to induce and LH surge which 
may account for the conflicting results (Clarkson et al. 2008; Dungan et al. 2007). 
Kisspeptin administration can stimulate ovulation in gonadotrophin primed prepubertal rats 
with comparable rates to human chorionic gonadotropin (hCG) treatment (Matsui et al. 2004). 
In addition infusions of kisspeptin can induce timed LH surges and ovulation in progesterone 
primed cyclical ewes (Caraty et al. 2007); even during anestrous kisspeptin infusions were 
able to elicit ovulation in acyclic ewes (Caraty et al. 2007). In keeping with these findings in 
animals, peripheral administration of kisspeptin stimulates gonadotrophin release during 
each phase of the menstrual cycle in healthy women but its effects were most potent during 
the preovulatory phase (Dhillo et al. 2007). 
 
1.6 Metabolic regulation of the reproductive axis 
Idiopathic hypogonadotrophic hypogonadism, resulting from either a hypothalamic defect in 
secretion of GnRH or the defective action of GnRH on the pituitary, results in a failure to 
undergo puberty and infertility. Women with functional hypothalamic amenorrhoea (HA) are 
hypogonadal or eugonadal, have low oestrogen levels and a lack of menses without any 
associated organic pathology. As a result these women are infertile and studies indicate that 
hypothalamic amenorrhoea is a major cause of infertility, accounting for 30% of cases of 
30 
 
amenorrhoea (Reindollar 1986). Hypothalamic amenorrhoea results from a failure of 
pulsatile GnRH secretion from the hypothalamus and may be triggered by energy deficits 
associated with weight loss, exercise and eating disorders as well as psychological stress. 
Recent studies have identified that certain women with rare variants in genes associated 
with idiopathic hypogonadotrophic hypogonadism may have increased genetic susceptibility 
for hypothalamic amenorrhoea (Caronia 2011).  
Fertility and body nutritional status are closely interwoven, during periods of under nutrition 
or a lean body weight GnRH production is decreased and thus reproductive ability is 
reduced or absent (Schneider 2004). By contrast states of obesity can also negatively 
impact reproductive ability. The hormone leptin is synthesised and secreted by adipocytes in 
accordance to body energy stores, circulating leptin is proportional to fat stores and falls 
after weight loss. Leptin has been postulated to relay signals between nutritional status and 
reproductive functioning. Leptin deficient ob/ob rodent models have hypogonadotrophic 
hypogonadism with a resultant failure to undergo puberty and infertility (Zhang et al. 1994). 
Humans with mutations in either the leptin receptor or leptin also display the phenotype of 
hypogonadotrophic hypogonadism (Farooqi & O'rahilly 2004). LH secretion is suppressed 
with fasting but these effects are overcome with the administration of leptin in both rodent 
and primate leptin deficient models (Finn et al. 1998; Nagatani et al. 1998). Leptin 
administration to juvenile mice stimulates the onset of puberty (Ahima et al. 1996 Chehab, 
Lim, & Lu 1996). Healthy men and women exposed to calorie restriction have 
hypoleptinaemia (Chan et al. 2003; Schurgin et al. 2004). Women with hypothalamic 
amenorrhoea; including those of normal weight, (Miller et al. 1998) have reduced plasma 
levels of leptin, and treatment with twice daily injections of leptin in these women results in 
stimulation of gonadotrophin release and ovulation (Chou et al. 2011; Welt et al. 2004).  
Leptin does not appear to have a direct action on GnRH neurons (Quennell et al. 2009) and 
GnRH neurons in the hypothalamus do not express the leptin receptor. Kisspeptin has been 
proposed as a potential mediator between leptin and GnRH signaling. Forty percent of 
31 
 
kisspeptin neurons in the hypothalamus express the leptin receptor (Smith 2006). In rodent 
models of leptin deficiency, hypothalamic kiss1 expression is reduced and leptin 
replacement results in an increase in expression (Smith 2006). Short term fasting leads to 
decrease in hypothalamic expression of KiSS-1 mRNA and an increase in receptor GPR54 
mRNA in prepubertal rats (Castellano et al. 2005). Administration of kisspeptin to rats with 
delayed puberty due to under nutrition results in restoration of pubertal signs as measured 
by vaginal opening and gonadotrophin secretion (Castellano et al. 2005). Conversely a 
recent study has reported that mice lacking the leptin receptor on kisspeptin neurons had 
normal pubertal development (Donato, Jr. et al. 2011). However, the effects of leptin on 
kisspeptin neurons may differ in mechanism in specific regions of the hypothalamus, with 
those kisspeptin neurons in the rodent arcuate nucleus having a direct leptin action on 
kisspeptin neurons and those in the rostral periventricular area of the third ventricle (RP3V) 
having an indirect action mediated by currently unknown upstream leptin sensitive neurons 
(Quennell et al. 2011).  
 
1.7 Potential therapeutic applications of kisspeptin  
Kisspeptin may have therapeutic potential in manipulating the human HPG axis via release 
of GnRH. Various animal models have demonstrated that kisspeptin can stimulate the HPG 
axis. Two studies in healthy male and female volunteers have also demonstrated its 
potential in human use with no reported side effects (Dhillo et al. 2005; Dhillo et al. 2007). 
The first study investigated the effects of intravenous kisspeptin-54 administration to six 
healthy males in a double blind placebo controlled trial (Dhillo et al. 2005). Compared to 
placebo, infusion of kisspeptin-54 at a dose of 4 pmol/kg/min resulted in increases of mean 
plasma LH by 100%, and FSH 18%. The second study of subcutaneous administration of 
kisspeptin-54 to healthy females demonstrated that kisspeptin can stimulate the HPG axis in 
females in a dose dependent manner with significant increases in mean plasma LH and FSH; 
and its effects were most pronounced in the preovulatory phase of the menstrual cycle 
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(Dhillo et al. 2007). Both these studies confirmed that kisspeptin, similar to animal models, 
can stimulate reproductive hormone release in humans. They also reported no adverse 
effects associated with kisspeptin administration. Kisspeptin has been shown to have 
vasoconstrictor actions in vitro (Mead et al. 2007) however in vivo studies in humans have 
not observed any changes in blood pressure or heart rate following kisspeptin administration 
(Nijher et al. 2010). 
Thus kisspeptin has a number of possible therapeutic uses. The stimulation of the HPG axis 
is required for ovulation and kisspeptin has a potential role in the treatment of infertility and 
in vitro fertilisation treatment. Kisspeptin stimulates the release of endogenous 
gonadotrophins, so potentially may offer a more controlled HPG axis stimulation without the 
risk of excessive stimulation of gonadotrophin release and possible subsequent ovarian 
hyperstimulation syndrome. 
In addition the mode of administration of kisspeptin may determine its therapeutic use; acute 
administration of kisspeptin stimulates the HPG axis whilst chronic administration of 
kisspeptin may downregulate the HPG axis (Ramaswamy et al. 2007; Seminara et al. 2006; 
Thompson et al. 2006). In certain clinical cases such as sex steroid dependent tumours 
chronic administration of kisspeptin or long acting KISS1R agonists may have a role in 
achieving medical castration. Exciting studies on the development of kisspeptin antagonists 
and agonists, will further our understanding of the role of kisspeptin in the regulation of 
gonadotrophin release and potential therapeutic uses. Specific kisspeptin receptor 
antagonists have been shown to inhibit the simulation of GnRH neuron firing by kisspeptin 
(Roseweir et al. 2009). These studies demonstrated that kisspeptin antagonists can inhibit 
GnRH pulses but do not affect basal GnRH levels in pubertal female rhesus monkeys; 
additionally there were no effects on basal LH levels but the stimulation of gonadotrophin 
release by kisspeptin was reduced in uncastrated male mice pretreated with a kisspeptin 
antagonist. Castration and the subsequent reduction in sex steroids result in removal of 
negative feedback on the HPG axis and an increase in gonadotrophins; kisspeptin 
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antagonists were able to inhibit this increase in LH in castrated male mice in a dose 
dependent manner. Central administration of a kisspeptin antagonist resulted in a reduced 
LH pulse amplitude in ovariectomised ewes. These findings illustrate that kisspeptin is 
required for pulsatile GnRH secretion in terms of both frequency and amplitude. The effects 
of kisspeptin antagonist on basal LH are exciting as they offer a therapeutic method of 
inhibiting pulsatile gonadotrophin release without reducing basal levels. This would offer a 
potential new method of contraception (Roseweir et al. 2009). 
The kisspeptins share a 10 amino acid c-terminal region required for receptor activation 
(Kotani et al. 2001). The development of smaller peptides with GPR54 agonist properties 
have demonstrated that the c-terminal five amino acid residues are necessary for GPR54 
receptor activation, with the generation of pentapeptide analogues as GPR54 agonists (Niida 
et al. 2006; Tomita et al. 2006; Tomita et al. 2007; Tomita et al. 2007). Novel studies of 
structure and biological activity of kisspeptin-10 analogues have identified the importance of 
combined in vitro and in vivo experiments. Amino acids 6 and 10 appear to be essential for 
in vitro kisspeptin-10 GPR54 receptor binding (Gutierrez-Pascual et al. 2009). However in 
vivo studies demonstrate that kisspeptin-10 analogues with Ala point substitutions at amino 
acid 6 still function as partial agonists with an ability to stimulate gonadotrophin release in 
adult male Wistar rats (Gutierrez-Pascual et al. 2009). The development of low molecular 
weight oral KiSS-1R agonists and antagonists may offer practical advantages to current 
treatments for disorders of reproductive function in humans (Gutierrez-Pascual et al. 2009; 
Niida et al. 2006; Orsini et al. 2007; Tomita et al. 2006; Tomita et al. 2008). 
1.8 Hypothesis and Aims 
Kisspeptin has been identified to be a key regulator in the control of the hypothalamo-
pituitary-gonadal axis. The 145-amino acid precursor of kissepeptin-54 encoded by KISS1 is 
also processed to 14, 13 and 10 amino acid sequences (Kotani et al. 2001). Previous work 
from our laboratory has shown that kisspeptin-54 stimulates gonadotrophin release in 
healthy men and women without any adverse effects (Dhillo et al. 2005, Dhillo et al 2007). 
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However, no previous studies have examined the effects of kisspeptin in women with 
infertility due to hypothalamic amenorrhoea. Rodent models of hypothalamic amenorrhoea 
suggest that there is a decrease in hypothalamic expression of kisspeptin in this condition 
(Castellano et al. 2005). I hypothesise that women with hypothalamic amenorrhoea, may 
also have low hypothalamic kisspeptin expression and kisspeptin may restore the 
functioning of their HPG axis. It is therefore essential that we examine the effects of both 
acute and chronic kisspeptin administration, as well as different dosing regimes, on women 
with hypothalamic amenorrhoea.  
Animal models suggest that kisspeptin-10 and kisspeptin-54 act similarly to stimulate 
reproductive hormone release however, kisspeptin-10 is characterised by a shorter half-life. 
Recently it has been reported that an intravenous bolus of kisspeptin-10 potently stimulates 
LH secretion while continuous infusion also increases testosterone, LH pulse frequency and 
amplitude in healthy men (George et al. 2011). In addition kisspeptin-10 appears to reset the 
GnRH pulsatile clock in men (Chan et al. 2011). The shorter amino acid sequence of 
kisspeptin-10 makes it simpler and cheaper to synthesize than kisspeptin-54, therefore it 
may be a more attractive pharmaceutical agent than kisspeptin-54. However, there have 
been no previous studies on the effects of kisspeptin-10 on women. I hypothesise that 
kisspeptin-10 will stimulate reproductive hormone release in healthy men and women in a 
similar fashion to kisspeptin-54.  
The aims of this thesis are to investigate the role of kisspeptin in disorders of reproduction 
specifically investigating: 
 The acute and chronic effects of kisspeptin-54 administration on the HPG axis 
in women with hypothalamic amenorrhoea. 
 To compare the effects of different dosing regimens of kisspeptin-54 
administration on the HPG axis in women with hypothalamic amenorrhoea. 
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 To investigate the effects of kisspeptin-10 on the HPG axis in healthy men 
and women. 
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Chapter 2  
 
The effects of kisspeptin on the hypothalamo pituitary gonadal axis in 
women with hypothalamic amenorrhoea 
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2.1 Introduction 
Hypothalamic amenorrhoea is a common cause of infertility in women, accounting for 30% of 
cases of secondary amenorrhoea (Reindollar et al. 1986). In this condition, abnormal GnRH 
secretion due to deficient GnRH secretion from the hypothalamus or altered pulsatility 
patterns results in a failure of the synthesis and secretion of gonadotrophins from the 
pituitary and subsequently a failure in stimulation of the gonads to release sex steroids. This 
is similar to the phenotype described in hypogonadotrophic hypogonadism. Functional 
hypothalamic amenorrhoea describes cases where although there is no structural or organic 
defect identified in the hypothalamic pituitary gonadal axis, patients have amenorrhoea, low 
or normal serum gonadotrophins and low oestrogen (Reindollar et al. 1986). Functional 
hypothalamic amenorrhoea may be caused by energy deficient states caused by excessive 
exercise (Warren 1980), eating disorders (Boyar et al. 1974), weight loss (Frisch 1996; 
Frisch & McArthur 1974), chronic illness and psychological stress (Giles & Berga 1993) 
(Meczekalski et al. 2008). There also appears to be a genetic predisposition to hypothalamic 
amenorrhoea, recently genetic variants in the genes associated with hypogonadotrophic 
hypogonadism have been identified which may result in increased susceptibility to 
hypothalamic amenorrhoea in women carrying them (Caronia et al. 2011).  
Women with hypothalamic amenorrhoea appear to have leptin deficiency and when given 
leptin demonstrate restoration of GnRH pulsatility and menstruation (Welt et al. 2004). In a 
randomised double blinded, placebo controlled 36 week trial of twenty women with 
hypothalamic amenorrhoea; the administration of subcutaneous injections of human 
recombinant leptin (metreleptin) to the treatment group resulted in restoration of menstrual 
cyclicity, with over 50% of cycles being ovulatory (Chou et al. 2011). These authors also 
note that in addition to biochemical evidence for normalisation of the HPG axis, thyroid and 
adrenal axis, there were also positive changes in markers of bone formation and resorption.  
With regards to treatment, oral contraceptive pills are given to those women who require 
oestrogen replacement to avoid long term side effects of oestrogen deficiency; these of 
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course do not restore gonadotrophin release and ovulation and thus do not confer fertility. 
There is also no evidence as yet that oestrogen and progesterone replacement result in 
increased bone density (Gordon 2010).  
For those women being treating for infertility due to hypothalamic amenorrhoea the options 
are, clomiphene, GnRH pump therapy or in vitro fertilisation (IVF) with gonadotrophin 
injections. Women with hypothalamic amenorrhoea usually have low serum oestrogen levels 
(Gordon 2010), thus clomiphene has a poor rate of ovulation induction in these women, as 
its pharmacologic actions rely on removing oestradiol-mediated negative feedback on 
pituitary gonadotrophin release and thus increasing circulating gonadotrophin level. Both 
GnRH pump therapy and exogenous gonadotrophins result in similar rates of ovulation 
induction in women with hypogonadotrophic amenorrhea (Martin et al. 1993). Although 
efficacious, both treatment options have individual flaws associated. GnRH pump therapy 
has practical delivery problems associated with it. Gonadotrophin therapies are associated 
with risk of ovarian hyperstimulation syndrome (OHSS). Mild forms of ovarian 
hyperstimulation are common occurring in a third of women having IVF. However, 3-8% of 
women will have moderate or severe OHSS (HFEA Fertility Facts & Figures 2008). Ovarian 
hyperstimulation syndrome is a potentially life threatening condition, which can result in 
massive ovarian enlargement, ovarian torsion, ascites, hydrothorax, liver dysfunction, 
thromboembolism, electrolyte imbalance, renal failure and acute respiratory distress 
syndrome and death. 
 
2.2 Hypothesis and Aims 
Acute central and peripheral administration of kisspeptin results in release of gonadotrophin 
hormone release in animals. To date human studies on kisspeptin have demonstrated that 
kisspeptin administration acutely stimulates gonadotrophin release in healthy men and 
women. Rodent models of hypothalamic amenorrhoea have shown that administration of 
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kisspeptin-10 restores gonadotrophin secretion and associated pubertal signs (Castellano 
2005). Based on these data, I hypothesised that chronic administration of kisspeptin would 
stimulate reproductive hormone release and restore menstrual cyclicity in human female 
subjects with HA.  
The aim of this study was to determine the acute and chronic effects of subcutaneous 
administration of kisspeptin-54 compared with placebo saline injections on reproductive 
hormone release and ovulation in women with hypothalamic amenorrhoea. 
2.3 Methods 
2.3.1 Subjects 
 
Ethical approval was granted by the Hammersmith and Queen Charlotte‟s and Chelsea 
Hospitals Research Ethics Committee. The study was carried out in accordance with the 
declaration of Helsinki. All subjects gave full informed written consent prior to study 
commencement. Recruitment was via advertisements in the local press. After an initial 
telephone interview, participants were invited for a medical screening. This consisted of a 
clinical history including a detailed menstrual history, medical examination, 
electrocardiogram and blood tests. Blood samples were sent to the Imperial College London 
NHS Trust haematology and biochemistry laboratories and the following assays were 
conducted: full blood count, renal profile, liver profile, bone profile, thyroid profile, glucose, 
gonadotrophins, oestradiol, progesterone, androstenedione, dehydroepiandrosterone, 
testosterone, sex hormone binding globulin, prolactin, 17- hydroxyprogesterone and cortisol. 
Ten women with functional hypothalamic amenorrhorea were recruited. Hypothalamic 
amenorrhorea was diagnosed if the following criteria were met: secondary amenorrhorea of 
at least 6 months duration, body mass index (BMI) of below 25 kg/m2 with a stable body 
weight over the previous 6 months, age between 18–40 years, absence of hormonal 
contraceptive therapy for one year, absence of systemic disease co-morbidity or active 
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psychiatric illness; absence of therapeutic or recreational drug use; absence of clinical or 
biochemical hyperandrogenemia; structurally normal hypothalamus and pituitary region 
assessed by magnetic resonance imaging; structurally normal female reproductive tract 
visualised on ultrasound; absence of polycystic ovarian appearances on ultrasound; thyroid 
function biochemistry and serum prolactin levels within reference range and serum LH:FSH 
ratio <1.5.  
 
2.3 Kisspeptin 54  
 
Kisspeptin-54 was synthesised by the Advanced Biotechnology Centre, Imperial College 
London and purified by reverse-phase high performance liquid chromatography (HPLC). 
Electrospray mass spectroscopy and amino acid analysis confirmed the identity of the 
peptide. Toxicology testing in animals was conducted prior to administration to volunteers. 
The Limulus Amoebocyte Lysate assay test for pyrogen (LAL; Associates of Cape Cod, 
Liverpool, UK) was negative, and the peptide was sterile on culture (Microbiology 
Department, Hammersmith Hospital, London, UK).  
 
Study 1: Effect of chronic kisspeptin administration on reproductive hormone secretion in 
women with hypothalamic amenorrhoea 
This was a double-blind, placebo-controlled study, which was conducted over eight weeks. 
Each subject (n = 10) received a subcutaneous (sc) injection of kisspeptin-54 or a control 
injection of 0.9% saline solution. The dose of kisspeptin-54 used was 6.4 nmol/kg. This dose 
of kisspeptin-54 was chosen as human studies from our laboratories have identified 
previously that this dose stimulated the highest gonadotrophin release in healthy women 
(Dhillo et al. 2007). 
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Pre study training: each volunteer was trained how to self administer subcutaneous 
injections into the lower abdominal region. Saline injections were used for training. Subjects 
were provided with all the necessary equipment to safely self administer their injections and 
dispose of needles. Subjects were also trained to reconstitute the freeze dried vials 
containing either control saline or kisspeptin-54 with 0.5ml of 0.9% saline. Each subject was 
given a specific volume which was calculated according to their weight, to self administer. 
Subjects were instructed to keep the vials refrigerated.  
The study lasted eight weeks in total and this was divided into a 4 week baseline period, 
followed by a 2 week treatment phase and then a 2 week post treatment observation period. 
During the 8 week study subjects attended the clinical investigation unit for a review and 
blood tests twice per week. Measurements of serum gonadotrophin levels and sex 
hormones and plasma kisspeptin were made at each visit. In addition, pelvic ultrasound 
scans were performed once a week. These twice weekly measurements allowed calculation 
of mean levels of LH, FSH and oestradiol during the baseline, treatment and post treatment 
periods. Compliance was assessed with measurement of plasma kisspeptin 
immunoreactivity (IR). At each visit pregnancy was excluded using a urine hCG test 
(Clearview easy HCG, Inverness Medical Innovations Inc. Waltham, MA) (Figure 5). 
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Figure 5. The 8 week study protocol.  
The baseline period was from weeks 1- 4, weeks 5 and 6 were the treatment period (shaded 
black) and the post treatment period was week 7 and 8. During weeks 1 and 2 all subjects 
were given saline injections to acclimatise them to the study protocol. Each subject was 
randomised to receive twice daily double blinded saline or kisspeptin-54 (KP54) 6.4 nmol/kg 
injections during weeks 5 and 6. Following the first kisspeptin or saline injection, on day 1 of 
week 5, a four hour blood sampling study was performed. A second 4 hour study was 
performed on the last injection day which was on day 7, week 6 of the treatment period. LH 
pulsatility was assessed at the start of the study and after the treatment period. Ultrasound 
scans were performed once a week during the 8 week study. Twice weekly blood samples 
were taken for measurement of LH, FSH, E2 and kisspeptin-IR.  
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Baseline period (weeks 1-4) On the first day of the study subjects had an assessment of 
their LH pulsatility. This involved the subjects attending the clinical investigation unit for 8 
hours, a cannula was inserted into a forearm vein and 2.5 ml of blood was taken every 10 
minutes into plain red top serum vacutainer tubes (Becton, Dickinson, Oxford, UK). Subjects 
remained supine throughout the study. After clotting and centrifugation at 3000rpm for 10 
minutes, serum was separated and frozen at -200 C, until measurement of LH and FSH and 
oestradiol. All the eight hour pulsatilty studies were commenced in the morning between 
8am and 12pm. Blood pressure and heart rate were monitored every 30 minutes during the 
pulsatility study. 
During weeks 1-2 each volunteer administered twice daily subcutaneous injections of saline. 
At this stage only volunteers were blinded to the treatment they were receiving as the aim of 
this baseline period was to allow volunteers to become acclimatised to the study conditions. 
Treatment period (weeks 5-6): each subject self administered either subcutaneous injections 
of saline (n=5) or kisspeptin-54 (n=5). Both subjects and investigators were blinded to the 
treatment assigned. The dose of kisspeptin administered was 6.4 nmol/kg.  
On the first day of the treatment period i.e. week 5 day 1 subjects underwent a four hour 
sampling study post injection of saline or kisspeptin. This was conducted in a dedicated 
clinical investigation unit. After a clinical review and negative pregnancy urine hCG test, 
subjects had a cannula inserted into a large forearm vein in the antecubital fossa. Blood was 
sampled on arrival (t = -30 min) and then at t = 0 min, following which a subcutaneous 
injection of either saline or kisspeptin-54 6.4 nmol/kg was administered by the investigator. 
Blood was then sampled at t = 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 and 240 minutes. 
3ml of blood was collected into lithium-heparin green top tubes (Becton, Dickinson, Oxford, 
UK LIP Ltd. Cambridge, UK) containing 5000 kallikrein inhibitor units (0.2ml) aprotinin 
(Trasylol, Bayer, Newbury, UK). After immediate centrifugation, plasma was rapidly 
separated and stored at -20ºC until measurement of kisspeptin immunoreactivity (IR). An 
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additional 3ml of blood was collected into plain red top serum vacutainer tubes (Becton, 
Dickinson, Oxford, UK), these samples were allowed to clot and then centrifuged at 3000 
rpm for 10 minutes after which serum was separated and frozen at -200 C until measurement 
of LH, FSH and oestradiol. Blood pressure and heart rate were measured at every time point. 
Subjects remained supine throughout the study and were asked if they felt any nausea or 
other side effects every 30 min. On the last day of the treatment period subjects received 
only one injection which was administered in the clinical investigation unit. This was followed 
by a second 4 hour sampling study (Figure 6). 
Figure 6. The four hour study protocol. 
Participants remained in a supine position throughout the four study. A cannula was inserted 
into a vein in the antecubital fossa on arrival. A randomised subcutaneous injection of either 
saline or kisspeptin was administered at time zero. Blood samples were taken at regular time 
intervals from -30 to 240 min.  
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Post treatment period (weeks 7-8) The day after their final injection (week 7, day 1) subjects 
had a second assessment of their LH pulsatility over 8 hours. Subjects continued to have 
twice weekly blood tests taken to measure reproductive hormones and pelvic ultrasounds 
performed once a week during the two week post treatment period. 
 
Study 2 Effect of chronic kisspeptin administration on GnRH sensitivity in women with 
hypothalamic amenorrhoea 
In order to assess their sensitivity to GnRH pre and post chronic kisspeptin-54 administration; 
five additional women with hypothalamic amenorrhoea had GnRH stimulation tests 
performed. These women had a baseline GnRH test conducted seven days prior to 
commencing twice daily kisspeptin-54 injections for two weeks. These GnRH tests were 
performed in the clinical investigation unit, women were cannulated and blood was sampled 
for serum LH, FSH and oestradiol (t=-30), they were then given a 100mcg iv bolus of GnRH 
(HRF, Intrapharm Ltd, Kent, UK) at time 0. Serial blood samples were taken at times -30, 0, 
15, 30, 45, 60, 90, and 120 minutes and serum gonadotrophins and oestradiol were 
measured. After two weeks of treatment with kisspeptin-54, they underwent a second GnRH 
test (Figure 7). 
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Figure 7. The GnRH study protocol. 
Five women with hypothalamic amenorrhoea had a GnRH test performed seven days prior 
to commencing twice daily injections of kisspeptin-54. After this two week treatment period 
they had a second GnRH test performed. The aim of this study was to assess sensitivity to 
GnRH pre and post chronic kisspeptin-54 administration. 
 
 
 
Measurement of LH, FSH, oestradiol, progesterone, SHBG 
LH, FSH, oestradiol and progesterone were measured using automated chemiluminescent 
microparticle immunoassays (Abbott Diagnostics, Maidenhead, UK). SHBG was measured 
using a solid-phase two-site chemiluminescent immunometric assay (DPC Immulite, 
Siemens, Llanberis, UK). Manufacturer stated reference ranges for females were LH 
(follicular), 2-10 IU/L, (midcycle) 20-60 IU/L (luteal), 4-14; FSH (follicular & luteal) 1.5-8 IU/L, 
oestradiol (early follicular) less than 300 pmol/l, (luteal) 200-1000 pmol/l; and SHBG 40-80 
nmol/l. Interassay coefficients of variation were LH 3.4%, FSH 3.5%, oestradiol 3.4%, 
progesterone 1.8% and SHBG 5.6%. The limit of detection for oestradiol was 70pmol/l, FSH 
0.05 mIU/mL, LH 0.07mIU/ml, progesterone 0.1ng/ml and SHBG 0.1nmol/L. 
 
Kisspeptin radioimmunoassay (RIA) 
Antibody GQ2 was raised in a sheep immunised with synthetic human kisspeptin-54 
(Bachem UK Ltd.) conjugated to BSA by glutaraldehyde and used at a final dilution of 1: 
47 
 
3,500,000. The antibody cross reacted 100% with human kisspeptin-54, kisspeptin-14, and 
kisspeptin-10 and less than 0.01% with any other related RFamide peptide including 
prolactin releasing peptide, RFRP1 (human and rat), RFRP2 (human), RFRP3 (human), 
neuropeptide FF (human) and neuropeptide AF (human). The 125I-kisspeptin-54 label was 
prepared using the iodogen method (Salacinski et al. 1981) and purified by HPLC. The 
specific activity of kisspeptin label was 56 Bq/fmol. The assay was performed in duplicate 
using dilutions of neat plasma in 0.7 ml of 0.06 M phosphate buffer pH 7.2 containing 0.3% 
BSA and incubated for 3 days at 4ºC. Free and antibody bound label were then separated by 
charcoal adsorption. The assay detected changes of 2 pmol/l of plasma kisspeptin with a 
95% confidence limit. The intra- and inter-assay coefficients of variation were 8.3% and 
10.2% respectively. 
Ultrasound scans  
All the pelvic ultrasound scans were performed in the department of Radiology at Charing 
Cross Hospital, Imperial College NHS Trust. The scans were transabdominal and performed 
once a week using Toshiba Apilo XG scanners (Toshiba Medical Systems, Nasu, Japan). 
Endometrial thickness, mean ovarian volume, mean number of follicles, and the maximum 
diameter of the largest follicle was measured and recorded at each scan. Ovulation was 
determined using the following diagnostic criteria: presence of a dominant follicle of diameter 
18mm or greater, subsequent collapse of a preovulatory follicle and an associated rise in 
serum progesterone levels to above 10nmol/l (Pache et al. 1990).  
 
Statistical analysis 
All results are presented as mean ± SEM. Statistical comparisons across multiple means 
were performed using one way ANOVA with the Bonferroni post-hoc correction. Pairs of 
means were compared using the unpaired two tailed t test. In all cases P<0.05 was 
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considered to be statistically significant. The GnRH tests and 4 hour studies were analysed 
using two way ANOVA with the Bonferroni post hoc correction.  
Assessment of LH pulses was made using the modified Santen and Bardin method (Adams 
et al. 1994; Hayes et al. 1999). An LH pulse was defined as consisting of at least two LH 
points, the first of which was at least 2 IU/l above the preceding nadir and greater than 3 
times the CV of the LH assay; and the second point fulfilled one these criteria. LH pulses of 
three points greater than 1 IU/l above the preceding nadir were also included.  
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3.Results 
Study 1: Effect of chronic kisspeptin administration on reproductive hormone secretion in 
women with hypothalamic amenorrhoea 
 
The demographics of the women in the kisspeptin and saline control groups is shown in 
table 2. There were five women with hypothalamic amenorrhea recruited into each group; all 
the women completed the study. There was no significant difference between the two groups 
in terms of age, weight, body mass index (BMI), duration of amenorrhoea and baseline 
gonadotrophin and oestradiol levels. Body weight was monitored throughout the study to 
ensure that all subjects maintained a constant weight. There were no adverse effects 
reported by subjects or observed in the 4 hour studies post kisspeptin-54 or saline 
administration.  
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Table 2. Characteristics of the women in the kisspeptin and saline control groups.  
There were five women randomised to either saline or kisspeptin-54 treatment groups. Data 
is presented as mean ± SEM. 
 Saline control group 
n=5 
Kisspeptin-54 group 
n=5 
P value 
Age (years) 24.8 ± 0.5 26.8 ± 2.4 0.28 
Weight (kg) 51.8 ± 3.3 54.5 ± 1.1 0.46 
BMI (kg/m2) 19.0 ± 0.7 19.9 ± 0.4 0.25 
Amenorrhoea 
duration (months) 
22.4 ± 9.9 23.2 ± 12.7 0.96 
LH (IU/L) 4.5 ± 1.6 2.6 ± 0.9 0.32 
FSH (IU/L) 6.6 ± 0.7 6.1 ± 1.0 0.69 
Oestradiol (pmol/l) 105 ± 13.9  78 ± 4.9  0.1 
 
Baseline plasma kisspeptin in women with hypothalamic amenorrhoea was <2pmol/L. 
Following administration of the first dose of kisspeptin-54 there was an acute rise in plasma 
kisspeptin immunoreactivity (IR) levels which peaked at 45 minutes post injection (Figure 8). 
There was no increase in plasma kisspeptin IR post injection of saline.  
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Figure 8. Plasma kisspeptin immunoreactivity (IR) levels over 4 hours post injection of 
kisspeptin-54 (KP54) 6.4 nmol/kg or saline control on the first day of the study.  
Injections were administered at time 0 minutes. Data is shown as mean ± SEM. **p<0.01, 
***p<0.001. 
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A similar response in kisspeptin IR was observed following the last saline or kisspeptin 
injection on the second 4 hour study. This was conducted on the last day of two weeks of 
treatment, with either twice daily injections of saline or kisspeptin-54 6.4 nmol/kg (Figure 9). 
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Figure 9. Plasma kisspeptin immunoreactivity (IR) levels over 4 hours post injection of 
kisspeptin-54 6.4 nmol/kg or saline control on the last day of two weeks treatment 
with either twice daily kisspeptin-54 (KP54) 6.4 nmol/kg or saline injections.  
Injections were administered at 0 minutes. Data is shown as mean ± SEM. *p<0.05, 
***p<0.001. 
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All of the women with HA underwent a 4 week baseline period. During weeks 1 and 2 of this 
baseline period women received twice daily subcutaneous injections of saline to acclimatise 
them to the study conditions. Plasma kisspeptin IR levels during this time were <2 pmol/ L. 
During weeks 5 and 6, which was the treatment period, the women were randomised to 
receive either twice daily subcutaneous injections of kisspeptin-54 6.4 nmol/kg or saline 
control. During the treatment period women who received kisspeptin-54 had a significant 
increase in plasma kisspeptin IR levels (Figure 10A) measured twice weekly. Those who 
received saline control did not have any increase in plasma kisspeptin IR (Figure 10B). 
  
55 
 
Figure 10. Weekly plasma kisspeptin IR levels in women with HA randomised to 
receive subcutaneous injections of (A) kisspeptin-54 6.4 nmol/kg or (B) saline. 
Plasma kisspeptin immunoreactivity was significantly elevated during treatment weeks 5 and 
6 compared to weeks 1-4, in those randomised to receive kisspeptin-54. Data is shown as 
mean ± SEM. ***p<0.001 
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On the first 4 hour study day, which was on the first day of the treatment day, administration 
of kisspeptin-54 resulted in significant increases in serum gonadotrophins and oestradiol in 
women with hypothalamic amenorrhoea. There were statistically significant (p<0.001) 
increases in serum LH levels from baseline from 150 min to 240 minutes post injection of 
kisspeptin-54. At 240 minutes a maximum increase in LH was noted at 24 ± 3.5 IU/L above 
baseline. Serum levels of FSH also significantly increased (p<0.001) at 180 to 240 minutes 
post kisspeptin-54 administration. This increase was not as high as that observed with LH, 
the maximum rise in FSH was 9.1 ± 2.5 IU/L at 240 minutes. Oestradiol levels showed a late 
rise, with significant increases only noted after 180 minutes. There were no observed 
changes in levels of LH, FSH and oestradiol from baseline post injection of saline. (Figure 
11). 
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Figure 11. Changes in serum levels of LH (A), FSH (B) and oestradiol (E2) (C) from 
baseline after administration of subcutaneous injection of either saline or kisspeptin-
54 6.4 nmol/kg (KP54) on the first day of the treatment period. 
Injections were administered at 0 min. Data is shown as mean ± SEM *p<0.05, **p<0.01, 
***p<0.001 
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On the last day of the treatment period i.e. after two weeks of twice daily subcutaneous 
injections of either kisspeptin-54 or saline, saline injection did not result in any change in 
serum levels of LH, FSH and oestradiol. Although kisspeptin-54 administration did result in a 
significant increase in serum LH, this was only at 240 minutes post injection. The maximal 
increase in LH at 240 minutes after an injection of kisspeptin-54 was only 2.48 ± 3.76. There 
was no significant change in serum FSH and oestradiol levels after kisspeptin-54 
administration. All the responses were significantly diminished at each time point compared 
to those achieved on the first day pre treatment (Figure 12). 
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Figure 12. Changes in serum levels of LH (A), FSH (B) and oestradiol (E2) (C) from 
baseline after administration of subcutaneous injection of either saline or kisspeptin-
54 6.4 nmol/kg on the last day of the treatment period. 
Data is shown as mean ± SEM *p<0.05, **p<0.01, ***p<0.001 
0 30 60 90 120 150 180 210 240
-4
0
4
8
12
16
20
24
28
injection
*
KP54
saline
Minutes
L
H
 i
n
c
re
a
s
e
 (
IU
/l
)
A
 
0 30 60 90 120 150 180 210 240
-4
0
4
8
12
injection Time (minutes)
F
S
H
 i
n
c
re
a
s
e
 (
IU
/l
)
B
 
0 30 60 90 120 150 180 210 240
-40
-30
-20
-10
0
10
20
30
40
50
injection
C
Time (minutes)
O
e
s
tr
a
d
io
l 
in
c
re
a
s
e
 (
p
m
o
l/
l)
 
60 
 
A summary of the differences in serum levels of gonadotrophins and oestradiol achieved 
post injection of kisspeptin-54 on the first and last day of the treatment period is shown in 
Figure 13. The area under the curve (AUC) represents the total increase in serum LH, FSH 
and oestradiol achieved in the four hours post injection of kisspeptin-54 6.4 nmol/kg. 
Significantly lower responses in LH, FSH and oestradiol were achieved post injection of 
kisspeptin-54 6.4 nmol/kg on day 14 compared to day 1 of the treatment period. 
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Figure 13. Comparison of the mean area under curve (AUC) increases in LH (A), FSH 
(B) oestradiol E2 (C) during the four hours post sc injection of kisspeptin-54 6.4 
nmol/kg on the first and last injection days on the treatment period. 
*p<0.05, **p<0.01, ***p<0.001 
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The mean levels of serum LH, FSH and oestradiol were calculated for the baseline period 
(weeks 1-4), the treatment period (weeks 5 & 6) and post treatment (weeks 7 & 8) in both 
the kisspeptin-54 and saline treated groups (table 3). The mean levels of LH during the 
baseline period were lower in the kisspeptin-54 treated group compared to those women in 
the saline study group (p=0.02). During the treatment period the women in the kisspeptin 
group had small rises in mean levels of LH (p=0.09) and FSH (p=0.02).  
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Table 3. Comparison of basal serum reproductive hormone levels at baseline, during 
and after 2 weeks treatment with either saline or kisspeptin injections. 
For each subject mean baseline serum levels of LH, FSH and oestradiol were calculated 
from the blood tests performed during the baseline period of weeks 1-4. Changes in serum 
levels of LH, FSH and oestradiol levels during the two week treatment period weeks 5-6, and 
the post treatment period weeks 7-8 were calculated for each subject. Data shown as mean 
± SEM. 
  Study group P value 
  Saline  
n=5 
 
Kisspeptin54 
n=5 
 
LH (iU/l) 
 
Baseline 
Change during 2 
week treatment 
period 
Change during post 
treatment period 
3.7 ± 0.6 
 
-0.8 ± 0.7 
 
-0.6 ± 0.5 
1.8 ± 0.3 
 
+1.2 ± 0.7 
 
-0.4 ± 0.2 
0.02 
 
0.09 
 
0.51 
FSH (iU/l) Baseline 
Change during 2 
week treatment 
period 
Change during post 
treatment period 
7.0 ± 0.8 
 
-1.8 ± 0.4 
 
0.0 ± 0.57 
5.3 ± 0.2 
 
+0.6 ± 0.4 
 
-0.6 ± 0.3 
0.07 
 
0.02 
 
0.35 
Oestradiol 
(pmol/l) 
Baseline 
Change during 2 
week treatment 
period 
Change during post 
treatment period 
109 ± 15 
 
+33 ± 48 
 
+16 ± 7 
91 ± 6 
 
+77 ± 67 
 
+17 ± 14 
0.28 
 
0.61 
 
0.92 
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An eight hour LH pulsatility study was performed on day 1 of the baseline period and 
repeated after two weeks of treatment with either twice daily subcutaneous injections of 
saline or kisspeptin-54 6.4 nmol/kg. A modified Santen and Bardin method was used to 
assess LH pulsatility. There were no significant changes in mean LH, number of LH pulses 
or LH pulse amplitude (Table 4). 
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Table 4. Comparison of LH pulsatility before and after 2 weeks treatment with saline or 
kisspeptin-54 6.4 nmol/kg injections in women with HA. 
Mean levels of serum LH, number of LH pulses and mean LH pulse amplitude are shown as 
mean ± SEM. 
Characteristic  Study group P value 
  Saline  
n= 5 
Kisspeptin54 
n= 5 
 
Mean LH (iU/l) 
 
Baseline 
Post-treatment 
Change 
2.5 ± 0.5 
2.5 ± 0.8 
-0.08 ± 0.5 
1.5 ± 0.4 
3.2 ± 2.2 
+1.7 ± 1.9 
0.16 
0.77 
0.40 
Number of LH 
pulses 
Baseline 
Post-treatment 
Change 
0.8 ± 0.5 
1.6 ± 0.8 
+0.8 ± 0.5 
1.0 ± 0.8 
0.8 ± 0.6 
-0.2 ± 0.2 
0.24 
0.48 
0.12 
Mean pulse 
amplitude (iU/l) 
Baseline 
Post-treatment 
Change 
2.7 ± 0.6 
2.4 ± 0.2 
-0.4 ± 0.4 
1.1 ± 0.05 
2.1 ± 0.1 
+1.5 ± 0.3 
0.24 
0.48 
0.12 
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There was no observed change in any of the parameters measured in the transabdominal 
ultrasound scans. Ovulation was determined using the following diagnostic criteria, presence 
of a dominant follicle of diameter 18mm or greater, subsequent collapse of a preovulatory 
follicle and an associated rise in serum progesterone levels to above 10nmol/l (Pache et al. 
1990). None of the women ovulated during the eight week study (Table 5). 
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Table 5. Summary of ultrasound parameters at baseline, during and after 2 weeks 
treatment with saline or kisspeptin injections in women with HA.  
Endometrial thickness, ovarian volume, follicle number and maximum follicle diameter are 
shown as mean ± SEM. Baseline mean values were calculated from the four scans 
performed during the baseline period, weeks 1-4. The change in value of each ultrasound 
parameter was calculated from the two scans during the treatment period (weeks 5-6) and 
the two scans performed in the post treatment period (weeks 7-8). 
Characteristic  Saline  
n=5  
kisspeptin54  
n= 5 
P value 
Ovulation (number 
of subjects 
 
 
0 0 - 
Preovulatory follicle 
≥ 18mm (no. of 
subjects) 
 1 1 - 
Dominant follicle ≥ 
11mm (no. of 
subjects) 
 1 3 - 
Endometrial 
thickness (mm) 
 
Baseline 
Change during treatment 
Change post-treatment 
3.2 ± 0.4 
+0.4 ± 0.3 
+0.8 ± 0.6 
4.3 ± 0.9 
-0.5 ± 0.5 
+0.1 ± 0.5 
0.29 
0.15 
0.36 
Ovarian volume 
(cm3) 
Baseline 
Change during treatment 
Change post-treatment 
5.2 ± 1.2 
+0.9 ± 0.4 
+1.2 ± 0.5 
5.8 ± 0.6 
+1.3 ± 0.8 
+0.7 ± 0.6 
0.67 
0.69 
0.50 
Follicle number per 
ovary 
Baseline 
Change during treatment 
Change post-treatment 
12.4 ± 2.1 
-2.3 ± 1.5 
-0.6 ± 1.8 
11.8 ± 1.2 
+0.8 ± 1.2 
-0.2 ± 1.2 
0.79 
0.13 
0.86 
Maximum follicle 
diameter (mm) 
Baseline 
Change during treatment 
Change post-treatment 
6.9 ± 0.3 
+0.5 ± 1.3 
0.0 ± 0.8 
8.0 ± 0.5 
+0.1 ± 0.6 
+0.2 ± 0.6 
0.11 
0.83 
0.84 
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Study 3.2: Effect of chronic kisspeptin administration on GnRH sensitivity in women 
with hypothalamic amenorrhoea 
 
GnRH tests were performed in order to ascertain if there was an effect of twice daily 
kisspeptin-54 6.4 nmol/kg subcutaneous injections on the sensitivity of women with HA to 
GnRH. Although there was a reduction in the gonadotrophin response to GnRH this was not 
statistically significant different prior to or following two weeks of twice daily kisspeptin-54 
injections (p = 0.23) (Figure 14).  
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Figure 14. Mean gonadotrophin response to GnRH 100 mcg bolus pre (A) and post (B) 
treatment with twice daily injections of kisspeptin-54 (KP54) 6.4 nmol/kg. 
Data is shown as mean ± SEM, n= 5 women with hypothalamic amenorrhoea. 
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4. Discussion 
 
This is the first study to investigate the effects of kisspeptin-54 in women with infertility due 
to hypothalamic amenorrhoea. This study has identified that acute administration of 
kisspeptin to women with HA results in stimulation of reproductive hormones but chronic 
administration for two weeks of twice daily injections of kisspeptin at a dose of 6.4 nmol/kg 
results in tachyphylaxis. The second 4 hour study which was conducted after two weeks of 
treatment with either saline or kisspeptin-54 twice daily showed much lower responses in 
gonadotrophin and oestradiol stimulation in the kisspeptin group compared to those 
achieved in the first four study, which was performed on the first day of the treatment period. 
Tachyphylaxis to the effects of kisspeptin on gonadotrophin release occurred despite 
retained sensitivity to GnRH, suggesting that the desensitisation was occurring at the level of 
the KISS1R. Thus as seen in animal models the method of administration of kisspeptin 
appears to determine its effects on the HPG axis.  
The second 4 hour study was conducted using an injection of a vial returned from each 
subject. To ensure that peptide degradation had not caused the lower gonadotrophin 
response to kisspeptin at the end of the two week treatment period, plasma kisspeptin levels 
were measured. Plasma kisspeptin immunoreactivity was similar following the first and last 
injection of kisspeptin-54. Plasma kisspeptin IR levels were raised for 6 hours post injection 
of kisspeptin-54. Thus the twice daily administration of kisspeptin54 would have led to 
prolonged exposure to raised kisspeptin levels. Animal model studies have demonstrated 
that a continuous exposure to kisspeptin fails to sustain gonadotrophin stimulation. Juvenile 
agonadal rhesus male monkeys given a 98 hour continuous intravenous infusion of 
kisspeptin-10 resulted in a stimulation of gonadotrophins for only the initial three hours of the 
infusion (Seminara et al. 2006). Adult male rats given a three day infusion of kisspeptin-54 
also demonstrated gonadotrophin stimulation only in the first 24 hours of the infusion, after 
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which LH returned to baseline values (Thompson et al. 2006). These effects appear to be 
secondary to desensitisation of the KISS1R.  
A study in adult male rhesus monkeys (Ramaswamy et al. 2007) demonstrated that a 98 
hour continuous intravenous infusion of kisspeptin-10 led to reduced responsiveness to 
GnRH. The monkeys all displayed an acute initial dose related stimulation in gonadotrophin 
release with a bolus intravenous administration of kisspeptin, however a continuous infusion 
of 200mcg/hour and a second higher dose infusion of 400 mcg/hour of kisspeptin-10 led to a 
stimulation in gonadotrophin for only the first 3 hours of the infusion; after which LH fell to 
baseline levels. In their study Ramaswamy et al. report that there was reduced 
responsiveness to GnRH which was dose dependent and occurred only with the higher 
400mcg/hour infusion (Ramaswamy et al. 2007). We conducted a GnRH study in order to 
ascertain whether women with hypothalamic amenorrhoea maintained responsiveness to 
GnRH after two weeks of twice daily kisspeptin-54 6.4 nmol/kg injections. Our results 
indicate that these women did maintain responsiveness to GnRH, although there was a 
reduced response in gonadotrophin stimulation, this did not reach statistical significance. 
Thus the twice daily administration of kisspeptin appears to have led to desensitisation 
upstream of the GnRH receptor probably at the level of the kisspeptin receptor. A further 
study examining the effects of kisspeptin administration on GnRH response in healthy 
women would be interesting. Weight and serum oestradiol levels appear to influence 
pituitary responsiveness to GnRH (Aono et al. 1975; Knobil 1980). A study of a larger 
number of women with hypothalamic amenorrhea and healthy women would allow 
examination of any correlation between BMI and oestradiol levels and the effects of 
kisspeptin on responsiveness to GnRH.  
The effects of twice daily kisspeptin-54 injections at a dose of 6.4 nmol/kg on LH pulsatility 
were also assessed in this study. We did not demonstrate any statistically significant change 
in either LH pulse frequency of the mean amplitude of LH increase in women with 
hypothalamic amenorrhoea. The study by Ramaswamy et al. on the effects of continuous 
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intravenous infusion of kisspeptin-10 in rhesus male monkeys reported that the high dose of 
kisspeptin-10 (400mcg/hour) resulted in a reduction in the mean number of LH pulses and 
LH pulse amplitude (Ramaswamy et al. 2007). These effects were dose related and did not 
occur with a lower dose (200mcg/hour) of kisspeptin-10. These studies were performed in 
healthy monkeys with normal GnRH pulsatility. Women with hypothalamic amenorrhoea 
have abnormal LH pulsatility (Reame et al. 1985) and thus may not be expected to respond 
in a similar fashion. 
Functional hypothalamic amenorrhoea is often a consequence of undernutrition, due either 
to decreased calorie intake or increased energy output. Rodent models of undernutrition 
have demonstrated that kisspeptin-10 stimulates higher gonadotrophin responses in 
undernourished female rats (Castellano et al. 2005). Seventy-two hours of fasting led to a 
significant decrease in hypothalamic KiSS-1 mRNA levels and increase in GPR54 mRNA 
expression in male and female prepubertal rats. Intracerebroventricular injections of 
kisspeptin-10 stimulated higher LH levels in those rats that were fasted compared to those 
fed ad libitum (Castellano et al. 2005). Comparing the rise in serum gonadotrophins post 
administration of kisspeptin in women with HA with those achieved in previous studies in 
healthy women in the follicular phase of the menstrual cycle (Dhillo et al 2007), it was noted 
that the women with HA appear to more responsive to kisspeptin. They achieved LH levels 
which were 4 fold greater than those in healthy women. A comparison with the follicular 
phase of the menstrual cycle was made because similar to the state in hypothalamic 
amenorrhoea, the follicular phase is characterised by low gonadotrophin and oestradiol 
levels. The increased expression of hypothalamic kisspeptin receptor GPR54 in rodent 
models of under-nutrition, (Castellano et al. 2005) may explain the increased potency of 
kisspeptin stimulation on gonadotrophin release.  
This is the first human study showing the effects of acute and chronic administration of 
kisspeptin-54 to women with hypothalamic amenorrhoea. The results show that after an 
initial acute stimulation of gonadotrophin release, two weeks therapy of kisspeptin-54 at a 
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dose of 6.4 nmol/kg led to reduced gonadotrophin response, suggesting desensitisation. The 
results of this study will have important implications of the use of kisspeptin as a therapy in 
disorders of reproduction.  
Although I did not administer kisspeptin-54 as a continuous infusion, the twice daily 
injections did lead to raised plasma kisspeptin IR for 6 hours post injection resulting in 
prolonged exposure to elevated levels of kisspeptin. Animal data has shown that continuous 
administration of kisspeptin results in desensitisation to its effects on gonadotrophin release 
(Ramaswamy et al. 2007; Seminara et al. 2006; Thompson et al. 2006). Therefore a different 
study protocol of kisspeptin-54 administration i.e. a lower dose or reduced frequency of 
injections may reduce the desensitisation seen in stimulation of gonadotrophin release.  
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Chapter 3 
 
The effects of chronic twice weekly kisspeptin administration in women 
with hypothalamic amenorrhoea 
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3.1 Introduction  
 
In Chapter 2 it was demonstrated that a single injection of kisspeptin-54 stimulated 
gonadotrophin release in women with hypothalamic amenorrhoea. However, women with HA 
treated for two weeks with twice daily kisspeptin-54 injections had a markedly reduced 
reproductive hormone response to kisspeptin-54 at the end of the study when compared with 
the first kisspeptin injection, despite maintaining their responsiveness to GnRH injection. 
This suggests that desensitisation was occurring at the level of the kisspeptin receptor 
(KISS1R). 
The kisspeptin receptor also known as the GPR54 (abbreviated to KISS1R in humans) is a 
G protein coupled receptor (GPCR). The binding of kisspeptin to its receptor stimulates 
phospholipase C which in turn activates second messenger systems inositol 1,4,5-
trisphosphate and diaclyglycerol resulting in increased intracellular calcium (Kotani et al. 
2001; Muir et al. 2001; Stafford et al. 2002). G protein coupled receptors exhibit receptor 
desensitisation (Lefkowitz 1998; Ritter & Hall 2009). Acutely, desensitisation occurs via loss 
of signalling to secondary messenger systems due to persistent ligand binding and 
subsequently receptor internalization. Degradation rather than recycling of these receptors 
results in chronic desensitisation (Ferguson 2001). Degradation of the kisspeptin receptor 
appears to be via proteasomes rather than the more common pathway of GPCR degradation 
which is via lysosomes (Bianco et al. 2011). 
Plasma kisspeptin immunoreactivity levels remain elevated for at least four hours following a 
single subcutaneous injection of kisspeptin-54, therefore twice daily injections of kisspeptin 
would have led to prolonged exposure to kisspeptin of at least 8 hours a day. Animal models 
have also shown that chronic administration of kisspeptin-10 to both rats and monkeys 
results in an acute stimulation of gonadotrophin release followed by a fall in gonadotrophin 
levels to baseline values when desensitisation occurs.  
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Acute administration of kisspeptin to women with HA results in a potent stimulation of LH 
release, but twice daily kisspeptin-54 administration for 2 weeks led to tachyphylaxis 
(Jayasena et al. 2009f). These data suggest that kisspeptin-54 could potentially be used to 
downregulate the hypothalamo-pituitary gonadal axis for the treatment of sex hormone 
dependant tumours and precocious puberty. In addition it is possible that a modified dosing 
protocol of kisspeptin-54 administration which prevents tachyphylaxis from occurring could 
be used to stimulate reproductive hormone release long term in women with HA.  
3.2 Hypothesis and Aims 
 
I hypothesised that modification of the protocol of repeated kisspeptin administration would 
reduce the observed desensitisation to its effects in women with HA.  
The aims of this study were to determine in women with hypothalamic amenorrhoea 
 The time course over which desensitisation to the effects of kisspeptin-54 occurs 
 If varying dosing regimens of kisspeptin-54 administration could reduce the 
desensitisation of the effects of kisspeptin on reproductive hormone release.  
 The effects of long-term twice-weekly kisspeptin-54 injections on reproductive 
hormone release by conducting a randomised, double-blinded placebo-controlled 
parallel design study over eight weeks in women with hypothalamic amenorrhoea. 
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3.3 Methods  
3.3.1 Subjects 
 
Ethical approval was granted by the Hammersmith and Queen Charlotte‟s and Chelsea 
Hospitals Research Ethics Committee (registration number: 05/Q0406/142). Written 
informed consent was obtained from all subjects. This study was performed in accordance 
with the Declaration of Helsinki.  
Subjects were recruited through advertisements placed in local newspapers. Responders to 
adverts were evaluated with a detailed menstrual history, clinical examination and blood 
tests. Screening blood tests performed were as follows: full blood count; renal profile; liver 
profile; bone profile; glucose; thyroid profile; LH; FSH; oestradiol; progesterone; 
androstenedione; dehydroepiandrostenone; testosterone; SHBG; prolactin; 17-
hydroxyprogesterone and cortisol. Women were diagnosed with HA and included within the 
study if they fulfilled the following criteria: body mass index < 25kg/m2; stable body weight 
over the previous 6 months; age between 18 and 40 years; secondary amenorrhea of at 
least 6 months duration; absence of oral contraceptive pill therapy for at least one year; 
absence of co-morbidity; absence of active psychiatric illness; stable body weight; absence 
of therapeutic or recreational drug use; absence of clinical or biochemical signs of 
hyperandrogenemia; structurally normal hypothalamus and pituitary region assessed by 
magnetic resonance imaging; structurally normal female reproductive tract visualised on 
ultrasound; absence of polycystic ovarian appearances on ultrasound; normal thyroid 
function tests; normal serum prolactin levels; serum LH:FSH ratio <1.5. Thirty subjects with 
HA were recruited to the study.  
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3.3.2 Study 1: Determination of the time-course of desensitisation to the effects of 
kisspeptin on gonadotophin release in women with HA 
 
Five subjects with HA received twice-daily injections of 6.4 nmol/kg of kisspeptin-54. On day 
1 (the first injection day), days 2, 3, 4, and day 14 (the last injection day) of the study 
protocol, each subject underwent a 4 hour sampling study post-injection of kisspeptin. 
Protocol for 4 hour blood sampling after injection: 
Subjects were admitted to our Clinical Investigation unit and asked to lay supine. Kisspeptin-
54 was subcutaneously administered at time 0 minutes by an investigator, and blood was 
sampled for serum LH, FSH, oestradiol, and SHBG at -30, 0, 15, 30, 45, 60, 75, 90, 120, 150, 
180, 210 and 240 minutes (Figure 15). 
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Figure 15. The four hour study protocol. 
Participants remained in a supine position throughout the four studies. A cannula was 
inserted into a vein in the antecubital fossa on arrival. A randomised subcutaneous injection 
of either saline or kisspeptin was administered at time zero. Blood samples were taken at 
regular time intervals from -30 to 240 min as indicated by the arrows. 
 
 
 
 
  
-30
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3.3.3 Study 2: Effects of reduced dose and increased dose-interval on serum 
reproductive hormone release in women with HA administered kisspeptin injections 
for 2 weeks 
 
In order to assess the effects of altering kisspeptin-54 dose and dose interval between 
kisspeptin-54 injections on reproductive hormone release in women with HA, four different 2 
week regimes of subcutaneous kisspeptin-54 injections were investigated: 6.4 nmol/kg 
twice-daily; 1 nmol/kg once-daily; 0.3 nmol/kg once-daily; 6.4 nmol/kg twice-weekly. For 
each unblinded 2 week pilot study, 5 subjects with HA (see Table 6 for baseline 
characteristics) attended our clinical investigation unit twice per week. Basal measurements 
of reproductive hormone were performed twice weekly. On the first (day 1) and last injection 
day (day 14), the injection of kisspeptin was administered by a study investigator during a 4 
hour sampling study. 
 
3.3.4 Study 3: Effects of twice weekly kisspeptin-54 (6.4nmol/kg) administration for 8 
weeks on reproductive hormone release in women with HA 
 
Results from Study 2 showed that administration of kisspeptin-54 6.4 nmol/kg twice weekly 
significantly reduced desensitisation to the effects of kisspeptin-54 on reproductive hormone 
release. In order to determine if longer term administration of kisspeptin-54 6.4 nmol/kg 
twice-weekly would continue to stimulate reproductive hormone release a randomised, 
double blinded, placebo-controlled, parallel design study was performed. Ten subjects with 
HA (see Table 6 for baseline characteristics) were randomised to receive either saline or 
kisspeptin 6.4 nmol/kg injections (n=5 per group) twice weekly for 8 weeks. 
Each subject attended a hospital investigation unit twice per week (Figure 16). Twice-weekly 
basal measurements of serum LH, FSH, oestradiol, progesterone and SHBG were taken 
from subjects throughout the 8 week study protocol between 0800 and 1800h. Trans-
abdominal ultrasound scans were performed once a week throughout the 8 week study 
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protocol. During each scan the following parameters were measured: endometrial thickness 
in millimetres (mm); mean ovarian volume in cubic centimetres (cm3); number of mean 
follicles; maximum diameter of largest follicle in each ovary in mm. Ovulation was confirmed 
by satisfaction of all of the following criteria: visualisation of a dominant follicle (diameter 
11mm or greater); enlargement of dominant follicle into a pre-ovulatory follicle (diameter 
18mm or greater); subsequent collapse of pre-ovulatory follicle or appearance of internal 
echoes on ultrasonography; a rise in serum progesterone to over 10nmol/l (Pache et al. 
1990). 
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Figure 16. Protocol to investigate the effects of twice-weekly kisspeptin-54 
administration for 8 weeks in women with HA. 
Subjects with HA were randomised to receive twice-weekly injections of saline or kisspeptin-
54 (KP54) 6.4 nmol/kg for 56 days. Four hour blood sampling was performed immediately 
following saline or kisspeptin injection on days 1, 14, 28, 42 and 56. Once-weekly ultrasound 
scans and twice-weekly blood sampling for measurement of LH, FSH, oestradiol (E2) and 
plasma kisspeptin immunoreactivity (IR) were also performed. 
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During each visit, a double-blinded subcutaneous injection of either saline or kisspeptin was 
administered to each subject. Following the first injection of saline or kisspeptin a 4 hour 
sampling study (Figure 15) was performed in order to investigate the acute effects of the 
treatment on reproductive hormone release. The 4 hour sampling study was repeated at 2, 4 
and 6 weeks, and on the final day of the study protocol after 8 weeks.  
During each study visit, urine was tested in order to exclude pregnancy (Clearview easy-
HCG, Inverness Medical Innovations Inc. Waltham, MA). Diastolic and systolic blood 
pressure and heart rate were recorded during 4 hour blood sampling studies performed post-
injection of kisspeptin or saline.  
 
3.3.5 Kisspeptin-54 
 
Kisspeptin-54 was synthesised by the Advanced Biotechnology Centre, Imperial College 
London and purified by reverse-phase high performance liquid chromatography (HPLC). 
Electrospray mass spectroscopy and amino acid analysis confirmed identity of the peptide 
as previously described (Dhillo et al. 2005; Dhillo et al. 2007). The peptide was tested for 
bioactivity and toxicity as previously described (Dhillo et al. 2005). The Limulus amebocyte 
lysate assay (Associates of Cape Cod, Liverpool, UK) was negative for endotoxin, and the 
peptide was sterile on culture (Department of Microbiology, Hammersmith Hospital, London). 
Although kisspeptin-10, -13, -14, and -54 display similar potency in vitro, we used kisspeptin-
54 due to its higher in vivo potency than the other kisspeptin fragments (Thompson et al. 
2006; Tovar et al. 2006).  
 
 
 
 
84 
 
3.3.6 Injections of Kisspeptin-54  
 
Vials of freeze-dried saline or kisspeptin were reconstituted in 0.5 ml of 0.9% saline. Then a 
0.5 ml insulin syringe was used to inject a weight-adjusted dose of kisspeptin into the lower 
anterior abdominal region. Depending on the protocol, subjects received kisspeptin doses of 
0.3, 1.0 or 6.4 nmol per kg.  
Once- or twice-daily injections of kisspeptin: Due to the frequency of these injections, they 
were self-administered by subjects at home; except during 4 hour blood sampling studies, 
when injections were administered in our Clinical investigation Unit by an investigator. Prior 
to commencement of the study protocol, subjects were trained to perform subcutaneous self-
injection. A box containing unlabelled vials of freeze-dried saline or kisspeptin-54, alcohol 
wipes, saline vials, needles and needle disposal bins was given to each subject. Instructions 
were given to refrigerate vials stored at home.  
Twice-weekly injections of kisspeptin or saline: All injections were administered to subjects 
by study investigators when the subjects attended our clinical investigation unit twice a week.  
 
3.3.7 Collection and processing of blood samples 
 
Blood samples for serum analysis were collected in plain serum Vacutainer tubes (Beckton 
Dickson, Franklin Lakes, NJ, USA). Clotted samples underwent centrifugation using a 
Hettich EBA 20 machine (Hettich International, Tuttlingen, Germany) for 10 minutes at 
3000rpm. Serum was then separated and stored at -20OC until analysis.  
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3.3.8 Analytical methods 
 
Serum LH, FSH, oestradiol, and progesterone were measured using automated 
chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead, UK). SHBG was 
measured using a solid-phase automated enzyme immunoassay (Immulite; Siemens, 
Llanberis, UK). Reference ranges for females were as follows: LH (follicular), 2–10 IU/l; LH 
(midcycle), 20–60 IU/l; LH (luteal), 4–14 IU/l; FSH (follicular and luteal), 1.5–8 IU/l; oestradiol 
(early follicular), less than 300 pmol/l; oestradiol (midcycle), 400-1500 pmol/l; oestradiol 
(luteal), 200-1000 pmol/l; and SHBG 40–80 nmol/l. Interassay coefficients of variation were 
as follows: LH, 3.4%; FSH, 3.5%; oestradiol, 3.4%; progesterone, 1.8%; and SHBG, 5.6%. 
Limits of detection for each assay were as follows: oestradiol 70pmol/l; FSH 0.05mIU/ml; LH 
0.07mIU/ml; progesterone 0.1ng/ml; SHBG 1nmol/l. 
 
3.3.9 Data analysis 
 
Data are presented as mean +/- standard error of mean (SEM). Hormone profiles during 4 
hour blood sampling studies were analysed using repeated measures 2-way ANOVA with 
Bonferonni post hoc correction. Pairs of means were analysed using the unpaired two-tailed 
t-test. Multiple means were compared using one-way ANOVA with Bonferonni‟s Multiple 
Comparison Test. In all cases, P < 0.05 was considered statistically significant. 
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3.4 Results 
 
Baseline characteristics of age, weight and BMI were similar for all groups of subjects with 
HA included in this study and are shown in table 6. 
Table 6. Comparison of baseline characteristics of women with hypothalamic 
amenorrhea 
Subjects participating in 2 week pilot studies of kisspeptin administration (n=20 in total), and 
an 8 week study of saline versus kisspeptin administration (n=5 per group). Data shown as 
mean +/- SEM. 
Protocol 2 week pilot 
studies 
8 week study      P 
value Treatment Kisspeptin54 Saline 
 
Kisspeptin54  
Age (years) 
 
28.1 ± 1.1 27.0 ± 2.6 27.2 ± 2.4 NS 
Weight (kg) 
 
52.6 ± 0.7 54.5 ± 3.9 53.4 ± 3.0 NS 
Body mass index (kg/m2) 19.1 ± 0.3 19.7 ± 1.1 19.6 ± 0.7 NS 
Duration of amenorrhea 
(months) 
22.4 ± 9.9 20.4 ± 5.1 28.8 ± 12.0 NS 
Serum LH (iU/l) 2.5 ± 0.6  1.7 ± 0.7 1.4 ± 0.5 NS 
Serum FSH (iU/l) 4.8 ± 0.3 3.8 ± 0.9 3.6 ± 0.6 
 
NS 
Serum oestradiol (pmol/l) 133 ± 10.0 87 ± 17.0 151 ± 28.0 NS 
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Study 1: Time course of desensitisation to the effects of kisspeptin on reproductive 
hormone release in women with HA 
 
Twice-daily sc administration of 6.4 nmol/kg kisspeptin was associated with a progressive 
reduction in acute LH responses following injection of kisspeptin, in women with HA (Figure 
17A). On the first injection day, the mean AUC LH response during the first 4 hours after 
kisspeptin injection was 59.3  19.0h.IU/l; however mean AUC LH response during the first 4 
hours after kisspeptin injection dropped to 36.0  18.8, 14.9  2.9, 12.9  2.4 and 5.3  
1.9h.IU/l on the 2nd, 3rd, 4th and 14th injection days, respectively (Figure 17 A). On the first 
injection day, the mean AUC FSH response during the first 4 hours after kisspeptin injection 
was 15.8  3.9h.IU/l; however acute FSH responses following kisspeptin injection were less 
than 3h.IU/l during the 2nd, 3rd, 4th and 14th injection days (Figure 17 B). Mean oestradiol 
levels did not significantly change during the study (mean AUC oestradiol response: day 1, 
109  119pmol/l; day 14, -65  30pmol/l). 
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Figure 17. Time course of desensitisation to the effects of kisspeptin-54 (6.4 nmol/kg) 
on reproductive hormone release administered twice-daily for 2 weeks in women with 
HA. 
Mean area under curve (AUC) LH (A) and FSH responses (B) during the first 4 hours 
following kisspeptin-54 injections were measured on the 1st, 2nd, 3rd, 4th and 14th days of 
twice-daily administration of 6.4 nmol/kg sc kisspeptin. Data is shown as mean +/- SEM. * P 
< 0.05 vs. day 14; *** P < 0.001 vs. day 1. 
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Study 2: Effects of reduced dose and increased dose-interval on serum reproductive 
hormones in women with HA, during a 2-week protocol of kisspeptin injections 
A: Effect of twice-daily sc injection of kisspeptin-54 (6.4 nmol/kg) on reproductive hormone 
release.  
 
Twice-daily sc injection of 6.4 nmol/kg kisspeptin-54 to women with HA led to a potent 
stimulation of gonadotrophin release on the first injection day, with the maximal increase 
observed 240 minutes after injection (mean maximal increase following injection: LH: 11.2  
4.6 IU/l; FSH: 7.2  2.1 IU/l). However on the last (14th) injection day, reproductive hormone 
responses were significantly reduced when compared with responses on the first injection 
day (mean maximal increase following injection on the 14th injection day: LH: 1.0  0.5 IU/l, 
P<0.05 when compared with 1st injection day; FSH: 0.2  0.3 IU/l, P<0.001 when compared 
with 1st injection day) (Figure 18 A, B). Furthermore the oestradiol response was non-
significantly lower on the 14th injection day when compared with the first injection day (mean 
maximal oestradiol increase following injection: first injection day, 48.2  29.7 pmol/l; 14th 
injection day, -12.7  7.0 pmol/l, P=0.06) (Figure 18 C).  
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Figure 18. Serum reproductive hormone levels following twice-daily regimens of 
kisspeptin-54 6.4 nmol/kg injection in 5 women with HA.  
Changes in serum LH (A), FSH (B) and oestradiol E2 (C);over 4 hours after sc kisspeptin-54 
(KP54) on the first day and 14th day following twice daily sc injection of 6.4 nmol/kg KP54.  
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B: Effect of once-daily sc injection of kisspeptin-54 (1 nmol/kg) on reproductive hormone 
release.  
 
We then investigated if protocols using lower cumulative doses of kisspeptin treatment would 
reduce the observed desensitisation in subjects with HA. First, we examined the effects of a 
protocol of once-daily 1 nmol/kg kisspeptin-54 injections in 5 further subjects with HA. On the 
first injection day, the maximal LH and FSH responses were 3.7  0.9 pmol/l and 1.9  0.3 
pmol/l, respectively (Figure 19 A, B). However on the 14th injection day, LH and FSH 
responses were significantly reduced when compared with responses on the first injection 
day (mean maximal increase following injection on the 14th injection day: LH: 1.5  0.2 IU/l, 
P<0.05 when compared with 1st injection day; FSH: 0.3  0.2 IU/l, P<0.005 when compared 
with 1st injection day) (Figure 19 A, B). The oestradiol response was non-significantly lower 
on the 14th injection day when compared with the first injection day (mean maximal 
oestradiol increase following injection: first injection day, 48.6  29.3 pmol/l; 14th injection day, 
0.8  13 pmol/l, P=0.11) (Figure 19 C). 
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Figure 19. Serum reproductive hormone levels following once daily dosing regimens 
of kisspeptin-54 1 nmol/kg injection in 5 women with HA.  
Changes in serum LH,(A), FSH (B), and oestradiol E2(C) over 4 hours following once daily 
sc injection of 1nmol/kg of KP54. Data is shown as mean +/- SEM. * P < 0.05; *** P < 0.001  
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C: Effect of once-daily sc injection of kisspeptin-54 (0.3 nmol/kg) on reproductive hormone 
release.  
 
We then performed a 2 week study of once-daily kisspeptin-54 injections at a lower dose of 
0.3 nmol/kg in order to determine if desensitisation would still occur with further reduced 
exogenous kisspeptin exposure. On the first injection day, following kisspeptin-54 (0.3 
nmol/kg) injection the peak LH was only moderately increased, and non-significantly reduced 
after 14 days of kisspeptin treatment (mean maximal LH increase following injection: first 
injection day, 5.3  1.8 IU/l; 14th injection day, 1.2  0.4 IU/l, P=0.10). FSH responses 
followed a similar pattern to LH response (mean maximal FSH increase following injection: 
first injection day, 0.8  0.6 IU/l; 14th injection day, -0.6  0.5 IU/l, P=0.20) (Figure 20 A, B). 
The peak oestradiol response was below 20 pmol/l on the first injection day, and non 
significantly lower on the 14th injection day (Figure 20 C).  
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Figure 20. Serum reproductive hormone levels following once daily dosing regimens 
of kisspeptin-54 0.3 nmol/kg injection in 5 women with HA. 
Changes in serum LH (A), FSH (B), and oestradiol (C); over 4 hours following once daily sc 
injection of 0.3 nmol/kg of KP54. 
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D: Effect of twice-weekly sc injection of kisspeptin-54 (6.4 nmol/kg) on reproductive hormone 
release. 
 
I had observed that 1.0 nmol/kg once-daily kisspeptin-54 sc administration led to significant 
desensitisation of gonadotrophin responses after 2 weeks of administration. Although I did 
not observe significant desensitisation with 0.3 nmol/kg once-daily kisspeptin-54 sc 
administration, the absolute rises in reproductive hormone levels at this dose were modest. I 
therefore studied the effects of further reducing the dose-interval of sc kisspeptin-54 
administration to twice-weekly, at a dose of 6.4 nnmol/kg per injection. On the 14th injection 
day, mean gonadotrophin responses following injection were non-significantly lower on the 
14th injection day when compared with the first injection day (mean maximal increase in IU/l 
following injection: LH: 18.8  6.6 vs. 11.5  4.0, P=0.08; FSH: 5.8  2.0 vs. 4.1  1.1, 
P=0.14) (Figure 21 A, B).The mean maximal increase in serum oestradiol following 
kisspeptin injection was similar on the 1st and 14th injection days (1st day: 44.8  15.7 pmol/l 
vs. 14th day: 27.5  15.5 pmol/l; P=0.47) (Figure 21 C). 
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Figure 21. Serum reproductive hormone levels following twice weekly daily dosing 
regimens of kisspeptin-54 6.4 nmol/kg injection in 5 women with HA.  
Changes in serum LH (A), FSH (B) and oestradiol E2 (C); over 4 hours following twice 
weekly sc injection of 6.4 nmol/kg of KP54. 
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A summary of the effects of sc kisspeptin-54 on the first and last day of each of these 
different 2 week dosing regimens of kisspeptin-54 is shown as a mean area under the curve 
for LH, FSH and oestradiol in Figures 22 A-C. 
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Figure 22. Serum reproductive hormone levels following different 2 week dosing 
regimens of kisspeptin-54 injection in women with HA. 
The effects of sc injection of KP54 on the first day and the 14th day of each of the different 2 
week dosing regimens of KP54 is shown as a mean area under the curve for LH, FSH and 
oestradiol in (A-C). Data is shown as mean +/- SEM. * P < 0.05; ** P < 0.01. 
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Study 3: Effects of twice-weekly kisspeptin-54 administration for 8 weeks on 
reproductive hormone levels in women with HA. 
 
Baseline age, weight and BMI were not significantly different between kisspeptin and saline 
study groups (Table 6). Subjects reported no side effects following injection of kisspeptin or 
saline. No significant acute changes in heart rate, systolic and diastolic blood pressure were 
observed following kisspeptin administration when compared with saline control.  
Saline had no significant effects on reproductive hormone release at any time during the 8 
week protocol of twice-weekly injections (Figure 23 A-C).  
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Figure 23. Serum reproductive hormone levels following twice-weekly saline injection 
for 8 weeks in women with HA. 
Changes in serum LH (A), FSH (B) and oestradiol E2 (C) after bolus sc injection of saline 
(n=5) on first day, and after 2, 4, 6 and 8 weeks of administration. Data is shown as mean +/- 
SEM. ** P < 0.01 vs. baseline; *** P < 0.001 vs. baseline. 
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As expected, kisspeptin-54 stimulated reproductive hormone release following administration 
on the first injection day. After 2 weeks of twice-weekly injections, LH responses following 
kisspeptin injection were significantly lower than LH responses following injection on the first 
injection day (mean maximal LH increase (IU/l): baseline, 21.5  10.7; 2 weeks, 10.0  4.3; 
P<0.001) (Figure 24 A). However, no further significant reductions in LH following injection of 
kisspeptin were observed at 4 weeks (mean maximal LH increase: 9.0  4.1 IU/l; P>0.05 vs. 
response at 2 weeks), 6 weeks (mean maximal LH increase: 8.9  3.5 IU/l; P>0.05 vs. 
response at 2 weeks) or 8 weeks (mean maximal LH increase: 7.9  4.5 IU/l; P>0.05 vs. 
response at 2 weeks) (Figure 24 A). FSH responses following kisspeptin injection changed 
in a similar manner to LH responses over the 8 week protocol (mean maximal increase in 
serum FSH following kisspeptin injection (IU/l): baseline, 6.4  3.2; 2 weeks, 2.7  0.7, 
P<0.001 vs. baseline response; 4 weeks, 2.6  0.7, P>0.05 vs. response at 2 weeks; 6 
weeks, 2.4  0.8, P>0.05 vs. response at 2 weeks; 8 weeks, 2.7  0.8, P>0.05 vs. response 
at 2 weeks) (Figure 24 B). Oestradiol responses following injection of kisspeptin were similar 
throughout the 8 week protocol of twice-weekly injections (mean maximal increase in serum 
oestradiol following kisspeptin injection (pmol/l): baseline, 44.4  19.9; 2 weeks, 39.2  14.8; 
4 weeks, 46.2  25.8; 6 weeks, 60.8  17.2; 8 weeks, 20.0  7.5) (Figure 24 C).  
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Figure 24. Serum reproductive hormone levels following twice weekly kisspeptin-54 
injection for 8 weeks in women with HA. 
Changes in serum LH (A), FSH (B) and oestradiol E2 (C) after bolus sc injection of 6.4 
nmol/kg kisspeptin-54 (n=5) on first day, and at after 2, 4, 6 and 8 weeks of administration. 
Injections were administered at 0 min. Data is shown as mean +/- SEM. ** P < 0.01, 2 weeks 
vs. day . *** P < 0.001, 2 weeks vs. baseline. 
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No significant changes in the twice-weekly basal reproductive hormone measurements were 
observed at any stage during the 8 week protocol, between subjects with HA receiving saline 
and kisspeptin injections (Table 7). No significant changes in follicle number, maximum 
follicle size, ovarian volume, or endometrial thickness were observed at any stage of the 8 
weeks protocol between subjects with HA who received kisspeptin and saline injections 
(Table 8). Although dominant follicles were observed in some subjects of both treatment 
groups, no preovulatory follicles were observed in any subject during the study. One subject 
receiving saline treatment developed a preovulatory LH surge after 8 weeks of saline 
treatment; however no subjects ovulated during the study. 
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Table 7. Comparison of basal serum reproductive hormone levels at baseline, during 
and 8 weeks of treatment with either saline or kisspeptin injections.  
Mean ± SEM basal serum hormone levels are provided for subject groups randomised to 
receive saline (n=5) or kisspeptin-54 (n=5). For each subject, baseline serum LH, FSH and 
oestradiol levels were measured at baseline, and calculated as the mean levels from 
separate blood tests performed during baseline, week 2, weeks 3-4 and weeks 5-8 of the 
study protocol.  
Hormone  Study group P value 
  Saline  
 
Kisspeptin54  
LH (iU/l) 
 
Baseline 
Week 2 
Weeks 3-4 
Weeks 5-8 
1.5 ± 0.6 
1.9 ± 0.5 
1.9 ± 0.5 
3.7 ± 2.7 
1.8 ± 0.7 
1.7 ± 0.6 
1.7 ± 0.4 
1.9 ± 0.5 
NS 
NS 
NS 
NS 
FSH (iU/l) Baseline 
Week 2 
Weeks 3-4 
Weeks 5-8 
3.7 ± 0.6 
2.8 ± 0.8 
3.1 ± 1.0 
3.2 ± 0.8 
3.4 ± 0.5 
4.5 ± 0.9 
3.1 ± 0.9 
4.3 ± 0.7 
NS 
NS 
NS 
NS  
Oestradiol 
(pmol/l) 
Baseline 
Week 2 
Weeks 3-4 
Weeks 5-8 
97 ± 13.0 
91 ± 10.0 
113 ± 33.0 
123 ± 37.0 
78 ± 9.0 
102 ± 11.0 
90 ± 8.0 
102 ± 11.0 
NS 
NS 
NS 
NS 
  
106 
 
Table 8. Summary of ultrasound parameters at baseline and throughout the 8 week 
treatment with saline or kisspeptin injections, in women with HA.  
Subjects randomised to receive saline (n=5) or kisspeptin-54 (n=5). Baseline mean values 
were calculated from results of four separate scans performed during weeks 1-4 of the study 
protocol. The change in value of each ultrasound parameter during weeks 5-6 (during 
treatment) or 7-8 (post-treatment), was based upon results of two separate scans performed 
during the respective 2 week period. Data shown as mean ± SEM. 
Characteristic  Study Group P value 
  Saline  
 
kisspeptin-54  
Ovulation (number of 
subjects) 
 
 
 
0 0 - 
Preovulatory follicle  ≥ 
18mm (no. subjects) 
 0 0 - 
Dominant follicle ≥ 
11mm (no.subjects) 
 3 6 - 
Endometrial thickness 
(mm) 
 
Weeks 1-2 
Weeks 3-4 
Weeks 5-6 
Weeks 7-8 
2.8 ± 0.1 
3.2 ± 0.4 
2.9 ± 0.3 
3.2 ± 0.7 
3.2 ± 0.5 
3.5 ± 0.4 
4.0 ± 0.5 
4.0 ± 0.5 
NS 
NS 
NS 
NS 
Ovarian volume (cm
3
) Weeks 1-2 
Weeks 3-4 
Weeks 5-6 
Weeks 7-8 
5.7 ± 1.8 
5.2 ± 1.5 
5.4 ± 1.3 
6.1 ± 1.9 
6.7 ± 2.1 
5.3 ± 1.0 
5.2 ± 0.6 
5.5 ± 0.7 
NS 
NS 
NS 
NS 
Follicle number per 
ovary 
Weeks 1-2 
Weeks 3-4 
Weeks 5-6 
Weeks 7-8 
12 ± 4.0 
11 ± 3.0 
11 ± 3.0 
9.0 ± 4.0 
13 ± 3.0 
15 ± 3.0 
16 ± 3.0 
13 ± 4.0 
NS 
NS 
NS 
NS 
Maximum follicle 
diameter (mm) 
Weeks 1-2 
Weeks 3-4 
Weeks 5-6 
Weeks 7-8 
5.0 ± 1.0 
6.5 ± 1.5 
6.0 ± 1.1 
6.3 ± 0.8 
7.0 ± 0.9 
7.8 ± 1.6 
7.3 ± 0.9 
7.3 ± 1.2 
NS 
NS 
NS 
NS 
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5. Discussion 
 
Intact kisspeptin signalling is pivotal in regulating the HPG axis and essential for 
reproductive maturation in humans (de Roux N. et al. 2003; Seminara et al. 2003). 
Kisspeptin receptor antagonists disrupt the activity of the hypothalamic-pituitary-gonadal 
(HPG) axis in adult monkeys, sheep and rodents (Roseweir et al. 2009). Hence there is a 
need to evaluate the therapeutic potential of kisspeptin. Short-term clinical studies suggest 
that kisspeptin safely stimulates reproductive hormone release; however chronic 
administration has until now been shown to cause profound tachyphylaxis in humans 
(Jayasena et al. 2009).  
The paradoxical effects of kisspeptin on reproductive hormone release has been 
demonstrated in monkeys; intermittent, hourly intracerebroventicular injections of kisspeptin-
10 to monkeys stimulates pulsatile LH release (Plant, Ramaswamy, & Dipietro 2006), 
whereas continuous icv infusion of kisspeptin-10 to monkeys leads to desensitisation of 
gonadotrophin release within 3 hours of commencement of the infusion (Ramaswamy et al. 
2007; Seminara et al. 2006). The phenomenon of desensitisation has also been 
demonstrated in rodents (Ramaswamy et al. 2007; Roa et al. 2008; Thompson et al. 2006). I 
have presented detailed data of the time-course of desensitisation to the effects of 
kisspeptin-54 on reproductive hormone release in women with HA. My data suggests that 
desensitisation of LH response to twice-daily kisspeptin-54 sc administration in women with 
HA, occurs gradually over the 14 day injection period. LH responses on the 4th injection day 
were significantly higher than on the 14th injection day. By contrast, FSH responses dropped 
to less than 3 h.IU/l after just 24 hours of twice-daily kisspeptin administration. Interestingly, 
Roa et al. showed that constant icv infusion of kisspeptin-10 to adult female cycling rats led 
to desensitisation of LH response by day 3, but desensitisation of the FSH response to 
kisspeptin took longer (Roa et al. 2008). The reason for this discrepancy between human 
and rodent FSH responses to kisspeptin is unclear. However, it is possible that icv and 
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peripherally administered kisspeptin have differential effects on gonadotrophin release. 
Furthermore, we cannot exclude that humans and rodents respond differently to kisspeptin, 
or indeed that different kisspeptin peptides (kisspeptin-54 used in our studies compared to 
kisspeptin-10 used by Roa et al. (Roa et al.2008) have differential effects on FSH release.  
In order to reduce the effect of desensitisation associated with repeated administration of 
kisspeptin (6.4 nmol/kg twice daily); I lowered the dose of sc kisspeptin injection by studying 
the effects of once-daily administration. Interestingly, once-daily 1 nmol/kg (total dose 14 
nmol/kg over 2 weeks) of kisspeptin administration still led to significant desensitisation of 
gonadotrophin responses in women with HA. I did not observe significant desensitisation 
with 0.3 nmol/kg (total dose 4.2 nmol/kg over 2 weeks) of kisspeptin. However, even on the 
first injection day, the stimulation of reproductive hormone release following 1.0 and 0.3 
nmol/kg sc kisspeptin injection was only moderate due to the reduced dose of kisspeptin 
used. Furthermore, on the 14th injection day residual LH and FSH responses following once-
daily kisspeptin injection (0.3 or 1.0 nmol/kg) and twice-daily kisspeptin injection (6.4 nmol.kg) 
were similar. Plasma kisspeptin immunoreactivity following a single subcutaneous injection 
of kisspeptin-54 persists for up to 6 hours in women with HA (Jayasena et al. 2009). My 
results therefore suggest that once-daily kisspeptin administration of kisspeptin leads to 
tachyphylaxis, even at low doses. This data suggests that either once-daily or twice-daily 
protocol of sc kisspeptin administration leads to tachyphylaxis. This has important 
implications for the future development of any kisspeptin-based endocrine therapy used to 
perform medical castration in patients with sex hormone-sensitive tumours.  
In view of the tachyphylaxis observed with once-daily administration of kisspeptin, I 
determined if lengthening the dose interval to twice-weekly would allow recovery from 
desensitisation to kisspeptin. The dose of 6.4 nmol/kg (total dose 32 nmol/kg over 2 weeks) 
kisspeptin was chosen, since acute injection of kisspeptin-54 at this dose results in  
adequate stimulation of gonadotrophin levels in women with HA (Jayasena et al. 2009). I 
performed a 2 week pilot study which suggested that gonadotrophin responses were only 
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partially diminished after twice-weekly 6.4 nmol/kgkisspeptin administration. This suggests 
that partial recovery of desensitisation of the kisspeptin receptor may have occurred during 
the interval between each injection of kisspeptin. 
In order to further assess the regime of twice-weekly 6.4 nmol/kgkisspeptin sc injection, I 
performed a longer 8 week study of its administration. As observed during the pilot study, 
this regime of kisspeptin administration still lead to partial desensitisation in gonadotrophin 
responses during the first 2 weeks of administration. However gonadotrophin responses to 
kisspeptin injection did not significantly diminish further beyond this initial 2 week period. My 
results therefore suggest that subjects with HA remained partially responsive to kisspeptin 
injection during the 8 week study period, and that some recovery from desensitisation had 
occurred between injections. Interestingly oestradiol responses to kisspeptin remained 
remarkably constant across the entire 8 week period, despite the initial reduction in pituitary 
responsiveness observed during the first 2 weeks of kisspeptin administration. It is possible 
that the initial stimulation of oestradiol secretion caused by kisspeptin administration at the 
beginning of the study, acted to further sensitise the ovaries to further gonadotrophin 
stimulation. On the other hand, it cannot be excluded that the stimulatory actions of 
kisspeptin on the ovaries are in part explained by a direct stimulatory action. Kisspeptin 
receptors are expressed on human ovaries (Gaytan et al. 2009), but no direct stimulatory 
action of kisspeptin on ovarian tissue has been reported.  
During the 8 week study of kisspeptin administration, I did not observe any significant 
changes in follicle growth when compared with saline administration. This might have 
reflected that FSH responses were lower than LH responses following kisspeptin 
administration, which is in agreement with previous data (Dhillo et al. 2005; Dhillo et al. 2007; 
Jayasena et al. 2009). Furthermore as discussed, I observed that FSH responses 
desensitised more rapidly following kisspeptin injection than LH responses. Thus, 
inadequate amplitude and duration of FSH stimulation might have accounted for the lack of 
detectable ovarian follicular growth in this study.  
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In summary, I have determined the time-course of desensitisation of LH and FSH responses 
during twice-daily administration of kisspeptin-54 in women with HA. Once or twice-daily 
administration of kisspeptin are associated with desensitisation, which may be utilised 
therapeutically in the treatment of hormone-sensitive tumours. I have also conducted the first 
long-term clinical study of kisspeptin administration. A single injection of kisspeptin still 
robustly elicits reproductive hormone release in women with HA, even after 2 months of 
twice-weekly kisspeptin-54 administration. These findings have important therapeutic 
implications; kisspeptin-54 may be a novel therapeutic tool for chronically inducing 
reproductive hormone release in HA and other conditions associated with 
hypogonadotrophic hypogonadism. 
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Chapter 4  
 
The Effects of Kisspeptin-10 on Reproductive Hormone Release Show 
Sexual Dimorphism in Humans 
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4.1 Introduction  
 
The KISS1 gene encodes a 145-amino acid precursor protein, this undergoes proteolytic 
processing to generate 54, 14, 13 and 10 amino acid sequences (Kotani et al. 2001) . These 
shorter peptides are named according to their number of constituent amino acids; they all 
share a common c terminal decapeptide sequence, which is required for in vitro biological 
activity. There have been a number of studies examining the effects of kisspeptin-10 in 
animals. These studies have demonstrated that central or peripheral administration of 
kisspeptin-10 to rodents, sheep, monkeys, hamsters, pigs and cows (Irwig et al. 2004; 
Navarro et al. 2004; Gottsch et al 2004; Messager et al. 2005; Caraty et al. 2007; Plant et al. 
2006; Ramaswamy et al. 2007; Shahab et al. 2005; (Lents et al. 2008); (Kadokawa et al. 
2008), stimulates gonadotrophin release. The stimulatory effects of kisspeptin-10 on 
gonadotrophin release are inhibited by the central administration of a GnRH antagonist.  
Studies examining the effects of kisspeptin-54 in humans have identified that kisspeptin-54 
stimulates gonadotrophin release in both healthy men and women (Dhillo et al. 2005; Dhillo 
et al. 2007). In women these effects are most pronounced in the preovulatory phase of the 
menstrual cycle (Dhillo et al. 2007). Kisspeptin-54 has also been shown to stimulate 
gonadotrophin release in women with a model of infertility due to hypothalamic amenorrhoea 
(Jayasena et al. 2009; Jayasena et al. 2010). Human male studies have demonstrated that 
an intravenous bolus injection of kisspeptin-10 potently stimulates LH secretion while a 
continuous infusion of kisspeptin-10 also increases testosterone, LH pulse frequency and 
amplitude (George et al. 2011). Administration of kisspeptin-10 appears to reset the GnRH 
pulsatile clock, by inducing an immediate LH pulse, regardless of the timing of the previous 
pulse and these pulses were on average of greater amplitude than endogenous pulses 
(Chan et al. 2011). The effects of kisspeptin-10 administration on women are not known.  
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Compared to kisspeptin-54, kisspeptin-10 has a shorter half-life and faster onset of action 
after intravenous administration in rodents (Mikkelsen et al. 2009). As kisspeptin-10 is 
simpler and cheaper to manufacture due to its shorter amino acid sequence, future 
kisspeptin based reproductive therapies may be based upon kisspeptin-10 rather than 
kisspeptin-54. It is therefore therapeutically important to determine whether kisspeptin-10 
can stimulate reproductive hormone release in healthy men and women. 
 
4.2 Hypothesis and Aim 
 
Animal models suggest that kisspeptin-10 and kisspeptin-54 act similarly to stimulate 
reproductive hormone release however, kisspeptin-10 is characterised by a shorter half-life. 
Recently it has been reported that administration of kisspeptin-10 potently stimulates LH 
pulse frequency and amplitude in healthy men (George et al. 2011). In addition kisspeptin-10 
appears to reset the GnRH pulsatile clock in men (Chan et al. 2011). There have been no 
previous studies on the effects of kisspeptin-10 on women. I hypothesise that kisspeptin-10 
will stimulate reproductive hormone release in healthy men and women in a similar fashion 
as kisspeptin-54.  
This study aimed to determine the effects of kisspeptin-10 administration on reproductive 
hormone release in healthy men and, for the first time, in healthy women. 
 
4.3 Methods 
4.3.1 Subjects 
 
This study was conducted with Ethics Committee approval (reference 08/H0707/95) in 
accordance with The Declaration of Helsinki. Recruitment was via advertisements in the 
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local press. Full written informed consent was obtained from all subjects, 25 healthy female 
volunteers and 11 male volunteers were recruited after medical screening (Table 9). 
Recruitment involved a clinical history, clinical examination, electrocardiogram, and blood 
tests (full blood count, renal profile, liver and bone profile, thyroid profile, random glucose, 
prolactin, gonadotrophins and sex hormone profile). Men and women were included in the 
study if they fulfilled the following criteria; age 18 to 40 years; no clinical or biochemical 
evidence of hypogonadism, thyroid dysfunction or hyperprolactinemia; no therapeutic or 
recreational drug use; no systemic disease co-morbidity. Additional inclusion criteria for 
women were as follows: regular menstrual cycles; no oral contraceptive pill therapy within 
the last year; no clinical or biochemical evidence of polycystic ovarian syndrome. 
4.3.2 Kisspeptin-10 and -54 peptide synthesis 
 
Human sequence kisspeptin-54 peptide was synthesised by Advanced Biotechnology 
Centre, Imperial College London. Human sequence kisspeptin-10 was synthesised by 
Bachem Holding AG (Bubendorf, Switzerland). Both peptides were purified by reverse-phase 
High Performance Liquid Chromatography (HPLC). Electrospray mass spectroscopy and 
amino acid analysis confirmed identity of the peptide. Toxicology testing in animals was 
conducted prior to administration to human volunteers. The Limulus amoebocyte lysate test 
(LAL) detected no endotoxin (Associates of Cape Cod, Liverpool, UK), and bacterial culture 
was sterile (Department of Microbiology, Hammersmith Hospital, London, UK), in samples of 
kisspeptin-10 and kisspeptin-54 peptide. Vials of freeze-dried kisspeptin-10 and kisspeptin-
54 were stored at minus 20oC and reconstituted in 0.9% saline. 
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4.3.3 Study Days 
 
Subjects were admitted to our clinical investigation unit and asked to lay supine for the 
duration of each study. Urine was tested to exclude pregnancy in women (Clearview Easy-
HCG; Inverness Medical Innovations Inc. Waltham, MA). All blood samples were analysed 
for measurement of serum LH, FSH, oestradiol, testosterone, and plasma kisspeptin 
immunoreactivity (IR). Serum and plasma samples were stored at -20oC until analysis. Heart 
rate, blood pressure, and the presence of any symptoms were recorded at regular intervals 
(10-15 minutes). Women in the follicular phase of their menstrual cycle were studied 
between days 2-10 of their cycle. Women in the preovulatory phase were studied 15-16 days 
before the start of their next menstrual cycle.  
4.3.4 Serum reproductive hormone measurement 
 
Blood samples for serum LH, FSH and oestradiol analysis were collected in plain serum 
vacutainer tubes (Beckton Dickson, Franklin Lakes, NJ, USA). Samples were allowed to clot 
prior to centrifugation and separation of serum. Serum samples were stored at -200C until 
analysis. LH, FSH, oestradiol and total testosterone were measured using automated 
chemiluminescent immunoassays (Abbott Laboratories, Abbott Park, IL). Reference ranges 
for males were as follows: LH, 4–14 IU/l; FSH, 1.5–8 IU/l; testosterone, 10–28 nmol/l. 
Reference ranges for females were as follows: LH 2–10 IU/L follicular, 20–60 IU/L midcycle, 
4–14 IU/L luteal; FSH 10-50 IU/L, mid-cycle, 1.5–8 IU/L, follicular and luteal; oestradiol <300 
pmol/L early follicular, 400-1500 pmol/L midcycle, 200-1000 pmol/L luteal. The respective 
intra- and inter-assay coefficients of variation for each assay were: LH 4.1% and 2.7%; FSH 
4.1% and 3.0%; oestradiol 3.3% and 3.0%; total testosterone 4.2% and 2.8%. Analytical 
sensitivities were: LH 0.5 IU/l, FSH 0.05 IU/l; oestradiol 37 pmol/l; total testosterone 2 nmol/l. 
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4.3.5 Kisspeptin measurement 
 
Blood samples for plasma kisspeptin analysis were collected in lithium heparin tubes 
(Beckton Dickson, Franklin Lakes, NJ, USA) containing 5000 kallikrein inhibitor units of 
aprotinin (0.2ml Trasylol; Bayer, Newbury, UK). Samples were immediately centrifuged at 
room temperature using a Hettich EBA 20 machine (Hettich International, Tuttlingen, 
Germany) for 10 minutes at 3000rpm, and then separated. Plasma samples were stored at 
minus 20OC until analysis. Plasma kisspeptin immunoreactivity (IR) was measured using an 
in house radioimmunoassay. Antibody GQ2 was raised in sheep immunised with synthetic 
human kisspeptin-54 (Bachem UK Ltd.) conjugated to bovine serum albumin (BSA) by 
glutaraldehyde and used at a final dilution of 1:3,500,000. The antibody cross-reacted 100% 
with human kisspeptin-54, kisspeptin-14, and kisspeptin-10 and less than 0.01% with other 
related RF amide proteins, including prolactin-releasing peptide, RF amide-related peptide 1 
(RFRP1, human and rat), RFRP2 (human), RFRP3 (human), QRFP43 (human), 
neuropeptide FF (human), and neuropeptide AF (human). The iodogen method was used to 
prepare the 125I-kisspeptin-54 label, which was subsequently purified by High Performance 
Liquid Chromatography (Salacinski et al. 1981). The assay was carried out in duplicate using 
dilutions of neat plasma in 0.7ml of 0.06M phosphate buffer (pH 7.2) containing 0.3% BSA. 
Incubation was for 3 days at 4oC. Subsequently free and antibody-bound label were 
separated by charcoal adsorption. The limit of detection was 2 pmol/l of plasma kisspeptin 
with 95% confidence interval, and the intra- and interassay coefficients of variation were 8.3% 
and 10.2%, respectively.  
 
 
 
 
117 
 
4.3.6 Study 1: The effects of intravenous bolus injection of saline or kisspeptin-10 in 
healthy male volunteers on plasma kisspeptin IR and reproductive hormones 
 
Intravenous bolus injection of 0.9% saline or kisspeptin-10 (at doses 0.3, 1.0, 3.0, or 10 
nmol/kg) was administered at time 0 min. For all studies the intravenous bolus was given via 
a cannulated antecubital vein over 10 seconds and subsequently flushed with 10ml of 0.9% 
saline. Blood samples were taken at -30, 0, 10, 20, 30, 40, 50, 60, 75, 90, 120, 150, and 180 
minutes for measurement of serum reproductive hormones and plasma kisspeptin IR (n=4-5 
per group). 
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4.3.7 Study 2: Effects of intravenous bolus injection of saline, kisspeptin-10 or 
kisspeptin-54 in healthy female volunteers 
 
A: Follicular phase of the menstrual cycle 
Women between day 2-10 of their menstrual cycle were administered an intravenous bolus 
injection of 0.9% saline, or kisspeptin-10 (at doses 1.0, 3.0, or 10 nmol/kg), or kisspeptin-54 
(1.0 nmol/kg) at time 0 min, and blood samples were taken at -30, 0, 10, 20, 30, 40, 50, 60, 
75, 90, 120, 150, and 180 min (n=4-5 per group). 
B: Preovulatory phase of the menstrual cycle 
Women 15-16 days before their next predicted period received intravenous bolus injection of 
10 nmol/kg kisspeptin-10 as described for the follicular phase study above (n=5). 
 
4.3.8 Study 3: Effects of subcutaneous bolus injection of saline or kisspeptin-10 on 
plasma kisspeptin-IR and serum reproductive hormones in healthy female volunteers 
in the follicular phase of menstrual cycle  
 
Subjects in the follicular phase of menstrual cycle were admitted to our clinical investigation 
unit. Kisspeptin-10 (at doses of 2, 4, 8, 16, or 32 nmol/kg) or 0.9% saline were 
subcutaneously administered at time 0 minutes, and blood samples taken at -30, 0, 15, 30, 
45, 60, 75, 90, 120, 150, 180, 210 and 240 minutes for measurement of serum LH, FSH 
oestradiol and plasma kisspeptin immunoreactivity (IR) (n=4-5 per group). 
 
4.3.9 Study 4: Effects of intravenous infusion of saline or kisspeptin-10 on plasma 
kisspeptin-IR and serum reproductive hormones in healthy female volunteers  
 
Subjects in the follicular phase of menstrual cycle were admitted to our Clinical Investigation 
Unit. Kisspeptin-10 was dissolved in saline containing gelofusine (5% vol/vol) (Braun Medical, 
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Sheffield, UK) to minimize peptide adsorption to the infusion system (Kraegen et al. 1975) 
and was infused over 90 minutes. During the first 30 minutes of infusion, the volunteers were 
infused with 20, 50, 90, 180, 360 or 720 pmol/kg/min. The infusion rate for each volunteer 
was then halved for the remaining 60 min of each infusion. This dosing regimen was 
designed to achieve a steady-state concentration of serum kisspeptin during the infusion 
period (Dhillo et al. 2005a;Edwards et al. 1999). Blood samples were taken at -30, 0, 15, 30, 
45, 60, 75, 90, 120, 150, 180, 210 and 240 minutes for measurement of serum LH, FSH 
oestradiol and plasma kisspeptin IR. 
4.3.9.1 Study 5: Pharmacokinetic profile of kisspeptin-IR during intravenous infusion 
of kisspeptin-10 
 
To determine the plasma half-life of kisspeptin-10 in men, and in women during the follicular 
and preovulatory phases of the menstrual cycle, frequent blood sampling was performed 
during intravenous infusion of 360 pmol/kg/min of kisspeptin-10. Detailed blood sampling 
was performed at 1 minutely (from 91-100 min) and 2 minutely (from 102-120 min) intervals 
immediately after stopping the kisspeptin-10 infusion (at time 90 min). Blood samples were 
assayed for plasma kisspeptin IR. The linear regression line of natural log plasma kisspeptin 
IR was used to calculate the half-time of disappearance (t1/2) for infused kisspeptin-10 in 
healthy males and females. 
 
4.3.9.2 Data Analysis 
 
Data are presented as mean ± SEM. Area under the curve (AUC) was calculated to provide 
a cumulative measure of kisspeptin/reproductive hormone change throughout the time 
course of the study. Time profiles of hormone levels were compared using two-way ANOVA 
with Bonferroni's multiple comparison test. Pairs of means were compared with unpaired t 
tests, and multiple means of AUC reproductive hormone release were compared using one-
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way ANOVA with Bonferonni's multiple comparison test. Slopes of linear regression lines 
were compared using an F test. Half-lives were calculated using natural log 2/gradient of 
linear regression line and compared using one-way ANOVA with Bonferonni‟s multiple 
comparison test. For all statistical tests, P < 0.05 was considered statistically significant. All 
data of serum reproductive hormones during treatment are presented as increases in serum 
levels after injection when compared with pre-injection level. 
4.4 Results 
 
Baseline characteristics of the subjects recruited after medical screening are summarised in 
table 9 below. There was no significant difference in age or body mass index (BMI) between 
the male and female volunteers. In accordance with normal physiology circulating levels of 
LH, FSH, and oestradiol were significantly higher in the preovulatory phase of the menstrual 
cycle in females. 
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Table 9. Baseline characteristics of healthy male and female volunteers recruited to 
the study.  
Data are shown as mean ± SEM. 
Baseline 
Characteristic 
Healthy male 
volunteers 
(n=11) 
Healthy female 
volunteers 
(n=15) 
 
Age (yr) 28.8 ± 2.1 31.8 ± 1.4 P = 0.23 
BMI (kg/m2) 24.5 ± 0.5 22.6 ± 0.8 P = 0.09 
Length of menstrual 
cycle (d) 
 28 ± 0.3  
LH (iU/l) 
  Follicular 
  Preovulatory 
2.9 ± 0.2  
3.9 ± 0.4 
28.0 ± 4.5a 
 
 
FSH (iU/l) 
  Follicular 
  Preovulatory 
2.6 ± 0.2  
3.8 ± 0.4 
9.8 ± 0.9a 
 
Testosterone (nmol/l) 21.6 ± 1.5   
Oestradiol (pmol/l) 
  Follicular 
  Preovulatory 
  
228 ± 53 
726 ± 71b 
 
 
a P < 0.0001 vs. follicular phase of the menstrual cycle 
b P < 0.001 vs. follicular phase of the menstrual cycle 
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4.4.1 Study 1: Effects of IV bolus injection of saline or kisspeptin-10 in healthy male 
volunteers 
 
Subjects reported no side effects following injection of kisspeptin-10 or saline. No significant 
changes in heart rate, or blood pressure were observed following kisspeptin-10 
administration. Levels of plasma kisspeptin-IR were undetectable following saline injection. 
The plasma kisspeptin IR was elevated after intravenous bolus injection of kisspeptin-10 at 
all doses in healthy male volunteers (Figure 25 A, B). The peak occurred for all doses at 10 
minutes after injection and was statistically significant (vs. saline) for 3 and 10 nmol/kg of 
kisspeptin-10 (Figure 25 A). Subsequently plasma kisspeptin IR returned to undetectable 
levels 50 minutes after injection. The highest plasma kisspeptin-IR was observed following 
intravenous bolus injection of 10 nmol/kg kisspeptin-10 (mean AUC kisspeptin-IR: 700  160 
h.pmol/l, P<0.001 vs. saline) (figure 25 B). At this dose, mean peak kisspeptin-IR (3350  
725 pmol/l) was observed 10 min post injection.   
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Figure 25. Plasma kisspeptin levels post intravenous bolus of saline or kisspeptin-10 
in healthy men. 
Plasma kisspeptin IR (A) after intravenous bolus injection of saline or 0.3, 1, 3, 10 nmol/kg 
kisspeptin-10. For 10 nmol/kg vs. saline: P<0.001. For 3 nmol/kg vs. saline: P<0.001. Mean 
kisspeptin IR AUC (B) post-intravenous injection of saline, 0.3, 1, 3, 10 nmol/kg kisspeptin-
10 over the 180 min timecourse. *, P<0.05; **, P<0.01; ***, P<0.001.  
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Serum LH was significantly elevated after administration of each tested dose of intravenous 
bolus kisspeptin-10 compared with saline (Figure 26 A, B) from 20-120 minutes. Peak 
stimulation of serum LH was observed 30-50 min after injection which was 20-40 minutes 
after peak plasma kisspeptin IR. Thereafter serum LH levels returned to baseline 180 min 
after injection (Figure 26 A). Maximal stimulation of LH was observed after intravenous bolus 
of 10 nmol/kg kisspeptin-10 (mean AUC LH increase was 5.3 ± 1.2 h.IU/l, P<0.001 vs. 
saline), although there was significant increase for all doses (Figure 26 B). 
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Figure 26. Serum LH levels following intravenous bolus administration of saline or 
kisspeptin-10 in healthy men.  
LH increase (A) after IVB injection of saline or 0.3, 1, 3, 10 nmol/kg kisspeptin-10. For 0.3 
nmol/kg vs. saline: α, P<0.05; ααα, P<0.001. For 1 nmol/kg vs. saline: β, P <0.05; ββ, 
P<0.01; βββ, P<0.001. For 3 nmol/kg vs. saline: γγ, P<0.01; γγγ, P<0.001. For 10 nmol/kg 
vs. saline: δ, P < 0.05; δδ, P < 0.01, δδδ, P < 0.001. Mean serum LH increase AUC (B) for 
saline, 0.3, 1, 3, 10 nmol/kg kisspeptin-10 post-intravenous bolus. *, P<0.05; **, P<0.01; ***, 
P<0.001. 
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Serum FSH was significantly increased compared with saline injection after intravenous 
bolus injection of 0.3 and 3.0 nmol/kg kisspeptin-10 (Figure 27 A, B) up to 90 minutes after 
injection. Peak FSH stimulation occurred slightly later than for LH, between 40-150 minutes 
after injection depending on dose (Figure 27 A). Maximal stimulation of FSH was observed 
after intravenous bolus of the smallest dose, 0.3 nmol/kg kisspeptin-10 (mean AUC FSH 
increase was 1.2 ± 0.5 h.iU/l, P<0.05 vs. saline), although significant stimulation was also 
seen at 3 nmol/kg (Figure 27 B). 
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Figure 27. Serum FSH levels following intravenous bolus (IVB) administration of 
saline or kisspeptin-10 in healthy men. 
Serum FSH (A) after IVB of saline or 0.3, 1, 3, 10 nmol/kg kisspeptin-10. For 0.3 nmol/kg vs. 
saline: α, P<0.05; αα, P<0.01; ααα, P<0.001. For 3 nmol/kg vs. saline: γ, P<0.05; γγ, P<0.01; 
γγγ, P<0.001. Mean serum FSH increase AUC (B) for saline, 0.3, 1, 3, 10 nmol/kg 
kisspeptin-10 over the 180 min post-intravenous bolus. *, P<0.05; **, P<0.01; ***, P<0.001. 
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Serum testosterone AUC was significantly increased compared with saline injection after 
intravenous bolus injection of 1.0 nmol/kg kisspeptin-10 (Figures 28 B). Serum levels of 
testosterone at this dose steadily increased to peak levels 150-180 min after injection 
(Figure 28 A). 
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Figure 28 Serum testosterone levels following intravenous bolus (IVB) administration 
of saline or kisspeptin-10 in healthy men. 
Serum Testosterone (A) after IVB of saline or 0.3, 1, 3, 10 nmol/kg kisspeptin-10. For 0.3 
nmol/kg vs. saline: α, P<0.05. For 1 nmol/kg vs. saline: β, P <0.05; ββ, P<0.01. For 10 
nmol/kg vs. saline: δ, P<0.05. Mean serum FSH increase AUC (B) for saline, 0.3, 1, 3, 10 
nmol/kg kisspeptin-10 over the 180 min post-intravenous bolus. *, P<0.05; **, P<0.01; ***, 
P<0.001. 
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4.4.2 Study 2: Effects of intravenous bolus injection of saline, kisspeptin-10 or 
kisspeptin-54 in healthy female volunteers 
 
A: Follicular phase of the menstrual cycle 
 
The plasma kisspeptin IR was elevated after intravenous bolus injection of kisspeptin-10 at 
all doses in healthy female volunteers during the follicular phase of the menstrual cycle 
(Figure 29 A, B). The highest plasma kisspeptin IR was observed after intravenous bolus 
injection of 10 nmol/kg kisspeptin-10 (mean AUC kisspeptin in healthy females during the 
follicular phase was 527 ± 108 h.pmol/l, P < 0.001 vs. saline). Although this was lower when 
compared with kisspeptin IR after the same dose of kisspeptin-10 to men (700 ± 160 h.pmol/l 
for men), this difference was not statistically significant (P = 0.42 vs. men). At the dose of 10 
nmol/kg kisspeptin-10, mean peak kisspeptin IR (2638 ± 302 pmol/l) was observed 10 min 
after injection. Plasma kisspeptin IR subsequently returned to undetectable levels 50 min 
after injection (Fig 29 A).  
Kisspeptin-54 was also administered as an IV bolus in this study as a positive control as 
previous work has demonstrated that it stimulates reproductive hormones in females. Peak 
kisspeptin IR occurred 30-40 minutes after injection of kisspeptin-54 in contrast to 
kisspeptin-10 which peaked at 10 minutes after injection (Figure 29 A). 
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Figure 29 Plasma kisspeptin levels following intravenous bolus (IVB) administration of 
saline or kisspeptin-10 in healthy women. 
Plasma kisspeptin IR (A) after IVB of saline, 1, 3, 10 nmol/kg kisspeptin-10 and 1 nmol/kg 
kisspeptin-54 in follicular or preovulatory phase. For 3 nmol/kg vs. saline: φφφ, P<0.001. For 
10 nmol/kg follicular vs. saline: λλλ, P<0.001. For 10 nmol/kg preovulatory vs. saline: µµµ, 
P<0.001. For kisspeptin-54 (1nmol/kg) vs. saline: ϴ, P<0.05; ϴϴϴ, P<0.001. Mean kisspeptin 
IR AUC (B) for saline, 1, 3, 10 nmol/kg kisspeptin-10 and 1 nmol/kg kisspeptin-54 post-
intravenous bolus in follicular and preovulatory phase. *, P<0.05; **, P<0.01; ***, P<0.001. 
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Unlike in the male study, no significant changes in serum LH, FSH or oestradiol were 
observed after intravenous bolus injection of kisspeptin-10 at all doses tested in the follicular 
phase (Figures 30, 31, 32). However mean LH and FSH AUC were significantly elevated 
after intravenous bolus injection of 1 nmol/kg of kisspeptin-54 (Figures 30, 31). 
B: Preovulatory phase of the menstrual cycle 
 
Kisspeptin IR was significantly elevated in women during the preovulatory phase after 
kisspeptin-10 injection compared with saline. This elevation was not significantly different 
when compared with kisspeptin IR after the same dose of kisspeptin-10 in follicular phase 
women or men (mean AUC kisspeptin IR in preovulatory phase was 320 ± 56 h.pmol/l, P = 
0.13 vs. follicular phase and P = 0.06 vs. men) (Figure 29). 
Serum LH and FSH were both significantly elevated after intravenous bolus injection of 10 
nmol/kg kisspeptin-10 in female volunteers during the preovulatory phase of the menstrual 
cycle (mean AUC increase was 30.4 ± 11.1 h.iU/l (LH), P < 0.05 vs. saline, and 6.9 ± 0.9 
h.iU/l (FSH), P < 0.01 vs. saline) (Figures 30, 31). This was in contrast to the lack of 
response seen in the follicular phase. Peak LH and FSH stimulation occurred 40 minutes 
after injection of kisspeptin-10 with significant elevation maintained until 75 minutes (Figures 
30, 31). 
Serum oestradiol, however, was not altered significantly by kisspeptin-10 in the preovulatory 
phase (mean AUC oestradiol increase was 111 ± 96 h/pmol/l, P =0.13 vs. saline) (Figure 32).  
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Figure 30. Serum LH levels following intravenous bolus (IVB) administration of saline 
or kisspeptin-10 in healthy women. 
Serum LH (A) after intravenous bolus injection of saline, 1, 3, 10 nmol/kg kisspeptin-10 and 
1 nmol/kg kisspeptin-54 in follicular or preovulatory phase. For 10 nmol/kg preovulatory vs. 
saline: µµ, P<0.01; µµµ, P<0.001. Mean serum LH AUC (B) for saline, 1, 3, 10 nmol/kg 
kisspeptin-10 and 1 nmol/kg kisspeptin-54 over the 180 min timecourse post-intravenous 
bolus in follicular and preovulatory phase. *, P<0.05; **, P<0.01; ***, P<0.001.  
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Figure 31. Serum FSH levels following intravenous bolus (IVB) administration of 
saline or kisspeptin-10 in healthy women.  
Serum FSH increase (A) after IVB of saline, 1, 3, 10 nmol/kg kisspeptin-10 and 1 nmol/kg 
kisspeptin-54 in follicular or preovulatory phase. For 10 nmol/kg preovulatory vs. saline: µ, 
P<0.05; µµ, P<0.01; µµµ, P<0.001. Mean serum FSH AUC (B) for saline, 1, 3, 10 nmol/kg 
kisspeptin-10 and 1 nmol/kg kisspeptin-54 post-intravenous bolus in follicular and 
preovulatory phase. *, P<0.05; **, P<0.01; ***, P<0.001. 
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Figure 32. Serum oestradiol levels following intravenous bolus (IVB) administration of 
saline or kisspeptin-10 in healthy women. 
Serum oestradiol increase (A) after IVB injection of saline, 1, 3, 10 nmol/kg kisspeptin-10 
and 1 nmol/kg kisspeptin-54 in follicular or preovulatory phase. Mean serum oestradiol AUC 
(B) for saline, 1, 3, 10 nmol/kg kisspeptin-10 and 1 nmol/kg kisspeptin-54 post-intravenous 
bolus in follicular and preovulatory phase. 
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4.4.3 Study 3: Effects of subcutaneous bolus injection of saline or kisspeptin-10 on 
plasma kisspeptin-IR and serum reproductive hormones in healthy female volunteers 
 
Subjects reported no side effects following subcutaneous injection of kisspeptin-10 or saline. 
No significant changes in heart rate, systolic or diastolic blood pressure were observed 
following kisspeptin-10 administration. Plasma kisspeptin-IR in healthy female volunteers 
was significantly raised during the 4 hours following subcutaneous (sc) injection of 
kisspeptin-10 at doses of 4 nmol/kg and higher, when compared with saline (Figure 33 A, B). 
Progressively higher plasma kisspeptin-IR was observed with each increment in sc dose of 
kissppeptin-10 injection. The highest plasma kisspeptin-IR following sc injection was 
observed following injection of 32 nmol/kg kisspeptin-10 (mean AUC kisspeptin-IR, 201  
16h.pmol/l, P<0.001 vs. saline). No significant changes in serum reproductive hormone 
levels were observed following sc bolus injection of kisspeptin-10 at any dose (Figure 34 A-
D).  
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Figure 33. Plasma kisspeptin immunoreactivity (IR) following subcutaneous bolus (sc) 
injection of kisspeptin-10 to healthy women.  
Time profiles (A) and area under curve AUC for plasma kisspeptin IR (B) during 4 hours after 
sc bolus injection of saline or kisspeptin-10 (n=4-5 per group). Data is shown as mean +/- 
SEM. *P<0.05; **P<0.01; ***P < 0.001 
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Figure 34. Serum reproductive hormone levels following subcutaneous bolus 
injection of kisspeptin-10 to healthy women.  
Time profiles and area under curve (AUC) changes in serum LH (A, B) and FSH (C, D) 
during 4 hours after sc bolus injection of saline or kisspeptin-10 (n=4-5 per group). Data is 
shown as mean +/- SEM. *P<0.05; **P<0.01; ***P < 0.001 
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4.4.4 Study 4: Effects of intravenous infusion of kisspeptin-10 on plasma kisspeptin-IR 
and serum reproductive hormones in healthy female volunteers 
 
Ninety minute intravenous infusions of kisspeptin-10 were administered to healthy female 
volunteers in the follicular phase of menstrual cycle at doses 20, 50, 90, 180, 360 or 720 
pmol/kg/min. Subjects reported no side effects during infusion of kisspeptin-10. No 
significant changes in heart rate, systolic or diastolic blood pressure were observed during 
kisspeptin-10 infusion. Plasma kisspeptin-IR increased during intravenous infusion of 
kisspeptin-10 at all doses (Figure 35 A). The highest plasma kisspeptin-IR was observed 
during intravenous infusion of 720 pmol/kg/min kisspeptin-10 (mean AUC kisspeptin-IR, 
2518  100 h.pmol/l). All intravenous infusion doses of kisspeptin-10 were associated with a 
higher mean plasma kisspeptin-IR than the highest studied sc dose of kisspeptin-10 (32 
nmol/kg, mean AUC kisspeptin-IR 201  16 h.pmol/l) (figure 35 B). No significant changes in 
serum reproductive hormone levels were observed for any dose of kisspeptin-10 infusion, in 
healthy female volunteers in the follicular phase of menstrual cycle (Figure 36 A-C).  
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Figure 35. Plasma kisspeptin immunoreactivity (IR) during a 90 minute intravenous 
infusion of kisspeptin-10 to healthy women.  
Time profiles (A) and area under curve AUC (B) for plasma kisspeptin IR. Data is shown as 
mean +/- SEM *P<0.05; **P<0.01; ***P < 0.001 
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Figure 36. Serum reproductive hormone levels during intravenous infusion of 
kisspeptin-10 to healthy women. 
Area under the curve AUC changes in serum LH (A), FSH (B) and oestradiol E2 (C) during 4 
hours after commencement of a 90 minute intravenous infusion of kisspeptin-10 in the 
follicular phase of menstrual cycle (n=4-5 per group). Data is shown as mean +/- SEM. **P < 
0.01; ***P < 0.001. 
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4.4.5 Study 5: Pharmacokinetic profile of kisspeptin-IR during intravenous infusion of 
kisspeptin-10 
 
To determine the plasma half-life of kisspeptin-10, detailed blood sampling was performed in 
men and women during the follicular and preovulatory phases of the menstrual cycle, during 
the 4 hours after commencing an intravenous infusion of 360 pmol/kg/min of kisspeptin-10. 
Peak mean kisspeptin-IR was observed 30 minutes after commencing kisspeptin-10 infusion 
(1088  243 pmol/l). Plasma kisspeptin-IR fell rapidly nearly ten-fold within 30 minutes of 
cessation of the kisspeptin-10 infusion (Figures 37, 38). The plasma half-life of kisspeptin-10 
was calculated to be 3.3 minutes. During the infusion males had higher plasma kisspeptin IR 
than females in both the follicular and preovulatory phases.  
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Figure 37. Plasma kisspeptin IR before, during and after a 90 minute infusion of 360 
pmol/kg/min kisspeptin-10.  
Blood was sampled every 1 min between 90-100 min and then every 2 min between 100-
120 min. For men vs. women during the follicular phase: ψ, P<0.05; ψψ, P<0.01; ψψψ, 
P<0.001. For men vs. women during the preovulatory phase: ω, P<0.05;  ωωω, P<0.001. 
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When plotted on a natural log scale, linear regression slopes were not significantly different 
among the three groups (F = 0.013; Degrees of Freedom = 2; Degrees of Freedom 
denominator = 137; P = 0.88). Plasma half-lives of kisspeptin-10 were calculated using these 
regression slopes and were also statistically similar between all three groups: male, 4.62 ± 
0.34 min; female follicular phase 4.72 ± 0.43 min; female preovulatory phase 4.40 ± 0.34 min 
(Fig 38). 
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Figure 38. Natural Logarithm kisspeptin IR against time immediately after cessation of 
a 90 minute infusion of 360 pmol/kg/min kisspeptin-10. 
Vertical detached lines indicate calculated half-lives for females in the follicular and 
preovulatory phase and males. 
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5. Discussion 
 
This study reveals a previously unknown sexual dimorphism in responsiveness to kisspeptin-
10, by intravenous bolus injection in healthy men and women. Numerous studies in various 
male and female animal species have demonstrated that kisspeptin-10 robustly stimulates 
gonadotrophin release. Thus kisspeptin signalling is a potential therapeutic target for treating 
reproductive disorders (Arreguin-Arevalo et al. 2007; Caraty et al. 2007; Irwig et al. 2004; 
Kadokawa et al. 2008; Lents et al. 2008; Navarro et al. 2004; Plant et al. 2006; Ramaswamy 
et al. 2007; Shahab et al. 2005). Studies on the effects of kisspeptin 10 on male primate 
models have demonstrated gonadotrophin stimulation (Plant et al. 2006; Ramaesh et al. 
2010; Shahab et al. 2005). Central administration of kisspeptin10 into the stalk median 
eminence/medial basal hypothalamus stimulates release of GnRH (Keen et al. 2008; 
Roseweir et al. 2009). Two studies on the effects of kisspeptin-10 on healthy men have also 
demonstrated that kisspeptin-10 stimulates gonadotrophin release (Chan et al. 2011; 
George et al. 2011). A recent study in pubertal and prepubertal female monkeys has 
demonstrated that central administration of kisspeptin-10 stimulated GnRH release in both 
groups in a dose dependent fashion (Guerriero et al. 2012).  
I observed that an intravenous bolus injection of kisspeptin-10 significantly stimulated LH 
release in healthy men at all doses tested. These results are consistent with previous reports 
on the effects of the administration of kisspeptin-54 (Dhillo et al. 2005) and kisspeptin-10 
(Chan et al. 2011; George et al. 2011) on the HPG axis in healthy men. 
I noted that intravenous bolus doses of kisspeptin-10 ranging from 0.3 – 10 nmol/kg were 
associated with similar degrees of gonadotrophin secretion in healthy male subjects. George 
et al. report that peripheral intravenous administration of kisspeptin-10, stimulates serum LH 
secretion at doses as low as 0.01 μg/kg with a maximal response seen at 1 μg/kg (George et 
al. 2011). Therefore, the doses of kisspeptin-10 selected during my study may have 
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stimulated near-maximal levels of gonadotrophin secretion in healthy men. Tachyphylaxis 
was noted in the George at al study; with increases in serum LH at higher kisspeptin doses 
of 3 μg/kg being lower than those stimulated by 1 μg/kg of kisspeptin-10 (George et al. 2011). 
This is consistent with previous reports of tachyphylaxis occurring in women after chronic 
kisspeptin-54 injections (Jayasena et al. 2009). Thus, the similarity between LH responses at 
all doses between 0.3 and 10 nmol/kg kisspeptin-10 in men might be explained in part by 
tachyphylaxis to kisspeptin-10 at the higher tested doses. Additional studies are required to 
investigate these observations.  
Surprisingly, intravenous bolus injection of kisspeptin-10 failed to stimulate reproductive 
hormone release in healthy female volunteers during the follicular phase of menstrual cycle. 
Plasma kisspeptin IR was raised for only 40 min following intravenous bolus injection of 
kisspeptin-10 to male and female volunteers. Our previous clinical studies suggest that sc 
bolus injection of kisspeptin-54 raises kisspeptin IR for a longer period of time when 
compared with intravenous administration of kisspeptin-54. I therefore studied the effects of 
sc bolus injection of kisspeptin-10 in order to determine if a more sustained exposure to 
exogenous kisspeptin-10 would stimulate reproductive hormone release in healthy women. 
Despite elevations in plasma kisspeptin IR for up to 90 min post-injection, serum 
gonadotrophin levels were not elevated following sc bolus injection of kisspeptin-10 in 
healthy women in the follicular phase of menstrual cycle.  
In order to study the effects of sustained, high dose kisspeptin-10 administration on 
reproductive hormone release, I then administered intravenous infusions of kisspeptin-10 to 
healthy women. Despite markedly raised plasma levels of kisspeptin IR up to 2000pmol/l, 
serum gonadotrophin levels were not elevated during intravenous infusion of kisspeptin-10 
to healthy female volunteers in the follicular phase of menstrual cycle. Our data therefore 
suggest that intravenous bolus injection, subcutaneous bolus injection, or intravenous 
infusion of kisspeptin-10 fails to stimulate gonadotrophin release in healthy women during 
the follicular phase of menstrual cycle, at the doses tested in this study. This is the first study 
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to investigate the effects of kisspeptin-10 in women. This study demonstrates that women in 
the follicular phase of menstrual cycle are less responsive to kisspeptin-10 administration 
than men.  
Only a marginal elevation of plasma kisspeptin IR (approximately 10 h.pmol/l) was 
necessary to stimulate significant LH secretion in men after injection of kisspeptin-10 (0.3 
nmol/kg iv bolus); by contrast, a 50-fold greater elevation in plasma kisspeptin IR failed to 
stimulate LH release in women given the high dose 10 nmol/kg kisspeptin-10 during the 
follicular phase. Furthermore the doses used in the study produced similar cumulative 
plasma kisspeptin-IR in both males and females (P = 0.42 for 10 nmol/kg kisspeptin-10 in 
men vs. women). It may be expected, therefore that levels of kisspeptin-10 may have been 
modified by factors known to differ between the sexes, such as body fat content or clearance 
of the peptide from the plasma (Soldin, Chung, & Mattison 2011). However this study also 
demonstrated no differences in plasma half-life and linear regression gradient for kisspeptin-
10 in males and females.  
Consistent with our previous studies, (Dhillo 2007, Jayasena et al. 2009, Jayasena 2010) 
kisspeptin-54 was able to significantly stimulate LH and FSH increases in women. Previous 
studies have suggested that kisspeptin 54 has a higher in vivo potency for stimulating the 
kisspeptin receptor. Jayasena et al. reported an increased potency of kisspeptin-54 over 
kisspeptin-10 (Jayasena et al. 2011) for stimulating LH in female adult rats. It has also been 
previously described that kisspeptin-52 (Irwig et al. 2004) and kisspeptin-54 (Thompson et al. 
2004) stimulate LH more potently when compared with kisspeptin10 in male rats. Therefore 
our findings may be explained by an increased potency of kisspeptin 54 compared to 
kisspeptin 10. However, a ten-fold increase in molar dose for kisspeptin-10 compared to 
kisspeptin-54 still failed to stimulate reproductive hormone release in women in the follicular 
phase on the menstrual cycle in this study. 
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This difference between kisspeptin-10 and kisspeptin-54 on gonadotrophin release may be a 
consequence of rapid breakdown of kisspeptin-10 in the circulation. Indeed the in vivo 
plasma half-life of iv kisspeptin-10 in this study was calculated as approximately 4 minutes, 
which is 7-fold shorter than the calculated in vivo plasma half-life of kisspeptin-54; which is 
28 minutes (Dhillo et al. 2005). It is possible that the kisspeptin receptor requires a 
prolonged exposure to raised plasma kisspeptin levels for activation. However, the 
administration of a subcutaneous dose of kisspeptin 10 or a 90 minute infusion of kisspeptin-
10; which resulted in a similar time-profile of plasma kisspeptin IR as that seen with 
kisspeptin-54, also failed to cause reproductive hormone stimulation. 
Women in the preovulatory phase of the menstrual cycle are known to be significantly more 
sensitive to the effects of kisspeptin-54 on gonadotrophin release when compared with 
women in the follicular phase of the menstrual cycle (Dhillo et al. 2007). In keeping with this 
observation, an intravenous bolus injection of kisspeptin-10 significantly stimulated LH and 
FSH release in women during the preovulatory phase of the menstrual cycle in this study. As 
the pharmacokinetic profiles of plasma kisspeptin IR in both the follicular and preovulatory 
phases were similar, these results suggest that as with kisspeptin-54, women have 
heightened sensitivity to kisspeptin-10 during the preovulatory phase of the menstrual cycle. 
This suggests that the different background hormonal milieu with higher oestradiol levels in 
the pre-ovulatory phase may influence the responsiveness to kisspeptin-10.  
A recent study, published after the completion of my work, examined the effects of 
kisspeptin-10 in women at different stages of the menstrual cycle and supports my findings. 
In this study the authors also demonstrate a difference in response to an intravenous bolus 
of kisspeptin-10 across the menstrual cycle, with stimulation in gonadotrophin release in the 
luteal and preovulatory phase and a minimal response seen in the follicular phase (Chan et 
al. 2012). In this study the authors report that an intravenous bolus dose of 0.24 nmol/kg of 
kisspeptin-10 consistently stimulated a significant LH pulse in the preovulatory and luteal 
phase, with the response in the preovulatory phase being significantly higher. However, 
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despite increasing the administered dose of kisspeptin-10 to 0.72 nmol/kg no consistent 
response in LH stimulation was noted in the follicular phase (Chan et al. 2012). The authors 
suggest that GnRH neurones may have varied responsiveness to exogenous kisspeptin 
stimulation across the menstrual cycle. They postulate a theory that GnRH neurones are 
maximally stimulated by endogenous kisspeptin in the follicular phase and thus the 
additional ability to respond to exogenous kisspeptin is limited. Further studies are required 
to investigate this hypothesis.  
Studies in rodents have identified two distinct kisspeptin neuronal populations that have 
different responses to oestradiol. In female rodents, c-fos expression within kisspeptin 
neurones and levels of KISS1 expression are increased within the AVPV nucleus of the 
hypothalamus immediately preceding ovulation as a result of positive feedback on this 
nucleus by oestradiol (Smith et al. 2006). This contrasts against the negative feedback by 
oestradiol on a different distinct population of kisspeptin neurones in the ARC as evidenced 
by reduced levels of ARC KISS1r expression in rat hypothalamic fragments at proestrus 
when compared with diestrus (Roa et al. 2006). This suggests a complex interplay between 
AVPV and ARC neurones with GnRH neurones in rodents. 
KISS1 expressing neurones have only been identified in humans in the infundibular nucleus 
and to a lesser extent the medial preoptic area (Rometo et al. 2007). These neurones 
express the oestrogen receptor α (ERα). GnRH neurones express ERβ, but this is not 
involved in feedback mechanisms and hence it is thought that gonadal steroid feedback on 
the hypothalamus in the reproductive axis is via the kisspeptin neurones. In the low 
oestrogen state of menopause there is significant increase in KISS1 expression in the 
infundibular nucleus together with hypertrophy and increased numbers of these KISS1-
expressing neurones when compared to pre-menopausal specimens (Rance, 2009). Hence 
this suggests that higher oestogen states may downregulate KISS1 expression in humans. 
However, to explain the preovulatory surge of gonadotrophins there is likely to be a currently 
unidentified subpopulation of kisspeptin neurones in women that are stimulated by increased 
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oestrogen levels. To explain the results of the current study it is possible that there is a 
complex interaction dependent on background oestradiol levels between these kisspeptin 
neurones, exogenous kisspeptin-10 and the kisspeptin receptor of the GnRH neurones.  
Guerriero et al. report that in female rhesus monkeys low doses of kisspeptin 10 (10nM) 
stimulated larger GnRH responses in pubertal monkeys compared to prepubertal monkeys 
(Guerriero, Keen, & Terasawa 2012). The authors note that circulating oestradiol levels are 
higher in pubertal monkeys and that ovariectomy in these animals, which reduces oestradiol 
levels, eliminated the GnRH response to low and high doses of kisspeptin-10. Thus the 
difference in response to kisspeptin appears to be related to oestradiol levels. However, the 
replacement of oestradiol in pubertal monkeys who had undergone ovariectomy resulted in 
only a partial restoration of the GnRH response to kisspeptin-10. The authors postulate 
whether this may be due to absence of other ovarian hormones, or failure in adequate 
amount and length of oestradiol replacement or a change in properties of the oestrogen 
receptor post ovariectomy (Guerriero et al. 2012).  
In this study I noted that in both men and preovulatory women, kisspeptin-10 stimulated LH 
secretion more potently than FSH. This is consistent with previous studies of the effects of 
kissepptin-10 and kisspeptin-54 in healthy men and women (Chan et al. 2011; Dhillo et al. 
2005; Dhillo et al. 2007; George et al. 2011). In addition, in men the peak FSH increase 
occurred slightly later than the peak LH increase following iv bolus of kissepptin-10 (40-150 
min for FSH vs. 30-50 min for LH). This difference has previously been observed for both 
males and females (Dhillo et al. 2005; Dhillo et al. 2007). This study therefore suggests that 
both kisspeptin-10 and kisspeptin-54 stimulate LH secretion more potently and more rapidly 
than FSH. Administration of GnRH demonstrates a similar pattern of differing LH/FSH 
potency and rapidity of effect. Combining this with the additional similarity that LH and FSH 
responses to GnRH are also heightened in the pre-ovulatory phase, provides further 
evidence to suggest that GnRH is the intermediary messenger for kisspeptin to stimulate the 
anterior pituitary production of LH and FSH. 
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I did not observe any consistent stimulation of testosterone secretion after iv bolus 
kisspeptin-10 injection in healthy men when compared with the robust increases in serum LH 
and FSH observed at all tested doses. Significant increases in serum testosterone were 
observed only at 1.0 nmol/kg iv bolus kisspeptin-10, but these rises were marginal (no more 
than 10 h.nmol/l above baseline). Similarly, iv bolus injection of kisspeptin-10 stimulated 
gonadotropin release in women during the preovulatory phase of the menstrual cycle but did 
not increase serum oestradiol during 3 h after injection. Previous data suggest that at least 4 
hours are required for serum levels of sex steroids to peak after a sc bolus injection of 
kisspeptin-54 (Dhillo et al. 2005; Dhillo et al. 2007; Jayasena et al. 2009). A longer period of 
blood sampling after injection may have revealed more pronounced alterations in sex steroid 
secretion in subjects after injection of kisspeptin-10. Alternatively it is possible that an iv 
bolus injection of kisspeptin-10 and kisspeptin-54 have a duration of action inadequate to 
stimulate significant gonadal sex steroid release. 
In summary, this is the first clinical study to compare the effects of kisspeptin-10 
administration on reproductive hormone release in healthy men and women. Kisspeptin-10 
robustly stimulates gonadotrophin release in men and women in the preovulatory phase but 
fails to stimulate gonadotrophin release in the follicular phase. This sexual dimorphism as 
well as the different responses between the follicular and preovulatory phase have important 
clinical implications for the potential therapeutic use of kisspeptin-10 or kisspeptin-54 to treat 
disorders of reproduction and suggest that kisspeptin-54 may offer a more potent alternative. 
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Chapter 5  
 
General Discussion  
  
155 
 
Since 2003 and the discovery of the role of kisspeptin in hypothalamo-pituitary-gonadal 
function our understanding of reproductive physiology has been revolutionised. Inactivating 
mutations of KISS1R in humans and rodents results in hypogonadotrophic hypogonadism 
and pubertal failure (de Roux et al. 2003; Seminara et al. 2003). Activating mutations of the 
KISS1R result in the clinical phenotype of central precocious puberty (Teles et al. 2008). 
The novel finding that administration of kisspeptin to healthy men and women stimulates 
gonadotrophin hormone release (Dhillo et al. 2005; Dhillo et al. 2007), has revealed the 
potential of kisspeptin as a therapeutic agent for those patients with disorders of 
reproduction. In this thesis I report the first clinical studies examining the acute effects of 
administration of kisspeptin-54 on the reproductive axis in women with infertility due to 
hypothalamic amenorrhoea; as well as the effects of chronic administration of kisspeptin-54. 
I also report on the original discovery of sexual dimorphism in gonadotrophin response to 
exogenous administration of kisspeptin-10.  
Hypothalamic amenorrhoea is a common cause of infertility, accounting for 30% of cases of 
amenorrhoea (Reindollar 1986). Hypothalamic amenorrhoea results from a failure of 
pulsatile GnRH secretion from the hypothalamus and may be triggered by energy deficits as 
well as psychological stress (Berga et al. 1989). In this thesis I report that exogenous 
administration of kisspeptin-54 results in an acute stimulation of serum levels of LH and FSH 
in women with hypothalamic amenorrhoea. Women with hypothalamic amenorrhoea 
appeared to be more sensitive to the effects of kisspeptin on gonadotrophin stimulation, with 
a 4 fold greater response, compared to previously published data on kisspeptin 
administration to healthy women. Castellano et al. reported that negative energy balance 
due to short term fasting in rats results in a decrease in hypothalamic expression of Kiss-1 
mRNA and an increased hypothalamic expression of kisspeptin receptor GPR54 mRNA 
(Castellano et al. 2005). In vitro and rodent in vivo experiments have demonstrated an 
increased sensitivity to the effects of kisspeptin-10 administration on GnRH secretion and 
gonadotrophin stimulation in fasted animals (Castellano et al. 2005). Our finding of increased 
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sensitivity to the effects of kisspeptin on the HPG axis, in women with hypothalamic 
amenorrhoea, is consistent with these animal model data. 
Although acute administration of kisspeptin has been shown to stimulate gonadotrophin 
release in healthy men and women (Dhillo et al. 2005; Dhillo et al. 2007), there have been 
no previous studies conducted on the effects of long-term chronic administration of 
kisspeptin in humans. I report that twice daily injections of kisspeptin-54 6.4 nmol/kg to 
women with hypothalamic amenorrhoea for two weeks results in tachyphylaxis. The 
reproductive hormone response to kisspeptin was much lower following the last kisspeptin 
injection compared to the first kisspeptin injection. In order to investigate whether the 
desensitisation to the effects of kisspeptin was due to desensitisation at the level of the 
hypothalamus on GnRH secretion or whether there was a decrease in sensitivity of the 
pituitary gonadotrophs to GnRH; I conducted a second experiment in which I investigated 
the effects of exogenous GnRH administration on gonadotrophin release following chronic 
kisspeptin administration. Despite losing sensitivity to the effects of kisspeptin, women with 
hypothalamic amenorrhoea treated with twice daily injections of kisspeptin-54, remained 
responsive to the gonadotrophin stimulation with GnRH. Thus, tachyphylaxis to the effects of 
kisspeptin administration appears to be upstream of the GnRH receptor probably at the level 
of hypothalamic KISS1R rather than at the pituitary gonadotrophs.  
Continuous administration of kisspeptin has been shown to result in desensitisation of the 
effects of kisspeptin on gonadotrophin stimulation in monkeys and rodents (Seminara et al. 
2006; Thompson et al. 2006; Roa et al. 2008). Delayed desensitisation of the KISS1R due to 
an Arg386Pro mutation, results in the clinical phenotype of precocious puberty (Teles et al. 
2008). In vitro studies measuring total inositol phosphate production as a marker of KISS1R 
signalling, have demonstrated that the KISS1R is desensitised in a time dependent manner 
(Bianco et al. 2011). A proportion of internalised KISS1R is recycled and the remainder 
degraded by proteasomes, which results in long term desensitisation of the KISS1R (Bianco 
et al. 2011). The Arg386Pro mutation associated with precocious puberty results in reduced 
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degradation of the KISS1R resulting in an increased responsiveness to kisspeptin (Bianco et 
al. 2011).  
Although I did not administer kisspeptin-54 as a continuous infusion, the twice daily 
injections did lead to raised plasma kisspeptin IR for 6 hours post injection resulting in 
prolonged exposure to elevated levels of kisspeptin. Therefore a different study protocol of 
kisspeptin-54 administration i.e. a lower dose or reduced frequency of injections may reduce 
the desensitisation seen in stimulation of gonadotrophin release. My subsequent studies 
went on to investigate the time course of the desensitisation of gonadotrophin response and 
the effects of different dosing regimens of kisspeptin to women with hypothalamic 
amenorrhoea. I found that tachyphylaxis of LH response to twice-daily sc kisspeptin-54 6.4 
nmol/kg occurred gradually over the 14 day injection period, but FSH responsiveness 
reduced much more rapidly.  
The studies comparing different dosing regimens of kisspeptin-54 showed that once- and 
twice-daily administration of kisspeptin-54 led to significant desensitisation of gonadotrophin 
responses in women with HA. The tachyphylaxis in response to chronic administration of 
kisspeptin-54 may be utilised for its clinical effects on down regulating the HPG axis. It has 
been suggested that chronic kisspeptin administration may be a useful a therapy for sex 
hormone responsive cancers (Seminara et al. 2006). In addition, pharmacological blockade 
of kisspeptin signalling may suppress LH pulsatility rather than basal LH levels (Roseweir et 
al. 2009), posing the potential development of a contraceptive therapy.  
My studies demonstrated that twice-weekly administration of 6.4 nmol/kg kisspeptin-54 was 
only associated with partial desensitisation of gonadotrophin responses during a 2 week pilot 
study. I therefore conducted a randomised placebo controlled double blind study of twice 
weekly kisspeptin-54 6.4 nmol/kg administration to women with hypothalamic amenorrhoea. 
The findings from this study showed that over the study period of eight weeks participants 
remained responsive to kisspeptin with a partially sustained gonadotrophin response. There 
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were no adverse effects noted. Although there was stimulation of gonadotrophin release, on 
review of pelvic ultrasounds there was no significant changes in follicle growth in those 
women who received kisspeptin-54. This failure in stimulating follicle growth may be 
secondary to a reduced FSH response to kisspeptin compared to LH. Previous studies in 
healthy men and women have demonstrated that kisspeptin-54 administration does 
stimulate LH and FSH, but that the FSH reponse is lower (Dhillo et al. 2005; Dhillo et al. 
2007). In addition my results demonstrate that the FSH responses to kisspeptin-54 
desensitised more rapidly following twice-daily kisspeptin-54 injection than LH responses. 
Thus, FSH stimulation on the gonads may not have been high enough in amplitude or 
pulsatility to stimulate follicle growth.  
Kisspeptin-10 is a shorter peptide produced by protelytic processing of a 145-amino acid 
precursor protein encoded by the KISS1 gene (Kotani et al. 2001). Previous studies have 
demonstrated that central or peripheral administration of kisspeptin-10 to a number of 
mammalian species stimulates gonadotrophin release (Irwig et al. 2004; Navarro et al. 2004; 
Gottsch et al 2004; Messager et al. 2005; Caraty et al. 2007; Plant et al. 2006; Ramaswamy 
et al. 2007; Shahab et al. 2005; Grieves et al. 2007; Lents et al. 2008; Kadokawa et al. 2008). 
The stimulatory effects of kisspeptin-10 on gonadotrophin release are inhibited by the central 
administration of a GnRH antagonist. Compared to kisspeptin-54, kisspeptin-10 has a 
shorter half-life and faster onset of action after intravenous administration in rodents 
(Mikkelsen et al. 2008;Mikkelsen et al. 2009). As kisspeptin-10 is simpler and thus cheaper 
to manufacture, future kisspeptin-based reproductive therapies may be based upon 
kisspeptin-10 rather than kisspeptin-54. Human male studies have demonstrated that an 
intravenous bolus injection of kisspeptin-10 potently stimulates LH secretion while a 
continuous infusion of kisspeptin-10 also increases testosterone, LH pulse frequency and 
amplitude (George et al. 2011, Chan et al. 2011). I carried out the first study comparing the 
effects of kisspeptin-10 administration in women versus men.  
159 
 
I report a previously unknown sexual dimorphism in responsiveness to kisspeptin-10 in 
healthy men and women. I observed that an intravenous bolus injection of kisspeptin-10 
significantly stimulated LH release in healthy men. These results are consistent with 
previous reports on the effects of the administration of kisspeptin-54 (Dhillo et al. 2005) and 
kisspeptin-10 (Chan et al. 2011; George et al. 2011) on the HPG axis in healthy men. 
However, an intravenous bolus injection of kisspeptin-10 failed to stimulate reproductive 
hormone release in healthy female volunteers during the follicular phase of menstrual cycle.  
In order to assess whether a more sustained exposure to exogenous kisspeptin-10 would 
stimulate reproductive hormone release in healthy women I studied the effects of 
subcutaneous bolus administration of kisspeptin-10 in addition to an intravenous bolus 
administration. Despite elevations in plasma kisspeptin IR for up to 90 min post-injection, 
serum gonadotrophin levels were not elevated by sc bolus injection of kisspeptin-10 in 
healthy women in the follicular phase of menstrual cycle.  
I then went on to investigate the effects of administering intravenous infusion of kisspeptin-
10 to healthy women to study the effects of sustained, high dose kisspeptin-10 
administration on reproductive hormone release. Despite markedly raised plasma levels of 
kisspeptin IR up to 2000pmol/l, serum gonadotrophin levels were not elevated during 
intravenous infusion of kisspeptin-10 to healthy female volunteers in the follicular phase of 
menstrual cycle.  
My data therefore demonstrates that intravenous bolus injection, subcutaneous bolus 
injection, or intravenous infusion of kisspeptin-10 fails to stimulate gonadotrophin release in 
healthy women during the follicular phase of menstrual cycle. This study demonstrates that 
women in the follicular phase of menstrual cycle are less responsive to kisspeptin-10 
administration than men.  
Women in the preovulatory phase of the menstrual cycle are known to be significantly more 
sensitive to the effects of kisspeptin-54 on gonadotrophin release when compared with 
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women in the follicular phase of the menstrual cycle (Dhillo et al. 2007). In keeping with this 
observation, I found an intravenous bolus injection of kisspeptin-10 significantly stimulated 
LH and FSH release in women during the preovulatory phase of the menstrual cycle. 
The pharmacokinetic profiles of plasma kisspeptin IR in both the follicular and preovulatory 
phases were similar; these results suggest that as with kisspeptin-54, women have 
heightened sensitivity to kisspeptin-10 during the preovulatory phase of the menstrual cycle.  
A recently published study also demonstrated a difference in response to kisspeptin-10 
across the menstrual cycle, with stimulation in gonadotrophin release in the luteal and 
preovulatory phase and an inconsistent response seen in the follicular phase (Chan et al. 
2012). The authors postulate that GnRH neurones may have varied responsiveness to 
exogenous kisspeptin stimulation across the menstrual cycle.  
Studies in rodents have identified two distinct kisspeptin neuronal populations that have 
different responses to oestradiol. In female rodents, c-fos expression within kisspeptin 
neurones and levels of KISS1 expression are increased within the AVPV nucleus of the 
hypothalamus immediately preceding ovulation as a result of positive feedback on this 
nucleus by oestradiol (Smith et al. 2006). This contrasts against the negative feedback by 
oestradiol on kisspeptin neurones in the ARC, as evidenced by reduced levels of ARC 
KISS1r expression in rat hypothalamic fragments at proestrus when compared with diestrus 
(Roa et al. 2006).  
In humans KISS1 expressing neurones have only been identified in the infundibular nucleus 
and to a lesser extent the medial preoptic area (Rometo et al. 2007). In the low oestrogen 
state of menopause there is significant increase in KISS1 expression in the infundibular 
nucleus together with hypertrophy and increased numbers of  KISS1-expressing neurones 
when compared to pre-menopausal specimens (Rance 2009).  
Guerriero et al. reported that in female rhesus monkeys low doses of kisspeptin-10 
stimulated larger GnRH responses in pubertal monkeys compared to prepubertal monkeys 
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(Guerriero et al. 2012). Oestradiol levels are higher in pubertal monkeys and ovariectomy in 
these animals, which reduces oestradiol levels, eliminated the GnRH response to low and 
high doses of kisspeptin-10. However, the replacement of oestradiol in pubertal monkeys 
who had undergone ovariectomy resulted in only a partial restoration of the GnRH response 
to kisspeptin-10; suggesting an effect of another ovarian factor in addition to oestradiol on 
the response to kisspeptin (Guerriero et al. 2012).  
In summary, in the course of this thesis I have reported on the first studies examining the 
effects of kisspeptin-54 in a model of infertility due to hypothalamic amenorrhoea and I have 
conducted the first clinical study to compare the effects of kisspeptin-10 administration on 
reproductive hormone release in healthy men and women. These studies suggest several 
important implications for the potential therapeutic use of kisspeptin-10 or kisspeptin-54 to 
treat disorders of reproduction. 
My future work will investigate the effects of kisspeptin to improve in invitro fertilisation (IVF) 
treatment for infertility. Infertility is commonly defined as the inability to conceive after two 
years of regular unprotected sexual intercourse (HFEA Fertility Facts and Figures 2008). 
Infertility has a high prevalence; it is estimated that around one in six UK couples have 
difficulty conceiving i.e. approximately 3.5 million couples (HFEA Fertility Facts and Figures 
2008). The inability to have children can be devastating, and has important implications for 
mental, social, and reproductive health. IVF treatment is widely and successfully used to 
allow infertile couples to conceive and is now approved by the National Institute for Health 
and Clinical Excellence. However, the most common serious complication of IVF is ovarian 
hyperstimulation syndrome (OHSS). This is a potentially life threatening condition which has 
significant morbidity and mortality (RCOG guideline 5, 2006). The major cause of OHSS is 
the use of human chorionic gonadotrophin (hCG) in current IVF protocols for oocyte 
maturation (Golan et al. 1989). Human chorionic gonadotrophin binds to the LH receptor and 
therefore mimics the actions of endogenous LH. However, hCG has a much longer 
circulating half life than LH; this results in overstimulation of the corpus luteum which is the 
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underlying cause of OHSS (Damewood et al. 1989). Human chorionic gonadotrophin 
circulates for up to a week after injection (Fauser et al. 2002), whereas the physiological 
stimulus, the LH surge, only lasts for 48 hours (Hoff et al. 1983). This overstimulation of the 
corpus luteum also results in an environment more hostile to embryo implantation (Macklon 
et al. 2006). A more physiological method for oocyte maturation in IVF treatment should 
prevent overstimulation of the corpus luteum and thus the subsequent development of 
OHSS (Macklon et al. 2006). Kisspeptin offers a novel approach in IVF therapy to improve 
pregnancy rates and avoid the complication of OHSS. Since kisspeptin stimulates the 
release of physiological levels of GnRH and the consequent release of endogenous 
gonadotrophins (Irwig et al. 2004; Thompson et al. 2004; Messager et al. 2005) it should 
lead to a physiological LH surge. A more physiological approach for oocyte maturation in IVF 
treatment would prevent overstimulation of the corpus luteum and OHSS in IVF treatment 
(Macklon et al. 2006). The significant advantage of kisspeptin over current treatments is that 
its effects would depend on the sensitivity of an individual‟s hypothalamic-pituitary gonadal 
(HPG) axis. This would result in a more physiological LH surge and oocyte maturation during 
IVF treatment, thereby improving safety and efficacy of IVF treatment.  
I am planning a future study in which I hypothesise that the use of kisspeptin in place of hCG 
in IVF protocols will result in the physiological release of the endogenous releasable pool of 
GnRH and subsequent gonadotrophin secretion; this in turn will lead to oocyte maturation. 
The aim of this study will be to provide proof of concept that administration of kisspeptin can 
induce oocyte maturation. Thus kisspeptin may have an exciting role in the treatment of 
infertility in the future. 
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Appendix 1 Principle of radioimmunoassay 
Radioimmunoasasy (RIA) is a technique in which unlabelled and radioactively labelled 
antigen (peptide) compete for an antibody binding site. Specificity is dependent upon the 
ability of the antibody to recognise subtle structural features of the antigen molecule. The 
most commonly used radiolabel is I-125, and antibodies are often obtained by immunising 
rabbits with antigen (peptide) plus adjuvant (though polyclonal antibodies from other species 
and monoclonal antibodies can be used). In the RIA both the labelled peptide and antibody 
are at specific, constant concentrations. The concentration of antibody is limiting, so antigen 
binding will be finite. This allows determination of the amount of unlabelled peptide in a 
sample. Unlabelled peptide in a sample will compete with labelled peptide for antibody 
binding. Thus the amount of radiolabelled antigen bound to the antibody is inversely 
proportional to the amount of unlabelled antigen in the sample being assayed. A „standard 
curve‟ is determined using known concentrations of pure peptide to calculate the percentage 
of labelled peptide bound for each concentration of unlabelled pure peptide. Separation of 
the unbound radiolabelled antigen from the radiolabelled antigen-antibody complex and 
counting the proportion of radiolabel present in the two fractions enables direct 
measurement of the amount of unlabelled antigen that has bound to the antibody. By 
reference to the standard curve, the unknown concentrations of peptide in the sample can 
be obtained by interpolation.  
 
Schematic representation of the principle of RIA: 
Ag* + Ab + Ag  ↔  Ag*Ab + AgAb 
 
Ag* = radiolabelled antigen 
Ag  = unlabelled antigen 
Ab = antibody 
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Various techniques may be used in order to distinguish antibody-bound antigen from free 
antigen, and to determine the distribution of radioactive antigen between the two fractions. 
The methods used in this work are separation by adsorption with charcoal (free radiolabelled 
antigen is contained in the charcoal pellet following centrifugation), or using a primary 
antibody / secondary antibody complex (free label is contained in the supernatant following 
centrifugation). 
With charcoal separation, dextran is added to a charcoal suspension to block the larger 
holes in porous charcoal. The suspension is then added to the RIA tubes, where it traps the 
free (unbound) radiolabelled antigen. The tubes are then centrifuged and the supernatant 
(containing antibody-antigen complex) and charcoal pellet (free radiolabelled antigen) are 
separated by aspiration with a Pasteur pipette. The bound and free labels are counted in a 
gamma counter. With the secondary antibody separation method, the secondary antibody is 
derived from an animal species different from the species used to generate primary (antigen-
binding) antibody. For example, the leptin primary antiserum is raised in a rabbit, and 
separation is achieved by using a goat anti-rabbit secondary antibody. Free radiolabelled 
antigen is in the supernatant, and the pellet contains antigen-antibody complexes. As with 
charcoal separation, bound and free label are counted in a gamma counter after incubation, 
centrifugation and separation.  
 
Each RIA has optimum reaction conditions with respect to buffer medium, assay volume, 
antibody titre, incubation time, temperature, and separation method used. Phosphate buffers 
are used for a wide range of RIAs. The in-house departmental assays used here are 
incubated for 3-5 days. 
 
All samples are added in duplicate. “Non-specific binding” tubes, minus primary antibody, 
are added at the beginning of the assay. Tubes containing half and twice the standard 
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volume of added labelled antigen are also included in order to confirm the quality of the label. 
Tubes with no samples („zero‟ tubes) are placed at regular intervals throughout the assay, 
and standard curves (containing known quantities of unlabelled antigen) are performed at 
the beginning and end of each assay, in order to calibrate the assay. The analytical 
sensitivity of an assay is determined by the smallest change in hormone concentration that 
can be reliably detected. This is essentially governed by the steepness of the standard curve, 
and the error of a known value on the curve. The analytical sensitivity is calculated as two 
standard deviations from the mean concentration of antigen measured in the zero standards 
(which contains no unlabelled peptide) 
Kisspeptin radioimmunoassay:  
 
Measurement of plasma kisspeptin immunoreactivity (IR) was performed using an 
established radioimmunoassay (RIA) (Dhillo et al. 2005; Dhillo et al. 2007). A rabbit 
antiserum was raised against kisspeptin. The antibody cross-reacted 100% with human 
kisspeptin-54, kisspeptin-14, and kisspeptin-10 and less than 0.01% with other related RF 
amide proteins, including prolactin-releasing peptide, RF amide-related peptide 1 (RFRP1), 
RFRP2, RFRP3, QRFP43, neuropeptide FF, and neuropeptide AF. The limit of detectability 
was 2pmol/l, and the intra- and interassay coefficients of variation were 8.3 and 10.2%, 
respectively.  
 
All kisspeptin RIAs were performed using 0.06M phosphate buffer (0.05M Na2HPO4.2H2O, 
0.006M KH2PO4, 0.01M disodium-EDTA.2H2O, 0.008M NaN3) (pH 7.4). A standard 
concentration of 0.5 pmol/mL kisspeptin-54 was used. Radiolabelled kisspeptin with a 
radioactivity 25-30 Bq/mL was used. Antiserum was used at a final dilution of 1:3,000,000. 
Assay tubes were set up in duplicate according to the volumes described in Table 10. 
Assays were incubated for 3-5 days at 4OC then separated using charcoal adsorption. 
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Table 10. Volumes of reactants for addition to kisspeptin radioimmunoassay.  
NSB, non-specific binding,1/2 X, addition of half-volume of labelled kisspeptin; 2 X, addition 
of double volume of labelled kisspeptin; XS, addition of excess volume of antibody. 
 
TUBE 
IDENTITY 
BUFFER 
VOLUME 
(µL) 
LABEL 
VOLUME 
(µL) 
ANTIBODY 
VOLUME 
(µL) 
SAMPLE / 
STANDARD 
(µL) 
TOTAL 
VOLUME 
 (µL) 
NSB 600 100 0 0 700 
1/2 X 550 50 100 0 700 
2 X 400 200 100 0 700 
ZERO 500 100 100 0 700 
STD 1-15 500 100 100 1-15 701-715 
STD 20 480 100 100 10 700 
STD 30 470 100 100 30 700 
50 450 100 100 50 700 
100 400 100 100 100 700 
XS 0 100 600 0 700 
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the effects of repeated administration of kisspeptin to humans are unknown.
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tration on gonadotropin release in women with HA.
Methods: We performed a prospective, randomized, double-blinded, parallel design study.
Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n 
5 per group) for 2 wk. Changes in serum gonadotropin and estradiol levels, LH pulsatility, and
ultrasound measurements of reproductive activity were assessed.
Results: On the first injection day, potent increases in serum LH and FSH were observed after sc
kisspeptin injection in women with HA (mean maximal increment from baseline within 4 h after
injection: LH, 24.0 3.5 IU/liter; FSH, 9.1 2.5 IU/liter). These responses were significantly reduced
on the 14th injection day (mean maximal increment from baseline within 4 h postinjection: LH,
2.5 2.2 IU/liter, P 0.05; FSH, 0.5 0.5 IU/liter, P 0.05). Subjects remained responsive to GnRH
after kisspeptin treatment. No significant changes in LH pulsatility or ultrasoundmeasurements of
reproductive activity were observed.
Conclusion: Acute administration of kisspeptin to women with infertility due to HA potently
stimulatesgonadotropin release,but chronicadministrationofkisspeptin results indesensitization
to its effects on gonadotropin release. These data have important implications for the develop-
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Hypothalamic amenorrhea (HA) is defined as the ces-sation of menstruation due to abnormal signaling
between thehypothalamusand thepituitarygland (1), and
it accounts for approximately30%of casesof amenorrhea
in women of reproductive age (2). Functional HA is de-
fined as HA occurring in the absence of a structural lesion
and often results from a relative energy deficit within the
body (low body weight or weight loss) (3–7). Although
current treatments for women with HA such as clomi-
phene, gonadotropin injections, andGnRHpump therapy
are efficacious, each has associated limitations (8, 9).
The kisspeptins are a group of arginine-phenylalanine
(RF) amidepeptides, encodedby theKISS1 gene, that have
been identified as potential novel agents for treating re-
productive disorders. They act as endogenous ligands for
the kisspeptin receptor (KISS1R, alternatively knownasG
protein-coupled receptor 54) (10–12).KISS1 andKISS1R
are expressed in thehypothalamus, pituitary, andplacenta
(10, 12–14). Kisspeptin signaling exerts powerful effects
on the mammalian reproductive system. Mice lacking
kisspeptin or the kisspeptin receptor fail to undergo pu-
berty and are infertile (15, 16). In humans, inactivating
mutations of KISS1R cause pubertal failure (16, 17), and
activatingmutations lead to precocious puberty (18). Fur-
thermore, central or peripheral administration of kisspep-
tin induces gonadotropin and sex steroid release in all
mammalian species investigated, including rats (19–21),
mice (22, 23), monkeys (24) and sheep (23, 25). We
have previously demonstrated that iv infusion or sc bo-
lus injection of kisspeptin-54 stimulates gonadotropin
secretion in healthy human male and female subjects,
respectively (26, 27). Kisspeptin may therefore be a po-
tential novel therapy for treating reproductive disorders
in humans. However, the effects of kisspeptin admin-
istration in patients with infertility have not been pre-
viously investigated.
Although it has been consistently demonstrated that
acute administration of kisspeptin stimulates gonadotro-
pin release (19–27), the effects of chronic administration
of kisspeptin on reproductive function are less clear.
Chronic administration of kisspeptin to nonhumanmam-
mals causes either sustained or nonsustained stimulation
of reproductive function, depending on the mode of ad-
ministration used. Intermittent administration of kisspep-
tin-10 to juvenile female rats (twice-daily injections) for
5 d and juvenile male monkeys (hourly injections) for 2 d
induces precocious reproductive maturation (28, 29). In
contrast, continuous peripheral infusion of kisspeptin-10
to monkeys or rats increases LH release only during the
first 3 h or the first day of administration, respectively; LH
concentrations subsequently return to levels observed be-
fore infusion of kisspeptin-10 (30, 31). The long-term ef-
fects of administration of kisspeptin in humans have not
been studied to date.
In prepubertal female rats, caloric restriction leads to
reduced gonadotropin levels, delayed vaginal opening,
and low hypothalamic kiss1 expression (32). Twice-daily
administration of kisspeptin-10 to these animals restores
vaginal opening and gonadotropin secretion (32). Based
on these data, we hypothesized that repetitive administra-
tion of kisspeptinwould restore gonadotropin secretion in
human female subjects with HA.
A randomized, double-blinded, placebo-controlled,
parallel design studywas conducted to determinewhether
twice-daily administration of kisspeptin to human female
subjects withHAwould sustainably stimulate gonadotro-
pin release.
Subjects and Methods
Kisspeptin-54
Kisspeptin-54 was synthesized by the Advanced Biotechnol-
ogy Centre, Imperial College London, and purified by reverse-
phase HPLC. Electrospray mass spectroscopy and amino acid
analysis confirmed identityof thepeptide aspreviouslydescribed
(26, 27). The peptide was tested for bioactivity and toxicity as
previously described (26). The Limulus amebocyte lysate assay
(Associates of Cape Cod, Liverpool, UK) was negative for en-
dotoxin, and the peptide was sterile on culture (Department of
Microbiology, Hammersmith Hospital, London). Although
kisspeptin-10, -13, -14, and -54 display similar potency in vitro,
we used kisspeptin-54 due to its higher in vivo potency than the
other kisspeptin fragments (31, 33).
Subjects
Ethical approval was granted by the Hammersmith and
Queen Charlotte’s and Chelsea Hospitals Research Ethics Com-
mittee (registration number: 05/Q0406/142). Written informed
consent was obtained from all subjects. This study was per-
formed in accordance with the Declaration of Helsinki.
Subjects were recruited through advertisements placed in lo-
cal newspapers. Responders to advertisements were evaluated
with a detailed menstrual history, clinical examination, electro-
cardiogram, and blood tests. Screening blood tests performed
were as follows: full blood count, renal profile, liver profile, bone
profile, glucose, thyroid profile, LH, FSH, estradiol, progester-
one, androstenedione, dehydroepiandrosterone, testosterone,
SHBG, prolactin, 17-hydroxyprogesterone, and cortisol. Women
were diagnosed with functional HA and included within the
study if they fulfilled the following criteria: body mass index
below 25 kg/m2; stable bodyweight over the previous 6months;
age between 18 and 40 yr; secondary amenorrhea of at least 6
months duration; absence of oral contraceptive pill therapy for
at least 1 yr; absence of systemic disease comorbidity; absence of
active psychiatric illness; stable body weight; absence of thera-
peuticor recreational druguse; absenceof clinical orbiochemical
hyperandrogenemia; structurally normal hypothalamopituitary
region assessedbymagnetic resonance imaging; structurally nor-
mal female reproductive tract visualized on ultrasound; absence
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of polycystic ovarian appearances on ultrasound; normal thy-
roid function tests; normal serum prolactin levels; and serum
LH:FSH ratio less than 1.5. Ten subjects withHAwere recruited
to the study. We have previously published baseline clinical and
biochemical data for healthywomen in the follicular phase of the
menstrual cycle and for their responses to kisspeptin-54 admin-
istration (27).
Protocol
A randomized, double-blinded, placebo-controlled, parallel
design study was performed. Ten subjects with HA (see Table 1
for baseline characteristics) were randomized to either saline or
kisspeptin treatment groups (five subjects per group). Before
commencement of the 8-wk study protocol, subjectswere taught
how to self administer sc injections of saline.
Baseline period
This initial 4-wk control period (wk 1–4) allowed the mea-
surement of baseline values of reproductive hormones and ul-
trasound markers and the acclimatization of subjects to study
conditions. During wk 1–2 of the protocol, all women with HA
self-administered twice-daily sc injections of saline (blinded to
subjects only). No injections were administered during wk 3–4
of the protocol.
Treatment period
During wk 5–6 of the protocol, women with HA either self-
administered twice-daily, double-blinded sc injections of saline
(five subjects) or kisspeptin-54 (five subjects), depending on the
treatment group to which they had been assigned. The dose of
kisspeptin administeredwas6.4nmol/kg [equivalent to 37g/kg
(26)]. Twice-daily injections were self-administered at home by
subjects during the treatment period, except on the last day (wk
6, d 7) when just one injection was administered in the morn-
ing. This final injection was administered within the investi-
gation unit as part of a 4-h sampling study (see 4-h blood
sampling after injection of saline or kisspeptin).
Posttreatment period
During wk 7–8, subjects underwent a posttreatment obser-
vationperiod tomeasure reproductive hormones andultrasound
markers. No injections were administered during this period.
Kisspeptin injections
All subjectswere trained in self-administrationof sc injections
by an investigator at the start of the study protocol. At the be-
ginning of each week when injections were to be performed, a
box containing unlabeled vials of freeze-dried saline or kisspep-
tin-54, alcohol wipes, saline vials, needles, and needle disposal
bins was given to each subject. For injection, vial contents were
reconstituted in 0.5 ml of 0.9% saline. Then a 0.5-ml insulin
syringe was used to inject a weight-adjusted volume of dissolved
vial contents into the lower anterior abdominal region. Subjects
were instructed to refrigerate vials stored at home.
4-h blood sampling after injection of saline or
kisspeptin
All subjects underwent blood sampling in the 4-h period im-
mediately after the first (wk 5, d 1) and final (wk 6, d 7) injection
of saline (five subjects) or kisspeptin-54 (five subjects) of treat-
ment period.These studiesweredone in an investigationunit.An
unusedvial returnedby each subject fromhome storagewasused
for their final injection of kisspeptin or saline. Saline or kisspep-
tin-54 (6.4 nmol/kg) was sc administered at 0 min by the inves-
tigator, and blood was sampled for serum LH, FSH, estradiol,
and SHBG, and plasma kisspeptin-immunoreactivity (IR) at
30, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, and 240min.
In one subject, the studywas extended to include blood sampling
at 270, 300, 330, 360, 390, 420, 450, and480minpostinjection.
Assessments of LH pulsatility
Subjects underwent assessment of LH pulsatility on the first
study day (wk 1, d 1) and approximately 24 h after the final
injection of the treatment period (wk 7, d 1). Bloodwas sampled
sequentially every10min for serumLHoveran8-hperiod.These
studies were commenced between the hours of 0800 h and
1200 h.
Basal measurement of reproductive hormones
Twice-weekly basal measurements of serum LH, FSH, estra-
diol, progesterone, SHBG, and plasma kisspeptin-IR were taken
from subjects throughout the 8-wk study protocol between0800
and 1800 h. During weeks when injections were self-adminis-
tered by volunteers (wk 1, 2, 5, and 6), these blood tests were
performed a mean of 4.5  0.4 h after the previous injection,
depending on the availability of volunteers. These twice-weekly
basal measurements were used to calculate mean values for se-
rumLH, FSH, and estradiol during the baseline period (wk1–4),
treatment period (wk 5–6) and posttreatment period (wk 7–8)
of the study protocol. Kisspeptin-IR was measured to confirm
subject compliance to kisspeptin injections.
Ultrasound scans
Transabdominal ultrasound scans were performed once a
week throughout the 8-wk study period. During each scan, the
following parameters were measured: endometrial thickness in
millimeters; mean ovarian volume in cubic centimeters; mean
follicles number; and maximum diameter of largest follicle in
each ovary in millimeters. Ovulation was confirmed by satisfac-
tion of all of the following criteria: visualization of a dominant
follicle (diameter, 11 mm or greater); enlargement of dominant
follicle into a preovulatory follicle (diameter, 18mmor greater);
subsequent collapse of preovulatory follicle or appearance of
TABLE 1. Comparison of baseline characteristics of
women with HA randomized to saline vs. kisspeptin-54
Characteristic
Study group P
valueSaline Kisspeptin-54
Age (yr) 24.8  0.5 26.8  2.4 0.28
Weight (kg) 51.8  3.3 54.5  1.1 0.46
Body mass index
(kg/m2)
19.0  0.7 19.9  0.4 0.25
Duration of
amenorrhea (months)
22.4  9.9 23.2  12.7 0.96
Serum LH (IU/liter) 4.5  1.6 2.6  0.9 0.32
Serum FSH (IU/liter) 6.6  0.7 6.1  1.0 0.69
Serum estradiol
(pmol/liter)
105  13.9 78  4.9 0.10
Values are provided for subjects randomized to receive saline (n  5)
or kisspeptin-54 (n  5). Data are shown as mean  SEM.
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internal echoes on ultrasonography; and a rise in serum proges-
terone to over 10 nmol/liter.
Other measurements
Weight was measured on the first study day (wk 1, d 1) and
subsequently every 2 wk during the 8-wk protocol. During each
study visit, urine was tested to exclude pregnancy (Clearview
easy-HCG; InvernessMedical Innovations Inc.,Waltham,MA).
Diastolic and systolic blood pressure and heart rate were re-
corded every 30 min during the LH pulsatility studies, to com-
pare mean values for each parameter before and after the treat-
ment period (wk 5–6). Blood pressure and heart rate were also
recorded during 4-h blood sampling studies performed after in-
jection of kisspeptin or saline.
Response of HA subjects to GnRH before and after
injections of kisspeptin
A second group of five female subjects was recruited using
identical inclusion criteria for HA described in this study, to
determine whether sensitivity to the effects of GnRH was re-
tained after desensitization to the effects of kisspeptin.Abaseline
GnRHtestwasperformed in all subjects in the investigationunit.
In brief, subjects were cannulated and given a 100-g iv bolus
injection of GnRH (HRF; Intrapharm Ltd., Kent, UK) at 0 min.
Blood was sampled for measurement of serum LH, FSH, and
estradiol at30, 0, 15, 30, 45, 60, 90, and 120 min. Seven days
after theGnRHtest, all fivewomen self-administered twice-daily
kisspeptin injections (6.4 nmol/kg) for 2wk. TheGnRH test was
repeated in each subject 8–12 h after their final kisspeptin
injection.
Collection and processing of blood samples
Blood samples for serum analysis were collected in plain se-
rum Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ).
Samples were allowed to clot before centrifugation and separa-
tion of serum.Blood samples for plasmakisspeptin analysiswere
collected in lithiumheparin tubes (BectonDickinson) containing
5000 kallikrein inhibitor units of aprotinin (0.2 ml Trasylol;
Bayer, Newbury, UK). Samples were immediately centrifuged at
room temperature using a Hettich EBA 20 machine (Hettich
International, Tuttlingen,Germany) for 10min at 3000 rpmand
then separated. Serum and plasma samples were stored at 20
C until analysis.
Analytical methods
Serum LH, FSH, estradiol, and progesterone were measured
using automated chemiluminescent immunoassays (Abbott Di-
agnostics,Maidenhead, UK). SHBGwasmeasured using a solid-
phase automated enzyme immunoassay (Immulite; Siemans,
Llanberis,UK).Reference ranges for femaleswere as follows:LH
(follicular), 2–10 IU/liter; LH (midcycle), 20–60 IU/liter; LH
(luteal), 4–14 IU/liter; FSH (follicular and luteal), 1.5–8 IU/liter;
estradiol (early follicular), less than 300 pmol/liter; estradiol
(midcycle), 400–1500 pmol/liter; estradiol (luteal), 200–1000
pmol/liter; and SHBG, 40–80 nmol/liter. Interassay coefficients
of variation were as follows: LH, 3.4%; FSH, 3.5%; estradiol,
3.4%; progesterone, 1.8%; and SHBG, 5.6%. Limits of detect-
ability for each assay were as follows: estradiol, 70 pmol/liter;
FSH, 0.05 mIU/ml; LH, 0.07 mIU/ml; progesterone, 0.1 ng/ml;
and SHBG, 0.1 nmol/liter.
Measurement of plasma kisspeptin immunoreactivity (IR)
was performed using an established RIA (26, 27). The antibody
cross-reacted 100% with human kisspeptin-54, kisspeptin-14,
and kisspeptin-10 and less than 0.01% with other related RF
amide proteins, including prolactin-releasing peptide,RF amide-
relatedpeptide1 (RFRP1),RFRP2,RFRP3,QRFP43, neuropep-
tide FF, and neuropeptide AF. The limit of detectability was 2
pmol/liter, and the intra- and interassay coefficients of variation
were 8.3 and 10.2%, respectively.
Data analysis
Data are presented as mean SEM. Hormone profiles during
4-h blood sampling studies andGnRH tests were analyzed using
repeated measures two-way ANOVA with Bonferonni post hoc
correction. Pairs ofmeanswere analyzedusing theunpaired two-
tailed t test. Multiple means were compared using one-way
ANOVA with Bonferonni’s Multiple Comparison Test. A pre-
viously described modified Santen and Bardin method was used
to assess LH pulsatility (34, 35). In all cases, P 0.05 was con-
sidered statistically significant.
Results
Characteristics of subjects recruited to the study
Baseline age, weight, and body mass index were not
significantly different between kisspeptin and saline study
groups (Table 1). Weight remained stable in both treat-
ment groups during the study (mean weight change from
beginning to end of study: saline, 0.5 kg; kisspeptin,
0.1 kg; P  0.09). Subjects reported no increased inci-
dence of nausea or other side effects after injection of
kisspeptin or saline. Mean heart rate and systolic and di-
astolic blood pressure were similar before and after the
treatment period (wk 5–6) in all participants (data not
shown). Furthermore, no significant acute changes in
heart rate or systolic and diastolic blood pressure were
observed after kisspeptin administration when compared
with saline control (data not shown).
Kisspeptin immunoreactivity in plasma was raised
after injection of kisspeptin
Baseline plasma kisspeptin-IR was below 2 pmol/liter
and remained unchanged during the 4-h period after in-
jection of saline (Fig. 1, A and B). Kisspeptin injection
resulted in a rise in plasma kisspeptin-IR, with peak mean
kisspeptin-IR of approximately 5000 pmol/liter at 45min
after injection (Fig. 1, A and B). Similar patterns of
kisspeptin-IR were observed after injection of kisspeptin
on the first and last injection days (Fig. 1, A and B).
In subjects randomized to receive saline injections,
plasma kisspeptin-IR remained less than 2 pmol/liter dur-
ing basal measurements taken throughout the 8-wk study
protocol (Fig. 1D). In subjects randomized to receive
kisspeptin injections, plasma kisspeptin-IR was raised
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during the 2-wk kisspeptin treatment period (wk 5–6) but
remainedbelow2pmol/liter for the remainder of the study
protocol (Fig. 1C). These twice-weekly blood samples
were taken at various times of the day (determined by
subject availability) between the twice-daily injections.
Accordingly, the mean kisspeptin-IR values during the
treatment period (wk 5, mean plasma kisspeptin-IR,
416 217 pmol/liter; and wk 6, mean plasma kisspeptin-
IR, 751  252 pmol/liter) were lower than the peak
kisspeptin-IR observed 45 min after kisspeptin injection.
Effects of first injection of saline or kisspeptin on
serum reproductive hormones in women with HA
On the first injection day of the treatment period (wk 5,
d 1), saline injection did not change serum LH, FSH, or
estradiol levels compared with baseline (Fig. 2, A–C).
Kisspeptin-54 injection acutely and potently increased se-
rumLH levels in subjects withHA in comparison to saline
(P  0.001 at time points 150 to 240 min; Fig. 2A). The
meanmaximal increase in LH frombaseline after kisspep-
tin injection was observed at 240 min and was 24.0 3.5
IU/liter above baseline. Kisspeptin-54 injection also po-
tently increased serum FSH levels compared with saline
(P 0.001 at time points 180 to 240 min; Fig. 2B). After
kisspeptin injection, themaximalFSHrisewasobservedat
240 min and was 9.1 2.5 IU/liter above baseline. Estra-
diol levels after kisspeptin injection were initially similar
to those following saline. However, estradiol levels sig-
nificantly increased above baseline between 180 and 240
min after kisspeptin administration (P  0.05; Fig. 2C).
Effects of last injection of saline or kisspeptin on
serum reproductive hormones in women with HA
On the last injection day of the treatment period (wk 6,
d 7), saline injection did not change serum LH, FSH, or
estradiol levels compared with baseline (Fig. 2, D–F).
Kisspeptin administration resulted in a significant rise
in LH only at 240 min after injection and no significant
rises in FSH or estradiol. Responses of LH, FSH, and
estradiol to the kisspeptin administration were all sig-
nificantly reduced after the last injection (wk 6, d 7)
when compared with the responses after the first
kisspeptin injection (wk 5, d 1) (P  0.05 for LH, FSH,
and estradiol responses).
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FIG. 1. Effect of injections of saline or kisspeptin-54 on plasma kisspeptin-IR in women with HA. A and B, Mean  SEM plasma kisspeptin-IR after
bolus sc injection of saline or kisspeptin-54 (KP54) 6.4 nmol/kg (n  5 per group) on the first day (A) or last (14th) day (B). Injections were
administered at 0 min. C and D, Mean  SEM basal plasma kisspeptin-IR during each week of the 8-wk study protocol in subjects randomized to
receive kisspeptin-54 (C) or saline (D) injections during wk 5–6. Data are shown as mean  SEM. *, P  0.05; **, P  0.01; ***, P  0.001.
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After the observation of significantly reduced gonado-
tropin responses to kisspeptin on the last injection day, we
decided to assess further the duration of response to
kisspeptin injection in one volunteer in whom blood sam-
plingwas extended to 8 h after injection. In this volunteer,
kisspeptin-IR was raised until 6 h after injection (data not
shown). Furthermore, serumLH, FSH, and estradiol were
still raised above baseline by the end of the 8-h sampling
period (data not shown).
We also examined responsiveness to iv GnRH in five
additional subjects with HA, both before and after
kisspeptin treatment. We observed LH responses to
GnRH in all subjects before commencing kisspeptin treat-
ment (mean peak LH increase during first 2 h after GnRH
injection, 14.4  4.6 IU/liter) (Fig. 3). Furthermore these
subjects remained responsive to GnRH injection 8–12 h
after their final kisspeptin injection (P 0.23 vs. baseline
LH response, using two-way ANOVA) (Fig. 3).
Reproductive hormones, LH pulsatility pattern,
and radiological findings after saline or kisspeptin
treatment
Mean LH levels from twice-weekly basal blood tests
during wk 1 to 4 (the baseline period) were slightly lower
in the kisspeptin group than the saline group [mean LH,
saline 3.7  0.6 vs. kisspeptin 1.8  0.3; P  0.05; Sup-
plementary Table 1, published as supplemental data on
TheEndocrine Society’s JournalsOnlineweb site at http://
jcem.endojournals.org]. Small rises in mean basal LH and
FSH levels were detected during wk 5 to 6 (the treatment
period) in women randomized to kisspeptin vs. saline
(mean basal LH, saline0.8 0.7 vs. kisspeptin1.2
0.7; P  0.09; mean basal FSH, saline 1.8  0.4 vs.
kisspeptin0.6 0.4; P 0.05). Basal serum reproduc-
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FIG. 3. Comparison of LH responses to GnRH administration before
and after kisspeptin-54 injections in women with HA. Intravenous
GnRH (100 g) was administered 7 d before commencement of a
14-d, twice-daily regime of sc kisspeptin injections (6.4 nmol/kg)
(baseline response to GnRH) (n  5). The GnRH test was repeated 8–
12 h after the last injection of kisspeptin (posttreatment response to
GnRH). When comparing baseline and posttreatment LH responses to
GnRH injection, overall responses were similar (P  0.23), as were LH
changes at each time-point after GnRH injection. Injections were
administered at 0 min. Data are shown as mean  SEM.
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FIG. 2. Effects of the first and last injections of saline or kisspeptin-54 on serum reproductive hormones in women with HA. A–C, Changes in
serum LH (A), FSH (B), and estradiol (C) after bolus sc injection of saline (n  5) or 6.4 nmol/kg kisspeptin-54 (KP54, n  5) on first day (wk 5, d 1)
of treatment period are shown. D–F, Changes in serum LH (D), FSH (E), and estradiol (F) after bolus sc injection of saline or kisspeptin-54 on the
last day (wk 6, d 7) of the treatment period are shown. Injections were administered at 0 min. Data are shown as mean  SEM. *, P  0.05;
***, P  0.001. E2, Estradiol.
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tive hormone levels were otherwise similar between
kisspeptin and saline groups throughout the 8-wk study
period.
There was no significant change in mean LH, number of
LH pulses, or mean pulse amplitude observed in patients
receiving saline or kisspeptin (Supplementary Table 2).
There was no significant change in mean values for
endometrial thickness, ovarian volume, follicle number,
ormaximumfolliclediameterobservedafterkisspeptinvs.
saline treatment (Supplementary Table 3). One subject
receiving kisspeptin developed radiological changes sug-
gesting possible ovulation, with subsequent symptoms of
premenstruation. Ultrasound scans of the subject revealed
the rupture of a preovulatory follicle (19-mm diameter)
together with subsequent appearance of a corpus luteum.
However, this subject had no detectable rise in serum pro-
gesterone level and reported no menstrual bleeding.
Discussion
We report the first study of kisspeptin administration in a
humanmodel of infertility and the first investigationof the
effects of chronic administration of kisspeptin in humans.
Our results show that acute administration of kisspep-
tin-54 increased serum gonadotropin levels in women
with HA but repeated injections lead to reduced effect.
Subjects with HA display a reproductive hormone pro-
file that resembles the follicular phase of the menstrual
cycle (low circulating gonadotropin and estradiol levels)
more closely than the other phases. Acute LH response to
kisspeptin injection was approximately 4-fold greater in
patients with HA than in previously studied healthy fe-
males in the follicular phase of the menstrual cycle given
an identical weight-adjusted dose (mean area under curve
LH increase during first 4 h post-kisspeptin injection in
h.iU/liter: women with HA in the current study, 40.2;
healthy females in follicular phase, 9.8; P  0.01) (27).
This is consistent with the observation that LH responses
to kisspeptin-10 may be higher in undernourished female
rats when compared with those fed ad libitum (32). Fur-
ther work in a single study comparing women with HA
and women with normal menstrual cycles is required to
confirm the observation made in this study. If confirmed,
it would be interesting to determine whether increased
responsiveness of women with HA to kisspeptin is attrib-
utable to factors such as increased sensitivity to kisspeptin
itself or increased pituitary sensitivity to GnRH.
In juvenile female rats, twice-daily intracerebroventric-
ular administration of kisspeptin-10 induces precocious
vaginal opening in ad libitum fed animals (28) and restores
vaginal opening under conditions of caloric restriction
(32). Furthermore, Plant et al. (29) found that hourly iv
kisspeptin-10 pulses were sufficient to induce a train of
GnRH discharges characteristic of puberty in juvenile
monkeys.Wewere therefore surprised to observe that LH,
FSH, and estradiol responses to the last kisspeptin injec-
tion were markedly lower than responses to the first in-
jection. In addition, reproductive ultrasound and basal
reproductive hormone parameters were similar between
the two treatment groups. The last kisspeptin injection,
which was reconstituted using peptide returned from
home storage by each volunteer, led to similarly elevated
plasma kisspeptin-IR to that observed after the first injec-
tion. This suggests that peptide degradation caused by
home storage of kisspeptin did not account for the mark-
edly reduced gonadotropin responses to kisspeptin on the
last injection day.
Kisspeptin-10 was used during the animal studies of
repetitive kisspeptin administration (28, 29), whereas the
54-aminoacid formofkisspeptinwasadministeredduring
this study. Our results reveal that plasma kisspeptin-IR is
raised for up to 6 h after each sc injection of kisspeptin-54.
Sustained exposure of monkeys and rodents to kisspeptin
also leads to desensitization to its effects. Seminara et al.
(30) demonstrated that continuous iv kisspeptin-10 ad-
ministration to male rhesus monkeys for 98 h led to in-
creased LH release lasting only 3 h, followed by a return
of gonadotropin concentrations to levels similar to those
observed before the kisspeptin-10 infusion. Similarly,
Thompson et al. (31) observed increased LH levels only
during the first day of a continuous 3-d sc kisspeptin-54
infusion to adult male rats. A recent publication by Keen
et al. (36) demonstrates the pattern of kisspeptin release
within the monkey hypothalamic median eminence to be
pulsatile. Animal data suggest that a protocol using inter-
mittent administration of kisspeptin (28–29, 32) may be
less likely to result in desensitization than a protocol using
continuous administration (30, 31). However, given the
prolonged action of sc kisspeptin-54 injection on plasma
kisspeptin-IR and reproductive hormone levels, our pro-
tocol of twice-daily kisspeptin-54 injections may have re-
sulted in desensitization through prolonged and nonpul-
satile kisspeptin exposure. An intermittent, iv method of
kisspeptin administration might minimize or prevent the
desensitizationof gonadotropin responsesobserved in this
study.
We observed GnRH administration to stimulate LH
secretion in HA subjects even after 2 wk of kisspeptin
treatment. A study by Ramaswamy et al. (37) demon-
strated that responsiveness to GnRH bolus was main-
tained in adult male rhesusmonkeys during an infusion of
kisspeptin-10 delivered at 200 g/h but was reduced at a
higher infusion rate of 400g/h. In our study, a lower LH
response to GnRH administration was observed after
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kisspeptin treatment when compared with the baseline
response; however, thisdifferencewasnot significant.Our
results therefore suggest that the protocol of kisspeptin
administration used during this study led to desensitiza-
tion upstream of the pituitary gland. It is possible that our
observations are explained by KISS1R down-regulation,
which has been previously demonstrated in vitro (38).
Kisspeptin antagonism has been shown to inhibit pul-
satile GnRH release in pubertal female rhesus monkeys
and pulsatile LH release in adult female sheep (39). Fur-
thermore, Ramaswamy et al. (37) observed that LH pulse
amplitude and frequency was reduced by infusion of
kisspeptin-10 at 400g/h (but not 200g/h) in adultmale
monkeys. In the current study, neither LHpulse amplitude
nor LH pulse frequency was significantly altered after
kisspeptin treatment in women with HA. Our results
might be explained by rapid recovery from kisspeptin ex-
posure during the 24-h period between the final kisspeptin
injection and the second assessment of LH pulsatility
study. It is also plausible that a protocol using higher or
more frequent doses of kisspeptin injections would have
significantly altered LH pulsatility.
This studydemonstrates that acute sc administrationof
kisspeptin-54 potently stimulates pituitary-gonadal func-
tion in human females with HA. However, significantly
reduced gonadotropin responses to kisspeptin-54 admin-
istration were observed after 2 wk of twice-daily kisspep-
tin-54 injections, suggesting desensitization. These results
have important implications for the therapeutic potential
of kisspeptin to treat patientswith reproductive disorders.
Acknowledgments
We are grateful to the Wellcome Trust and Sir JohnMcMichael
Centre for providing infrastructure for this study.
Address all correspondence and requests for reprints to: Prof.
Stephen R. Bloom, Department of Investigative Medicine, Im-
perial College London, Sixth Floor, Commonwealth Building,
Hammersmith Hospital, Du Cane Road, London W12 ONN,
United Kingdom. E-mail: s.bloom@imperial.ac.uk.
C.N.J. and G.M.K.N. are supported by Research Training
Fellowships from the Wellcome Trust. R.R. is supported by a
National Institute for Health Research Fellowship. V.S. is sup-
ported by a Medical Research Council Research Training Fel-
lowship. W.S.D. is supported by an NIHR Clinician Scientist
Award and a Wellcome Trust Value in People Award. K.G.M.
holds a Biotechnology and Biological Sciences Research Council
New Investigator Award. This work is funded by an MRC Ex-
perimentalMedicine project grant. The department is funded by
an Integrative Mammalian Biology Capacity Building Award
and the NIHR Biomedical Research Centre Funding Scheme.
Disclosure Summary: The authors have nothing to disclose.
References
1. Yen SS 1993 Female hypogonadotropic hypogonadism. Hypotha-
lamic amenorrhea syndrome. Endocrinol Metab Clin North Am
22:29–58
2. Reindollar RH, Novak M, Tho SP, McDonough PG 1986 Adult-
onset amenorrhea: a study of 262 patients. Am J Obstet Gynecol
155:531–543
3. Frisch RE, Revelle R 1970 Height and weight at menarche and a
hypothesis of critical body weights and adolescent events. Science
169:397–399
4. Laughlin GA, Dominguez CE, Yen SS 1998 Nutritional and endo-
crine-metabolic aberrations in women with functional hypotha-
lamic amenorrhea. J Clin Endocrinol Metab 83:25–32
5. LoucksAB,VerdunM,HeathEM1998Lowenergy availability, not
stress of exercise, alters LH pulsatility in exercising women. J Appl
Physiol 84:37–46
6. MarcusMD, Loucks TL, Berga SL 2001 Psychological correlates of
functional hypothalamic amenorrhea. Fertil Steril 76:310–316
7. Reame NE, Sauder SE, Case GD, Kelch RP, Marshall JC 1985 Pul-
satile gonadotropin secretion in women with hypothalamic amen-
orrhea: evidence that reduced frequency of gonadotropin-releasing
hormone secretion is themechanismofpersistent anovulation. JClin
Endocrinol Metab 61:851–858
8. MartinK, SantoroN,Hall J, FilicoriM,WiermanM,Crowley JrWF
1990 Clinical review 15: management of ovulatory disorders with
pulsatile gonadotropin-releasing hormone. JClinEndocrinolMetab
71:1081A–1081G
9. RossingMA,Daling JR,WeissNS,MooreDE,Self SG1994Ovarian
tumors in a cohort of infertile women. N Engl J Med 331:771–776
10. KotaniM,DetheuxM,VandenbogaerdeA,CommuniD,Vanderwinden
JM,Le Poul E, Bre´zillon S,TyldesleyR, Suarez-HuertaN,Vandeput
F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M 2001 The
metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural
ligands of the orphan G protein-coupled receptor GPR54. J Biol
Chem 276:34631–34636
11. Lee JH,MieleME, Hicks DJ, Phillips KK, Trent JM,Weissman BE,
Welch DR 1996 KiSS-1, a novel human malignant melanoma me-
tastasis-suppressor gene. J Natl Cancer Inst 88:1731–1737
12. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi
K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y,
Watanabe T, AsadaM, Yamada T, Suenaga M, Kitada C, Usuki S,
Kurokawa T, Onda H, Nishimura O, Fujino M 2001 Metastasis
suppressor gene KiSS-1 encodes peptide ligand of a G-protein-cou-
pled receptor. Nature 411:613–617
13. Lee DK, Nguyen T, O’Neill GP, Cheng R, Liu Y, Howard AD,
Coulombe N, Tan CP, Tang-Nguyen AT, George SR, O’Dowd BF
1999 Discovery of a receptor related to the galanin receptors. FEBS
Lett 446:103–107
14. Muir AI, Chamberlain L, Elshourbagy NA, Michalovich D, Moore
DJ, Calamari A, Szekeres PG, Sarau HM, Chambers JK, Murdock
P, Steplewski K, Shabon U, Miller JE, Middleton SE, Darker JG,
LarminieCG,Wilson S, BergsmaDJ, EmsonP, Faull R, Philpott KL,
Harrison DC 2001 AXOR12, a novel human G protein-coupled
receptor, activated by the peptide KiSS-1. J Biol Chem 276:28969–
28975
15. Lapatto R, Pallais JC, Zhang D, Chan YM,Mahan A, Cerrato F, Le
WW,HoffmanGE, Seminara SB 2007Kiss1/mice exhibit more
variable hypogonadism than Gpr54/mice. Endocrinology 148:
4927–4936
16. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno Jr
JS, Shagoury JK,Bo-AbbasY,KuohungW,SchwinofKM,Hendrick
AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF,
O’Rahilly S, Carlton MB, Crowley Jr WF, Aparicio SA, Colledge
WH 2003 The GPR54 gene as a regulator of puberty. N Engl JMed
349:1614–1627
17. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom
E 2003Hypogonadotropic hypogonadism due to loss of function of
4322 Jayasena et al. Effects of Kisspeptin in Women with HA J Clin Endocrinol Metab, November 2009, 94(11):4315–4323
the KiSS1-derived peptide receptor GPR54. ProcNatl Acad Sci USA
100:10972–10976
18. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S,
Seminara SB, Mendonca BB, Kaiser UB, Latronico AC 2008 A
GPR54-activatingmutation in a patient with central precocious pu-
berty. N Engl J Med 358:709–715
19. IrwigMS,FraleyGS, Smith JT,AcohidoBV,PopaSM,Cunningham
MJ,GottschML,CliftonDK, SteinerRA2004Kisspeptin activation
of gonadotropin releasing hormone neurons and regulation of
KiSS-1 mRNA in the male rat. Neuroendocrinology 80:264–272
20. Navarro VM, Castellano JM, Ferna´ndez-Ferna´ndez R, Barreiro
ML, Roa J, Sanchez-Criado JE, Aguilar E, Dieguez C, Pinilla L,
Tena-Sempere M 2004 Developmental and hormonally regulated
messenger ribonucleic acid expression of KiSS-1 and its putative
receptor, GPR54, in rat hypothalamus and potent luteinizing hor-
mone-releasing activity of KiSS-1 peptide. Endocrinology 145:
4565–4574
21. Thompson EL, Patterson M, Murphy KG, Smith KL, Dhillo WS,
Todd JF, Ghatei MA, Bloom SR 2004 Central and peripheral ad-
ministration of kisspeptin-10 stimulates the hypothalamic-pitu-
itary-gonadal axis. J Neuroendocrinol 16:850–858
22. Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV,
Crowley WF, Seminara S, Clifton DK, Steiner RA 2004 A role for
kisspeptins in the regulationof gonadotropin secretion in themouse.
Endocrinology 145:4073–4077
23. Messager S, Chatzidaki EE,MaD, Hendrick AG, Zahn D, Dixon J,
Thresher RR, Malinge I, Lomet D, Carlton MB, Colledge WH,
Caraty A, Aparicio SA 2005 Kisspeptin directly stimulates gonado-
tropin-releasing hormone release viaGprotein-coupled receptor 54.
Proc Natl Acad Sci USA 102:1761–1766
24. Shahab M, Mastronardi C, Seminara SB, Crowley WF, Ojeda SR,
Plant TM 2005 Increased hypothalamic GPR54 signaling: a poten-
tial mechanism for initiation of puberty in primates. ProcNatl Acad
Sci USA 102:2129–2134
25. Caraty A, Smith JT, Lomet D, Ben Saïd S, Morrissey A, Cognie J,
Doughton B, Baril G, Briant C, Clarke IJ 2007 Kisspeptin synchro-
nizes preovulatory surges in cyclical ewes and causes ovulation in
seasonally acyclic ewes. Endocrinology 148:5258–5267
26. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy
KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA,
Bloom SR 2005 Kisspeptin-54 stimulates the hypothalamic-pitu-
itary gonadal axis in human males. J Clin Endocrinol Metab 90:
6609–6615
27. Dhillo WS, Chaudhri OB, Thompson EL, Murphy KG, Patterson
M, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donaldson
M, Ghatei MA, Bloom SR 2007 Kisspeptin-54 stimulates gonadotro-
pin release most potently during the preovulatory phase of the men-
strual cycle in women. J Clin Endocrinol Metab 92:3958–3966
28. Navarro VM, Ferna´ndez-Ferna´ndez R, Castellano JM, Roa J,
Mayen A, Barreiro ML, Gaytan F, Aguilar E, Pinilla L, Dieguez C,
Tena-Sempere M 2004 Advanced vaginal opening and precocious
activation of the reproductive axis by KiSS-1 peptide, the endoge-
nous ligand of GPR54. J Physiol 561:379–386
29. Plant TM, Ramaswamy S, Dipietro MJ 2006 Repetitive activation
of hypothalamic G protein-coupled receptor 54 with intravenous
pulses of kisspeptin in the juvenile monkey (Macaca mulatta) elicits
a sustained train of gonadotropin-releasing hormone discharges.
Endocrinology 147:1007–1013
30. Seminara SB, Dipietro MJ, Ramaswamy S, Crowley Jr WF, Plant
TM 2006 Continuous human metastin 45-54 infusion desensitizes
G protein-coupled receptor 54-induced gonadotropin-releasing
hormone release monitored indirectly in the juvenile male Rhesus
monkey (Macaca mulatta): a finding with therapeutic implications.
Endocrinology 147:2122–2126
31. Thompson EL,Murphy KG, PattersonM, Bewick GA, Stamp GW,
Curtis AE, Cooke JH, Jethwa PH, Todd JF, Ghatei MA, Bloom SR
2006 Chronic subcutaneous administration of kisspeptin-54 causes
testicular degeneration in adult male rats. Am J Physiol Endocrinol
Metab 291:E1074–E1082
32. Castellano JM, Navarro VM, Ferna´ndez-Ferna´ndez R, Nogueiras
R, Tovar S, Roa J, Vazquez MJ, Vigo E, Casanueva FF, Aguilar E,
Pinilla L, Dieguez C, Tena-Sempere M 2005 Changes in hypotha-
lamic KiSS-1 system and restoration of pubertal activation of the
reproductive axis by kisspeptin in undernutrition. Endocrinology
146:3917–3925
33. Tovar S, Va´zquez MJ, Navarro VM, Ferna´ndez-Ferna´ndez R,
Castellano JM, Vigo E, Roa J, Casanueva FF, Aguilar E, Pinilla L,
Dieguez C, Tena-Sempere M 2006 Effects of single or repeated in-
travenous administration of kisspeptin upon dynamic LH secretion
in conscious male rats. Endocrinology 147:2696–2704
34. Adams JM, Taylor AE, Schoenfeld DA, Crowley Jr WF, Hall JE
1994 The midcycle gonadotropin surge in normal women occurs in
the face of an unchanging gonadotropin-releasing hormone pulse
frequency. J Clin Endocrinol Metab 79:858–864
35. Hayes FJ, McNicholl DJ, Schoenfeld D, Marsh EE, Hall JE 1999
Free -subunit is superior to luteinizing hormone as a marker of
gonadotropin-releasing hormone despite desensitization at fast
pulse frequencies. J Clin Endocrinol Metab 84:1028–1036
36. Keen KL,Wegner FH, Bloom SR, GhateiMA, Terasawa E 2008An
increase in kisspeptin-54 release occurswith the pubertal increase in
luteinizing hormone-releasing hormone-1 release in the stalk-me-
dian eminence of female rhesus monkeys in vivo. Endocrinology
149:4151–4157
37. RamaswamyS, Seminara SB, PohlCR,DiPietroMJ,Crowley JrWF,
Plant TM 2007 Effect of continuous iv administration of human
metastin 45–54 on the neuroendocrine activity of the hypothalamic-
pituitary-testicular axis in the adult male rhesus monkey (Macaca
mulatta). Endocrinology 148:3364–3370
38. Carvalho-Bianco SD, Teles M, Kuohung W, Xu S, Latronico AC,
Kaiser UB,Role ofGPR54 desensitization in kisspeptin action. Proc
of the American Endocrine Society Meeting, Boston, MA, 2006
(Abstract P3-251)
39. Roseweir AK, Kauffman AS, Smith JT, Guerriero KA, Morgan K,
Pielecka-Fortuna J, Pineda R, Gottsch ML, Tena-Sempere M,
Moenter SM, Terasawa E, Clarke IJ, Steiner RA, Millar RP 2009
Discovery of potent kisspeptin antagonists delineate physiological
mechanisms of gonadotropin regulation. JNeurosci 29:3920–3929
J Clin Endocrinol Metab, November 2009, 94(11):4315–4323 jcem.endojournals.org 4323
840 VOLUME 88 NUMBER 6 | dEcEMBER 2010 | www.nature.com/cpt
articles nature publishing group
Infertility affects 9% of couples worldwide.1 Gonadotrophin 
injections containing luteinizing hormone (LH) or follicle-
 stimulating hormone (FSH) are routinely used to treat such 
patients. Although this treatment is efficacious, it is associated 
with the risk of the potentially life-threatening condition known 
as ovarian hyperstimulation syndrome.2 It has recently emerged 
that kisspeptin plays a critical role in the mammalian reproduc-
tive system and may therefore offer a novel therapeutic target in 
the treatment of patients with reproductive disorders.
Kisspeptin is a group of arginine–phenylalanine amide peptides 
encoded by the KISS1 gene, which is expressed in the hypotha-
lamus, pituitary gland, and gonads.3,4 In humans, inactivating 
mutations of the kisspeptin receptor (KISS1R) cause pubertal 
failure,5,6 and activating mutations lead to precocious puberty.7 
In all the mammalian species that have been investigated, central 
or peripheral administration of kisspeptin induces the release of 
gonadotrophin.8–16 This effect is abolished by preadministration 
of an antagonist to the hypothalamic hormone gonadotrophin-
releasing hormone.13 Kisspeptin is therefore thought to indirectly 
stimulate the release of gonadotrophin from the pituitary gland 
by stimulating the release of gonadotrophin-releasing hormone 
from the hypothalamus. We have previously demonstrated that 
single injections of kisspeptin-54 (KP-54) stimulate the secre-
tion of gonadotrophin in healthy human male and female sub-
jects.15,16 It is therefore of interest to investigate whether KP-54 
can be used to stimulate the release of gonadotrophin in patients 
with infertility conditions that are associated with deficient secre-
tion of gonadotrophin (hypogonadotrophic hypogonadism).
Hypothalamic amenorrhea (HA) is a form of hypogonado-
trophic hypogonadism17 that accounts for ~30% of  amenorrhea 
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Twice-Weekly Administration of Kisspeptin-54 
for 8 Weeks Stimulates Release of Reproductive 
Hormones in Women With Hypothalamic 
Amenorrhea
CN Jayasena1, GMK Nijher1, A Abbara1, KG Murphy1, A Lim2, D Patel2, A Mehta2, C Todd2, 
M Donaldson3, GH Trew4, MA Ghatei1, SR Bloom1 and WS Dhillo1
Kisspeptin is a novel therapeutic target for infertility. A single kisspeptin-54 (KP-54) injection acutely stimulates the 
release of reproductive hormones in women with hypothalamic amenorrhea (HA), a commonly occurring condition 
characterized by absence of menstruation; however, twice-daily administration of KP-54 results in tachyphylaxis. We 
determined the time course of desensitization to twice-daily KP-54 injections, compared the effects of twice-daily and 
twice-weekly administration regimens of KP-54, and studied the effects of long-term twice-weekly administration 
of KP-54 on the release of reproductive hormones in women with HA. When KP-54 was administered twice daily, 
responsiveness to luteinizing hormone (LH) diminished gradually, whereas responsiveness to follicle-stimulating 
hormone (FSH) was nearly abolished by day 2. Twice-weekly KP-54 administration resulted in only partial desensitization, 
in contrast to the complete tolerance achieved with twice-daily administration. Women with HA who were treated with 
twice-weekly KP-54 injections had significantly elevated levels of reproductive hormones after 8 weeks as compared with 
treatment with saline. No adverse effects were observed. This study provides novel pharmacological data on the effects 
of KP-54 on the release of reproductive hormones in women with HA.
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(absence of menstruation) in women of reproductive age.18 
Functional HA is defined as occurring in the absence of a  structural 
 hypothalamo–pituitary lesion and often results from a low body 
weight or significant weight loss.19–24 We previously demonstrated 
that a single injection of KP-54 stimulates the release of gonado-
trophin in women with HA.25 However, women with HA who were 
treated with twice-daily KP-54 injections for 2 weeks were mark-
edly less responsive to KP-54 at the end of the study as compared 
with the start of the study. Interestingly, these women remained 
responsive to gonadotrophin-releasing hormone injection at the 
end of the study, thereby suggesting that the desensitization associ-
ated with repeated administration of KP-54 was occurring at the 
KISS1R. Consequently, acute administration of KP-54 to women 
with HA results in a potent stimulation of LH release, but twice-
daily KP-54 administration for 2 weeks leads to tachyphylaxis.25
Determining whether KP-54 can stimulate gonadotrophin 
release in a sustained manner has important implications for 
the treatment of patients with infertility. We hypothesized that 
an alternative protocol of repeated KP-54 administration would 
sustainably stimulate the release of gonadotrophin in women 
with HA. The aims of this randomized, double-blinded, placebo-
controlled parallel design study were to determine (i) the time 
course over which desensitization to the effects of KP-54 on the 
release of reproductive hormone occurs in women with HA, 
(ii) the effects of prolongation of the KP-54 dose interval on 
desensitization to KP-54 treatment, and (iii) whether the admin-
istration of KP-54 twice weekly can result in chronic stimula-
tion of gonadotrophin release and restore menstrual cyclicity in 
women with HA over an 8-week period.
Results
Characteristics of subjects recruited to the study
Baseline age, weight, and body mass index were similar for all 
groups of subjects in this study (Table 1).
study 1: time course of desensitization to the 
 gonadotrophin‑inducing effects of KP‑54 in women with HA
Twice-daily subcutaneous administration of 6.4 nmol/kg 
KP-54 was associated with a progressive reduction in acute 
LH responses after injection of KP-54 in women with HA 
(Figure 1a). On day 1, the mean maximal LH response during 
the first 4 h after KP-54 injection was 23.3 ± 12.1 IU/l; however, 
the mean maximal LH response during this period dropped to 
11.2 ± 5.7, 4.2 ± 1.1, 3.4 ± 0.5, and 1.1 ± 0.5 h·IU/l on days 2, 3, 
4, and 14 of injections, respectively (Figure 1a). On day 1, the 
mean maximal FSH response during the first 4 h after the KP-54 
injection was 7.2 ± 2.2 h·IU/l. However, the acute FSH responses 
after the injection were <2 U/l on days 2, 3, 4, and 14 (Figure 1b). 
Mean estradiol levels were not significantly different at any point 
during the study (Figure 1c).
study 2: two‑week study of release of reproductive 
 hormones in serum in women with HA receiving twice‑
daily KP‑54  injections as compared with those receiving 
twice‑weekly injections
A. Effect of twice-daily subcutaneous injection of KP-54 (6.4 nmol/ kg) 
on the release of reproductive hormone. Twice-daily subcuta-
neous injection of 6.4 nmol/kg KP-54 in women with HA 
potently stimulated gonadotrophin release on day 1, with 
the maximal increase being observed 240 min after the injec-
tion (mean maximal increase following KP-54 injection on 
day 1: LH: 23.2 ± 11.3 IU/l; FSH: 7.2 ± 2.1 IU/l). However, on 
day 14, reproductive hormone responses were  significantly 
reduced as compared with those on day 1 (mean maximal 
increase after KP-54 injection on day 14: LH: 1.0 ± 0.5 IU/l, 
P < 0.05 relative to day 1; FSH: 0.2 ± 0.3 IU/l, P < 0.001 rela-
tive to day 1) (Figure 2a,b). The estradiol response was 
nonsignificantly lower on day 14 as compared with that at 
day 1 (mean maximal estradiol increase after the injection: 
day 1, 48.2 ± 29.7 pmol/l; day 14, −12.7 ± 7.0 pmol/l, P = 0.06) 
(Figure 2c).
B. Effect of twice-weekly subcutaneous injection of KP-54 (6.4 nmol/kg) 
on release of reproductive hormone. We had observed that subcu-
taneous administration of KP-54 twice daily led to significant 
desensitization of gonadotrophin responses within 2 weeks of 
treatment. We therefore investigated whether the same sub-
cutaneous dose of KP-54 (6.4 nmol/kg) would be associated 
table 1 Comparison of baseline characteristics of women with hypothalamic amenorrhea participating in the 2‑week pilot studies 
of the effects of administering kisspeptin and the 8‑week study of the effects of administering saline vs. those of administering 
kisspeptin
Protocol treatment
2-Week pilot studies 8-Week study
P-valueKisspeptin-54 (n = 10) Saline (n = 5) Kisspeptin-54 (n = 5)
Age (years) 28.1 ± 1.1 27.0 ± 2.6 27.2 ± 2.4 NS
Weight (kg) 52.6 ± 0.7 54.5 ± 3.9 53.4 ± 3.0 NS
Body mass index (kg/m2) 19.1 ± 0.3 19.7 ± 1.1 19.6 ± 0.7 NS
duration of amenorrhea (months) 22.4 ± 9.9 20.4 ± 5.1 28.8 ± 12.0 NS
Serum LH (IU/l) 2.5 ± 0.6 1.7 ± 0.7 1.4 ± 0.5 NS
Serum FSH (IU/l) 4.8 ± 0.3 3.8 ± 0.9 3.6 ± 0.6 NS
Serum estradiol (pmol/l) 133 ± 10 87 ± 17 151 ± 28 NS
Mean values ± SEM data are shown.
FSH, follicle-stimulating hormone; LH, luteinizing hormone; NS, nonsignificant difference between the three groups of women with hypothalamic amenorrhea.
842 VOLUME 88 NUMBER 6 | dEcEMBER 2010 | www.nature.com/cpt
articles
with less desensitization if administered twice weekly (rather 
than twice daily). On day 14, mean gonadotrophin responses 
after the KP-54 injection were nonsignificantly lower relative 
to day 1 (mean maximal increase in IU/l after the injection: 
LH: day 1, 18.8 ± 6.6 vs. day 14, 11.5 ± 4.0, P = 0.08; FSH: day 
1, 5.8 ± 2.0 vs. day 14, 4.1 ± 1.1, P = 0.14) (Figures 2d,e). The 
mean maximal increases in serum estradiol on day 1 after the 
KP-54 injection was not significantly different from that at day 
14 (day 1 44.8 ± 15.7 pmol/l vs. day 14 27.5 ± 15.5 pmol/l; P = 
0.47) (Figure 2f).
A summary of the effects of subcutaneous administration of 
KP-54 injections on days 1 and 14 of each of the different 2-week 
dosing regimens of KP-54 is shown in Figures 2g–i as mean 
areas under the curve for LH, FSH, and estradiol responses.
study 3: effects of twice‑weekly KP‑54 administration for  
8 weeks on reproductive hormone levels in women with HA
The results from study 2 suggested that twice-weekly administra-
tion of KP-54 6.4 nmol/kg significantly reduces desensitization 
to the effects of KP-54 on the release of reproductive hormone. 
A randomized, double-blinded, placebo-controlled, parallel 
design study was therefore performed in order to determine 
whether twice-weekly administration of KP-54 at 6.4 nmol/kg 
would stimulate the release of reproductive hormone over an 
8-week period (protocol summary shown in Figure 3). Baseline 
age, weight, and body mass index were not significantly different 
between the group receiving KP-54 and the control group receiv-
ing saline (Table 1). The subjects reported no adverse effects 
after injections of either KP-54 or saline. No significant acute 
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Figure 1 Time course of desensitization to the effects of kisspeptin-54 (6.4 nmol/kg) on reproductive hormone release when administered twice daily for  
2 weeks in women with HA. (a–f) changes in serum levels of LH, FSH, and estradiol (E2) during the first 4 h after kisspeptin-54 (KP-54) injections were measured 
on days 1, 2, 3, 4, and 14 of twice-daily subcutaneous administration of 6.4 nmol/kg of KP-54 (n = 5). (d–f) Summary of the effects of subcutaneous KP-54 
injection as measured on days 1, 2, 3, 4, and 14 of twice-daily subcutaneous administration of 6.4 nmol/kg of KP-54, shown as mean AUc for (d) LH, (e) FSH, and 
(f) estradiol. The data are shown as mean values ± SEM. *P < 0.05 vs. day 1; **P < 0.01 vs. day 1; ***P < 0.001 vs. day 1. AUc, area under the curve; FSH, follicle-
stimulating hormone; HA, hypothalamic amenorrhea; LH, luteinizing hormone.
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changes were observed in heart rate or in systolic or diastolic 
blood pressure after the administration of KP-54 as compared 
with saline (data not shown).
Saline had no significant effects on the release of reproduc-
tive hormones at any time during the 8-week protocol of twice-
weekly injections (Figure 4a–c). As expected, KP-54 stimulated 
the release of reproductive hormones after the injection on day 1. 
After 2 weeks of twice-weekly injections, LH responses after 
the KP-54 injection were significantly lower relative to those 
on day 1 (mean maximal LH increase (IU/l): baseline, 21.5 ± 
10.7; 2 weeks, 10.0 ± 4.3; P < 0.001) (Figure 4d). However, no 
further significant reductions in LH KP-54 were observed after 
injection of KP-54 at 4 weeks (mean maximal LH increase: 9.0 ± 
4.1 IU/l; P > 0.05 vs. response at 2 weeks), 6 weeks (mean maxi-
mal LH increase: 8.9 ± 3.5 IU/l; P > 0.05 vs. response at 2 weeks), 
and 8 weeks (mean maximal LH increase: 7.9 ± 4.5 IU/l; P > 
0.05 vs. response at 2 weeks) (Figure 4d). FSH responses after 
KP-54 injection showed a pattern similar to those of LH over 
the 8-week protocol (mean maximal increase in serum FSH after 
KP-54 injection (IU/l): baseline, 6.4 ± 3.2; 2 weeks, 2.7 ± 0.7, 
P < 0.001 vs. baseline response; 4 weeks, 2.6 ± 0.7, P > 0.05 vs. 
response at 2 weeks; 6 weeks, 2.4 ± 0.8, P > 0.05 vs. response at 
2 weeks; 8 weeks, 2.7 ± 0.8, P > 0.05 vs. response at 2 weeks) 
(Figure 4e). Estradiol responses after injection of KP-54 were 
similar throughout the 8-week protocol of twice-weekly injec-
tions (mean maximal increase in serum estradiol after KP-54 
injection (pmol/l): baseline, 44.4 ± 19.9; 2 weeks, 39.2 ± 14.8; 
4 weeks, 46.2 ± 25.8; 6 weeks, 60.8 ± 17.2; 8 weeks, 20.0 ± 7.5) 
(Figure 4f).
No significant differences were observed at any stage during 
the 8-week protocol with respect to the number of follicles, 
the maximum size of the follicles, the volume of the ovary, and 
endometrial thickness between subjects who received KP-54 
and those who received saline injections (Table 2). More domi-
nant follicles were observed in subjects treated with KP-54 than 
in subjects treated with saline (six vs. three dominant follicles, 
respectively); however, no preovulatory follicles were observed 
in any subject during the study (Table 2). No significant dif-
ferences were observed in the values of the twice-weekly basal 
reproductive hormone measurements at any stage during the 
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8-week protocol, between subjects receiving saline and those 
receiving KP-54 injections (Table 3). One subject receiving 
saline treatment developed a preovulatory LH surge after 8 
weeks of saline treatment; however, none of the subjects ovu-
lated during the study.
DisCussion
Kisspeptin signaling offers an entirely novel therapeutic target 
for treating reproductive disorders; however, our understanding 
of the effects of kisspeptin in patients with infertility is limited. 
Short-term clinical studies suggest that a single injection of KP-54 
safely stimulates the release of reproductive hormones15,16,25 but 
that its repeated administration causes profound tachyphylaxis 
in humans.25 We present novel data suggesting that twice-weekly 
subcutaneous administration of KP-54 stimulates the release of 
reproductive hormones but does not restore menstrual cyclicity 
in women with HA over a 2-month period.
We present detailed data of the time course of desensitiza-
tion to the effects of KP-54 on reproductive hormone release in 
women with HA. Our data suggest that desensitization of LH 
response to twice-daily subcutaneous administration of KP-54 
in women with HA occurs gradually over the 14-day injec-
tion period. LH responses on day 4 were significantly higher 
than those on day 14. By contrast, FSH responses dropped 
to <3 h·IU/l after just 24 h of twice-daily administration of 
KP-54. It has also been suggested that chronic administration 
of  kisspeptin could be useful as a therapy for sex hormone– 
responsive cancers because of its inhibitory effects on the 
release of sex hormones26 and on tumor metastasis.27,28 Our 
data, which suggest that twice-daily subcutaneous administra-
tion of KP-54 leads to downregulation of the hypothalamo–
pituitary–gonadal axis, therefore has implications for such 
 kisspeptin-based therapies. Recent evidence suggests that 
pharmacological blockade of kisspeptin signaling may suppress 
LH pulsatility rather than basal LH levels.29 Further studies 
are required in order to investigate the use of kisspeptin for 
downregulating the reproductive axis as a treatment for sex 
hormone–responsive tumors.
In view of the tachyphylaxis associated with twice-daily 
administration of KP-54 (6.4 nmol/kg), we investigated whether 
lengthening the dose interval to twice-weekly would reduce 
desensitization. We performed a 2-week pilot study, and the 
results suggest that gonadotrophin responses are only partially 
diminished after twice-weekly administration of 6.4 nmol/kg of 
KP-54. This suggests that subjects with HA remained partially 
sensitive to KP-54 injection during this twice-weekly regimen. 
To further assess the efficacy of twice-weekly subcutaneous 
injection of 6.4 nmol/kg KP-54, we performed a longer, 8-week 
study. As observed during the pilot study, partial desensitiza-
tion in the gonadotrophin responses to KP-54 injection was 
observed during the first 2 weeks of administration. However, 
these responses did not significantly diminish further beyond 
this initial 2-week period. Our results therefore suggest that sub-
jects with HA remained partially responsive to KP-54 injection 
during the 8-week study period.
It is interesting to consider why no significant changes in 
 follicle growth were observed during the 8-week study of 
twice-weekly KP-54 vs. saline administration. Previous studies 
of KP-54 administration in humans demonstrated no signifi-
cant alterations in plasma inhibin in healthy male volunteers.15 
However, in this study, we did observe that FSH responses were 
lower than LH responses after the administration of kisspep-
tin. Consistent with this observation, kisspeptin has previously 
been shown to stimulate the release of LH more potently than it 
Twice-weekly blood sampling for LH, FSH, E2  
4-h Blood sampling postinjection (days 1, 14, 28, 42, 56)
Once-weekly pelvic ultrasound scans 
Randomization 
1 56Day of protocol: 14 28 42 
n = 5 
n = 5 
Twice-weekly saline injections
Twice-weekly KP-54 injections
Figure 3 Protocol summary for study 3: the effects of twice-weekly administration of KP-54 for 8 weeks in women with HA. Subjects with HA were randomized 
to receive twice-weekly injections of saline or of KP-54 at 6.4 nmol/kg for 8 weeks. Blood sampling was carried out at various time points during a 4-h period 
immediately after the saline or KP-54 injections on days 1, 14, 28, 42, and 56. Twice-weekly blood sampling was performed for measurement of LH, FSH, and 
estradiol (E2) levels. Ultrasound scans were also performed once a week. FSH, follicle-stimulating hormone; HA, hypothalamic amenorrhea; KP-54, kisspeptin-54; 
LH, luteinizing hormone.
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stimulates the release of FSH when administered to rodents,10 
to healthy male volunteers,15 or to healthy female volunteers.16 
Furthermore, intravenous bolus injection of gonadotrophin-
releasing hormone also stimulates the release of LH release 
more potently as compared with the release of FSH.30 We also 
observed that FSH responses were desensitized more rapidly 
after KP-54 injection than LH responses were. It is therefore 
possible that inadequacy in the magnitude and duration of FSH 
stimulation might have accounted for the lack of detectable 
ovarian follicular growth observed in this study.
The dose of KP-54 used during this study (6.4 nmol/kg) was 
selected because it was previously shown to stimulate a mean 
maximal rise in serum FSH of 9.1 IU, in women with HA.25 
It would be interesting to investigate whether higher doses of 
twice-weekly KP-54 administration would lead to more potent 
FSH stimulation and restoration of menstrual cyclicity.
In summary, we present important pharmacologic data 
regarding the effects of KP-54 on the release of gonadotrophin 
in a human model of infertility. We have determined the time 
course of desensitization of LH and FSH responses during 
twice-daily administration of KP-54 in women with HA. 
Twice-daily administration of KP-54 is associated with desen-
sitization, a characteristic that may be utilized in the treatment 
of hormone-sensitive tumors. We have also conducted the first 
long-term clinical study of KP-54 administration to women 
with HA. Twice-weekly administration of KP-54 resulted in 
only partial desensitization, in contrast to complete tolerance 
achieved with twice-daily administration. However, this pro-
tocol of administration of KP-54 did not restore menstrual 
cyclicity in women with HA. Further work is required to inves-
tigate the therapeutic potential of kisspeptin in the treatment 
of patients with disorders of the reproductive system.
MetHoDs
subjects. Ethical approval for this study was granted by the research 
ethics committee of Hammersmith and Queen Charlotte’s and Chelsea 
Hospitals (registration number 05/Q0406/142). Written informed 
consent was obtained from all the subjects. The study was performed 
in accordance with the Declaration of Helsinki.
Subjects were recruited through advertisements placed in local news-
papers.25 Women were diagnosed with functional HA if they fulfilled the 
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Figure 4 Reproductive hormone levels in serum after twice-weekly administration of saline or KP-54 for 8 weeks in women with HA. (a–c) changes in levels 
of (a) LH, (b) FSH, and (c) estradiol (E2) in serum after bolus subcutaneous injection of saline (n = 5) on day 1 and after 2, 4, 6, and 8 weeks of administration. 
(d–f) changes in levels of (d) LH, (e) FSH, and (f) estradiol after bolus s.c. injection of 6.4 nmol/kg of KP-54 (n = 5) on day 1, and at after 2, 4, 6, and 8 weeks of 
administration. The time point of injections is 0 min. The data are shown as mean values ± SEM. **P < 0.01; ***P < 0.001 vs. baseline. (g–i) A summary of the 
effects of twice-weekly administration of saline vs. KP-54 during the 8-week study period is shown as mean areas under the curve for (g) LH, (h) FSH, and  
(i) estradiol. The data are shown as mean values ± SEM. *P < 0.05; **P < 0.01; ***P < 0.01 vs. saline. FSH, follicle-stimulating hormone; HA, hypothalamic 
amenorrhea; KP-54, kisspeptin-54; LH, luteinizing hormone; s.c., subcutaneous.
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following criteria: body mass index <25 kg/m2; stable body weight for 
6 months; age 18–40 years; secondary amenorrhea >6 months; no oral 
contraceptive pill therapy within the last year; no clinical or biochemical 
evidence of polycystic ovarian syndrome, thyroid dysfunction, or hyper-
prolactinemia; a structurally normal hypothalamo–pituitary region (on 
magnetic resonance imaging) and female reproductive tract (on ultra-
sound); no therapeutic or recreational drug use; and no systemic disease 
comorbidity. Twenty subjects with HA were recruited.
study 1: determination of the time course of desensitization to the 
 gonadotrophin‑inducing effects of KP‑54 in women with HA. Five sub-
jects with HA received twice-daily injections of 6.4 nmol/kg KP-54. The 
dose of KP-54 chosen for this study has previously been shown to result 
in robust stimulation of gonadotrophin release in healthy female volun-
teers16 and in women with HA.25 On day 1 (the first injection day) and 
on days 2, 3, 4, and 14 (the last injection day) of the study protocol, blood 
samples were taken from each subject at specific time points for 4 h after 
the injection of KP-54. KP-54 was administered subcutaneously at our 
clinical investigation unit, with the subjects in the supine position. Blood 
samples were drawn at −30, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 
and 240 min after the injection.
study 2: two‑week study of release of reproductive hormone in serum 
in women with HA receiving twice‑daily KP‑54 injections as compared 
with those receiving twice‑weekly injections. Subjects with HA (n = 5 
per group) were randomized to receive, in a single-blinded manner, 
either twice-daily or twice-weekly injections of 6.4 nmol/kg KP-54 over 
a 2-week period (see Table 1 for baseline characteristics of the subjects). 
The subjects attended our clinical investigation unit twice a week, and 
measurements of reproductive hormone levels were carried out at each 
of these visits. On day 1 (first day of injection) and day 14 (last day of 
injection), blood samples were taken from each subject at various time 
points for 4 h after the injection of KP-54, as described above.
study 3: randomized, double‑blinded, 8‑week study comparing the 
effects of twice‑weekly KP‑54 (6.4 nmol/kg) vs. saline in women with HA. 
A randomized, double-blinded, placebo-controlled, parallel-design 
study was performed. Ten subjects with HA (see Table 1 for baseline 
characteristics) were randomized to either saline or 6.4 nmol/ kg KP-54 
injections (n = 5 per group) twice weekly for 8 weeks. Each subject 
attended our clinical investigation unit twice a week. During each visit, 
a subcutaneous injection of either saline or KP-54 was administered to 
each subject, in a double-blinded manner. After the first injection of 
saline or KP-54, blood samples were collected at various time points 
from each subject for 4 h as described above. This 4-h sampling pro-
tocol was repeated at 2, 4, and 6 weeks and on the final day of the 
study protocol at 8 weeks. Measurements of reproductive hormones 
were carried out twice a week, and transabdominal ultrasound scans 
were performed once a week.25 A summary of the protocol for study 
3 is shown in Figure 3. During each study visit, urine was tested in 
order to exclude pregnancy (Clearview Easy HCG; Inverness Medical 
Innovations, Waltham, MA). The subjects were interviewed by a physi-
cian during each visit to check for the presence of any adverse effects. 
During the 4-h blood sampling period, diastolic and systolic blood 
pressure and heart rate were recorded; after the injection (KP-54 or 
saline), the subjects were repeatedly asked at regular intervals about 
the presence of any adverse symptoms.
table 2 summary of ultrasound parameters at baseline 
and during and after 8 weeks of treatment with either saline or 
kisspeptin in women with hypothalamic amenorrhea
Characteristic
Study group
P-valueSaline Kisspeptin-54
Ovulation  
(no. of subjects)
0 0 —
Preovulatory follicle 
≥18 mm (no. of subjects)
0 0 —
dominant follicle 
≥11 mm (no. of subjects)
3 6 —
Endometrial  
thickness (mm)
Weeks 1–2 2.8 ± 0.1 3.2 ± 0.5 NS
Weeks 3–4 3.2 ± 0.4 3.5 ± 0.4 NS
Weeks 5–6 2.9 ± 0.3 4.0 ± 0.5 NS
Weeks 7–8 3.2 ± 0.7 4.0 ± 0.5 NS
Ovarian volume (cm3) Weeks 1–2 5.7 ± 1.8 6.7 ± 2.1 NS
Weeks 3–4 5.2 ± 1.5 5.3 ± 1.0 NS
Weeks 5–6 5.4 ± 1.3 5.2 ± 0.6 NS
Weeks 7–8 6.1 ± 1.9 5.5 ± 0.7 NS
Follicle number 
per ovary
Weeks 1–2 12 ± 4 13 ± 3 NS
Weeks 3–4 11 ± 3 15 ± 3 NS
Weeks 5–6 11 ± 3 16 ± 3 NS
Weeks 7–8 9 ± 4 13 ± 4 NS
Maximum follicular 
diameter (mm)
Weeks 1–2 5.0 ± 1.0 7.0 ± 0.9 NS
Weeks 3–4 6.5 ± 1.5 7.8 ± 1.6 NS
Weeks 5–6 6.0 ± 1.1 7.3 ± 0.9 NS
Weeks 7–8 6.3 ± 0.8 7.3 ± 1.2 NS
The values given are for subjects randomized to receive twice-weekly injections of 
saline (n = 5) or of 6.4 nmol/kg of KP-54 (n = 5). The change in value of each ultrasound 
parameter during each 2-week period of the study was based on the results of 
two separate scans performed during the respective 2-week period. Endometrial 
thickness, ovarian volume, the number of follicles, and the maximum follicular 
diameter are shown as mean values ± SEM.
KP-54, kisspeptin-54; NS, nonsignificant difference between KP-54 group vs. saline 
group during each 2-week time period.
table 3 Comparison of basal levels of reproductive hormones 
in serum at baseline and during and after 8 weeks of treatment 
with either saline or kisspeptin injections
Hormone
Study group
P-valueSaline Kisspeptin-54
LH (IU/l) Baseline 1.5 ± 0.6 1.8 ± 0.7 NS
Week 2 1.9 ± 0.5 1.7 ± 0.6 NS
Weeks 3–4 1.9 ± 0.5 1.7 ± 0.4 NS
Weeks 5–8 3.7 ± 2.7 1.9 ± 0.5 NS
FSH (IU/l) Baseline 3.7 ± 0.6 3.4 ± 0.5 NS
Week 2 2.8 ± 0.8 4.5 ± 0.9 NS
Weeks 3–4 3.1 ± 1.0 3.1 ± 0.9 NS
Weeks 5–8 3.2 ± 0.8 4.3 ± 0.7 NS
Estradiol (pmol/l) Baseline 97 ± 13 78 ± 9 NS
Week 2 91 ± 10 102 ± 11 NS
Weeks 3–4 113 ± 33 90 ± 8 NS
Weeks 5–8 123 ± 37 102 ± 11 NS
Mean ± SEM values of the basal hormone levels are given for subject groups 
randomized to receive twice-weekly injections of saline (n = 5) or of 6.4 nmol/kg KP-54 
(n = 5). For each subject, levels of LH, FSH, and estradiol in serum were measured at 
baseline, and the mean levels were calculated from separate blood tests performed 
during week 2, weeks 3–4, and weeks 5–8 of the study protocol.
FSH, follicle-stimulating hormone; KP-54, kisspeptin-54; LH, luteinizing hormone; NS, 
nonsignificant difference between KP-54 group vs. saline group during each 2-week 
time period.
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KP‑54 peptide. KP-54 was synthesized by the Advanced Biotechnology 
Centre, Imperial College London, and purified using reverse-phase high-
performance liquid chromatography. Electrospray mass spectroscopy 
and amino acid analysis confirmed the identity of the peptide.15,16 The 
peptide was tested for bioactivity and toxicity.15 The Limulus amebo-
cyte lysate assay (Associates of Cape Cod, Liverpool, UK) was nega-
tive for endotoxin, and the peptide was sterile on culture (Department 
of Microbiology, Hammersmith Hospital, London, UK). Although 
 kisspeptin-10, -13, -14, and -54 display similar potency in vitro, we used 
KP-54 because of its higher in vivo potency as compared with those of 
the other kisspeptin fragments.31,32
injections. Vials of freeze-dried saline or KP-54 were reconstituted in 
0.5 ml of 0.9% saline. In the studies involving twice-daily injections, the 
subjects were trained to self-administer these at home.25 In the studies 
involving twice-weekly injections, these were administered to the subjects 
by study investigators during scheduled visits.
Collection, processing, and analysis of blood samples. Blood samples for 
serum analysis were collected in plain serum Vacutainer tubes (Becton 
Dickinson, Franklin Lakes, NJ). Clotted samples were spun for 10 min 
at 3,000 r.p.m. in a Hettich EBA 20 centrifuge (Hettich International, 
Tuttlingen, Germany). Sera were separated and stored at −20 °C until 
analysis. Levels of LH, FSH, estradiol, and progesterone in the sera 
were measured using automated chemiluminescent immunoassays 
(Abbott Diagnostics, Maidenhead, UK). Sex hormone–binding globu-
lin was measured using a solid-phase automated enzyme immunoassay 
(Immulite; Siemens, Llanberis, UK).25
Data analysis. Data are presented as mean values ± SEM. Hormone pro-
files during the 4-h blood sample investigations were analyzed using 
repeated measures two-way analysis of variance with Bonferroni post hoc 
correction. Pairs of means were analyzed using the unpaired two-tailed 
t-test. Multiple means were compared using one-way analysis of variance 
with Bonferroni’s multiple-comparison test. In all cases, P < 0.05 was 
considered to be statistically significant.
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The Effects of Kisspeptin-10 on Reproductive
Hormone Release Show Sexual Dimorphism in
Humans
Channa N. Jayasena, Gurjinder M. K. Nijher, Alexander N. Comninos, Ali Abbara,
Adam Januszewki, Meriel L. Vaal, Labosshy Sriskandarajah, Kevin G. Murphy,
Zohreh Farzad, Mohammad A. Ghatei, Stephen R. Bloom, and Waljit S. Dhillo
Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 ONN,
United Kingdom
Background: Kisspeptin peptides are critical in human reproductive physiology and are potential
therapies for infertility. Kisspeptin-10 stimulates gonadotropin release in both male and female
rodents. However, few studies have investigated the effects of kisspeptin-10 on gonadotropin
release in humans, and none have investigated the effect inwomen. If kisspeptin is to be useful for
treating reproductive disease, its effects in both men and women must be established.
Aim: To compare the effects of kisspeptin-10 administration on reproductive hormone release in
healthy men and women.
Methods: Intravenous bolus kisspeptin-10 was administered to men and women (n  4–5 per
group). Subcutaneous bolus and iv infusion of kisspeptin-10 was also administered to female
women (n  4–5 per group). Circulating reproductive hormones were measured.
Results: Inhealthymen, serumLHandFSHwereelevatedafter ivboluskisspeptin-10,atdosesas lowas0.3
and 1.0 nmol/kg, respectively. In healthy women during the follicular phase of the menstrual cycle, no
alterations in serumgonadotropinswereobservedafter ivbolus, scbolus, or iv infusionofkisspeptin-10at
maximal doses of 10 nmol/kg, 32 nmol/kg, and 720pmol/kg/min, respectively. In women during the pre-
ovulatory phase, serum LH and FSHwere elevated after iv bolus kisspeptin-10 (10 nmol/kg).
Conclusion: Kisspeptin-10 stimulates gonadotropin release in men as well as women during the
preovulatoryphaseofmenstrual cyclebut fails to stimulategonadotropin release inwomenduring
the follicular phase. The sexual dimorphism of the responsiveness of healthy men and women to
kisspeptin-10 administration has important clinical implications for the potential of kisspeptin-10
to treat disorders of reproduction. (J Clin Endocrinol Metab 96: E1963–E1972, 2011)
The kisspeptins are critical regulators of mammalian re-productive physiology (1, 2). In humans, inactivating
mutations of the kisspeptin receptor (KISS1R) cause puber-
tal failure (3, 4), and activating mutations can lead to pre-
cocious puberty (5). The human kisspeptin peptides, kiss-
peptin-10, -13, -14, and -54, are named according to their
number of constituent amino acids (6). All kisspeptin pep-
tides share the C-terminal decapeptide sequence, kisspeptin-
10, which is required for biological activity in vitro (7).
Central orperipheral administrationof the shorterkiss-
peptin peptide, kisspeptin-10, has been demonstrated to
stimulate gonadotropin release in severalmammalian spe-
cies (8–18). This effect is abolished by preadministration
of an antagonist to the hypothalamic hormoneGnRH(10,
15). Kisspeptin-10 is therefore thought to stimulate the
releaseofGnRHfromthehypothalamus,which then stim-
ulates gonadotropin release from the pituitary gland. The
longer kisspeptin peptide, kisspeptin-54, has also been
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shown to stimulate gonadotropin release in rodents (19–
21). In addition, administration of kisspeptin-54 stimu-
lates gonadotropin secretion in humans (22–25). Kisspep-
tin therefore has the potential to become a novel therapy
for treatment of reproductive disorders in humans.
The shorter amino acid sequence of kisspeptin-10
makes it simpler and cheaper to synthesize than kisspep-
tin-54. Future kisspeptin therapiesmay therefore be based
upon kisspeptin-10 rather than kisspeptin-54. It is there-
fore therapeutically important to determine whether kiss-
peptin-10 can stimulate reproductive hormone release
in healthy men and women. Kisspeptin-10 stimulates
gonadotropin release in male rhesus monkeys (13–15).
Furthermore, two recent reports have suggested that
kisspeptin-10 administration to healthy men stimulates
gonadotropin release (26, 27). Although kisspeptin-10
is known to stimulate gonadotropin release in animals
(8, 9, 12, 17), there are no published data examining the
effects of administering kisspeptin-10 to female pri-
mates or humans.
This study aimed to determine the effects of kisspep-
tin-10 administration on reproductive hormone release in
healthy men and, for the first time, in healthy women.
Subjects and Methods
Subjects
The study was conducted with Ethics Committee approval
(reference 08/H0707/95) in accordance with The Declaration of
Helsinki. Written informed consent was obtained from all sub-
jects. Thirty-five healthy female subjects and 11 healthy male
subjects were recruited, using criteria summarized in Supple-
mental Table 1 (published on The Endocrine Society’s Journals
Online web site at http://jcem.endojournals.org).
Study days
Subjects were admitted to our Clinical Investigation Unit and
asked to lay supine for the duration of each study. Urine was
tested to exclude pregnancy in women (Clearview Easy-HCG;
Inverness Medical Innovations Inc., Waltham, MA). All blood
samples were analyzed for measurement of serum LH, FSH, es-
tradiol (in women) or testosterone (in men), and plasma kiss-
peptin immunoreactivity (IR). Heart rate, blood pressure, and
the presence of adverse symptoms were recorded at regular
intervals.
Study 1: effects of iv bolus injection of saline or
kisspeptin-10 in healthy male volunteers
Intravenous bolus injection of 0.9% saline or kisspeptin-10
(at dosesof0.3, 1.0, 3.0, or10nmol/kg)wasadministeredat time
0 min. Blood samples were taken at 30, 0, 10, 20, 30, 40, 50,
60, 75, 90, 120, 150, and 180 min (n  4–5 per group).
Study 2: effects of iv bolus injection of kisspeptin-
10 or kisspeptin-54 in healthy female volunteers
Follicular phase of the menstrual cycle
Women between d 2–10 of their menstrual cycle were ad-
ministered an iv bolus injection of 0.9% saline, kisspeptin-54
(1.0 nmol/kg), or kisspeptin-10 (at doses of 1.0, 3.0, or 10 nmol/
kg) at time 0 min, and blood samples were taken at30, 0, 10,
20, 30, 40, 50, 60, 75, 90, 120, 150, and 180 min (n 4–5 per
group).
Preovulatory phase of the menstrual cycle
Women 15–16 d before their next predicted period received
iv bolus injection of 10 nmol/kg kisspeptin-10 as described for
the follicular phase (n  5).
Study 3: effects of sc bolus injection of saline or
kisspeptin-10 in healthy female volunteers in the
follicular phase of the menstrual cycle
Kisspeptin-10 (at doses 2, 4, 8, 16, or 32 nmol/kg) or 0.9%
salinewas administered sc at time0min, andblood sampleswere
taken at30, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, and
240 min (n  4–5 per group).
Study 4: effects of iv infusion of saline or
kisspeptin-10 in healthy female volunteers in the
follicular phase of the menstrual cycle
Kisspeptin-10 was dissolved in saline containing gelofusine
(5% vol/vol) (B. BraunMedical, Sheffield, UK) and was infused
iv over 90min.During the first 30min of infusion, the volunteers
were administered 20, 50, 90, 180, 360, or 720 pmol/kg/min.
The infusion rate for each volunteer was then halved for the
remaining 60 min of each infusion. Blood samples were taken at
30, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, and 240min.
Study 5: determining the half-life of kisspeptin-10
in healthy female and male volunteers
To determine the plasma half-life of kisspeptin-10 in men,
and in women during the follicular and preovulatory phases of
the menstrual cycle, frequent blood sampling was performed
during iv infusion of 360 pmol/kg/min kisspeptin-10. The pro-
tocol was identical to that used in study 4; except that detailed
blood sampling was performed at 1-min (from 91–100min) and
2-min (from 102–120 min) intervals immediately after stopping
kisspeptin-10 infusion. Blood samples were assayed for plasma
kisspeptin IR. The decay curve of kisspeptin IR was used to
calculate the half-time of disappearance (t1/2) for infused kiss-
peptin-10 as described previously (22).
Data analysis
Data are presented as mean SEM. Time profiles of hormone
levelswere compared using two-wayANOVAwith Bonferroni’s
multiple-comparison test. Pairs of means were compared with
unpaired t tests (orMann-WhitneyU test if nonparametric), and
multiple means of area under curve (AUC) reproductive hor-
mone release were compared using one-way ANOVAwith Bon-
feronni’s multiple-comparison test (or Kruskall-Wallis with
Dunn’s multiple-comparison tests if nonparametric). Slopes of
linear regression curves were compared using an F test. In all
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cases, P 0.05 was considered statistically significant. All data
of serum reproductive hormones during treatment are presented
as increases in serum levels after injection when compared with
preinjection levels.
Results
Baseline characteristics of the subjects recruited to the
study are summarized in Table 1.
Study 1: effects of iv bolus injection of saline or
kisspeptin-10 in healthy male volunteers
Plasma kisspeptin IR was elevated after iv bolus injec-
tion of kisspeptin-10 at all doses in healthy male volun-
teers (Fig. 1, A and E). The highest plasma kisspeptin IR
was observed after 10 nmol/kg kisspeptin-10 (mean AUC
kisspeptin IR was 700  160 hpmol/liter, P  0.001 vs.
saline). At this dose,meanpeakkisspeptin IR (3350725
pmol/liter) was observed 10 min after injection, and
plasma kisspeptin IR returned to undetectable levels 50
min after injection. Serum LH was elevated significantly
after administration of each tested dose of iv bolus kiss-
peptin-10 injection comparedwith saline (Fig. 1, B and F).
Peak stimulation of serum LH was observed 30–40 min
after injection, and levels of serum LH gradually returned
to baseline 180 min after injection (Fig. 1B). Maximal
stimulation of LHwas observed after iv bolus 10 nmol/kg
kisspeptin-10 (meanAUCLH increasewas 6.11.3 hIU/
liter, P  0.001 vs. saline) (Fig. 1F). Serum FSH was sig-
nificantly increased comparedwith saline injection after iv
bolus injection of 1.0 or 3.0 nmol/kg kisspeptin-10 (Fig. 1,
C and G). Serum testosterone was significantly in-
creased compared with saline injection after iv bolus
injection of 0.3 or 1.0 nmol/kg kisspeptin-10 (Fig. 1, D
and H). Serum levels of testosterone at these doses
steadily increased to peak levels 150–180 min after
injection (Fig. 1D).
Study 2: effects of iv bolus injection of saline or
kisspeptin-10 or kisspeptin-54 in healthy female
volunteers
Follicular phase of the menstrual cycle
Plasma kisspeptin IR was elevated after iv bolus injec-
tion of kisspeptin-10 at all doses in healthy female volun-
teers during the follicular phase of menstrual cycle (Fig. 2,
A and E). The highest plasma kisspeptin IR was observed
after iv bolus injection of 10 nmol/kg kisspeptin-10 (mean
AUC kisspeptin IR in women during follicular phase was
527  108 hpmol/liter, P  0.001 vs. saline); this was
lowerwhen comparedwith kisspeptin IR after injection of
the same dose of kisspeptin-10 to men, but this difference
was not significant (P 0.42 vs.men). At this dose, mean
peak kisspeptin IR (2638 302 pmol/liter) was observed
10 min after injection, and plasma kisspeptin IR returned
to undetectable levels 50 min after injection. Gonadotro-
pin release was elevated significantly after iv bolus injec-
tion of 1 nmol/kg kisspeptin-54 [mean AUC increase (in
hIU/liter): 27.0  11.8 (LH), P  0.05 vs. saline, and
7.9  4.1 (FSH), P  0.05 vs. saline). Unexpectedly, no
significant changes in serum levels of reproductive hor-
mones were observed after iv bolus injection of kisspep-
tin-10 at doses up to 10 nmol/kg (Fig. 2, B–D and F–H).
Preovulatory phase of the menstrual cycle
Kisspeptin IRwas elevated significantly in women dur-
ing the preovulatory phase after kisspeptin-10 injection
compared with saline, and this elevation was nonsignifi-
cantly different when compared with kisspeptin IR after
the same dose of kisspeptin-10 in follicular-phase women
or men (mean AUC kisspeptin IR in preovulatory phase
was 320  56 hpmol/liter, P  0.13 vs. follicular phase,
and P 0.06 vs.men) (Fig. 2E). Serum LH and FSHwere
elevated significantly after iv bolus injectionof 10nmol/kg
kisspeptin-10 in women during the preovulatory phase of
the menstrual cycle [mean AUC increase was 30.3  7.7
hIU/liter (LH),P0.05 vs. saline, and6.90.9 hIU/liter
(FSH), P  0.01 vs. saline] (Fig. 2, B, C, F, and G); how-
ever, serum estradiol was not altered significantly (mean
AUC estradiol increase was 111  96 hpmol/liter, P 
0.14 vs. saline) (Fig. 2, D and H).
TABLE 1. Baseline characteristics of healthy male and
female volunteers administered kisspeptin-10
Baseline
characteristic
Healthy male
volunteers
(n  11)
Healthy female
volunteers
(n  35)
Age (yr) 28.8  2.1 30.4  0.19
BMI (kg/m2) 24.5  0.5 22.9  0.1
Length of menstrual
cycle (d)
27  0.1
LH (IU/liter) 2.9  0.2
Follicular 3.8  0.6
Preovulatory 6.8  1.6a
FSH (IU/liter) 2.6  0.2
Follicular 3.7  0.4
Preovulatory 6.8  1.6b
Testosterone
(nmol/liter)
21.6  1.5
Estradiol (pmol/liter)
Follicular 256  43
Preovulatory 562  195a
Female endocrine profiles are presented during the follicular and
preovulatory phases of the menstrual cycle. Data are shown as
mean  SEM.
a P  0.05 vs. follicular phase of the menstrual cycle.
b P  0.01 vs. follicular phase of the menstrual cycle.
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Study 3: effects of sc bolus injection of saline or
kisspeptin-10 in healthy female volunteers in the
follicular phase of the menstrual cycle
Plasma kisspeptin IR was significantly elevated during
the 4 h after sc injection of kisspeptin-10 at doses of 4
nmol/kg andhigher,when comparedwith saline (Fig. 3A).
The highest plasma kisspeptin IR after sc injection was
observed after injection of 32 nmol/kg kisspeptin-10
(mean AUC kisspeptin IR was 201 16 hpmol/liter, P
0.001 vs. saline).
No significant changes in serum reproductive hormone
levels were observed after sc bolus injection of kisspep-
tin-10 at any dose (Fig. 3, B–H).
Study 4: effects of iv infusion of
kisspeptin-10 in healthy female
volunteers in the follicular phase
of the menstrual cycle
Intravenous infusion of peptides
delivers the peptide directly into the
circulation, avoiding possible degra-
dation in sc tissue, and results in a
sustained increase in circulating levels
of the administered peptide.
Plasma kisspeptin IR increased dur-
ing iv infusion of kisspeptin-10 at all
doses (Fig. 4A). The highest plasma
kisspeptin IR was observed during iv
infusion of 720 pmol/kg/min kisspep-
tin-10 (mean AUC kisspeptin IR was
2518  100 hpmol/liter). All iv infu-
sion doses of kisspeptin-10 were asso-
ciated with a higher mean plasma kiss-
peptin IR than the highest studied sc
dose of kisspeptin-10 (32 nmol/kg,
mean AUC kisspeptin IRwas 201 16
hpmol/liter). No significant changes
in serum reproductive hormone levels
were observed after iv infusion of any
dose of kisspeptin-10 in healthy female
volunteers in the follicular phase of the
menstrual cycle (Fig. 4, B–H).
Study 5: pharmacokinetic profile
of kisspeptin IR during iv infusion
of kisspeptin-10 in healthy male
and female volunteers
To determine the plasma half-life of
kisspeptin-10, frequent blood sampling
was performed in women during the
follicular and preovulatory phases of
menstrual cycle, and in men, after ces-
sation of an iv infusion of 360 pmol/
kg/min kisspeptin-10 (Fig. 5). When
plotted on anatural log scale, linear regression slopeswere
not significantly different among the three groups (F 
0.099;degreesofFreedomnumerator2;degreesofFree-
domdenominator111;P0.91), and plasmahalf-lives
of kisspeptin-10 were calculated as 3.8  0.3 min (men),
4.1  0.4 min (follicular-phase women), and 4.1  0.4
min (preovulatory-phase women) (Fig. 5E).
Discussion
These studies reveal a previously unknown sexual dimor-
phism in responsiveness to kisspeptin-10 administration
FIG. 1. Plasma kisspeptin IR and serum reproductive hormone levels after iv bolus injection of
kisspeptin-10 to healthy male volunteers. A–D, Time profiles for plasma kisspeptin IR (A) and
changes in serum LH (B), FSH (C), and testosterone (D) during 4 h after iv bolus injection of
saline or kisspeptin-10 to healthy male volunteers (n  4–5 per group). For 10 nmol/kg vs.
saline: , P  0.05; , P  0.01; , P  0.001. For 3 nmol/kg vs. saline: , P  0.05; ,
P  0.001. For 1 nmol/kg vs. saline: , P  0.05; , P  0.001. E–H, AUC for plasma
kisspeptin IR (E) and changes in serum LH (F), FSH (G), and testosterone (H) during 4 h after iv
bolus injection of saline or kisspeptin-10 to healthy male volunteers (n  4–5 per group).
*, P  0.05; **, P  0.01; ***, P  0.001. T, Testosterone. Data are shown as mean  SEM.
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in healthy men and women. Numerous studies in animals
have demonstrated that kisspeptin-10 robustly stimulates
gonadotropin release, thus implicating kisspeptin signaling
as a potential therapeutic target for treating female patients
with infertility (8, 9, 12, 17).Kisspepin-10 stimulates gonad-
otropin release in male rhesus monkeys (13–15), and recent
reports have suggested that kisspepeptin-10 administration
stimulates gonadotropin release in healthy men (26, 27).
However, the effects of administration of kisspeptin-10 in
femaleprimates orwomenhavenotpreviouslybeen studied.
We observed that iv bolus injection of kisspeptin-10
robustly stimulated LH release in healthy men at all doses
tested. These results are consistent with
our previous observation that adminis-
tration of the longer formof kisspeptin,
kisspeptin-54, stimulates reproductive
hormone release in men (22). Further-
more, two recent reports have shown
that iv injection of kisspeptin-10 po-
tently stimulates LH release in healthy
male volunteers at doses similar to
those used in this study (26, 27) and
that prolonged infusion of kisspep-
tin-10 significantly stimulates LH pul-
satility in healthy male volunteers (27).
Studies in rodents suggest that kiss-
peptin-10 stimulates gonadotropin re-
lease in both males and females (8, 9).
Furthermore,weobserved that thekiss-
peptin-10 peptide used in this study
stimulated LH release in female adult
mice (Supplemental Fig. 1), although
with a much lower potency when com-
paredwithkisspeptin-54.Wewere there-
fore surprised to observe that doses of
kisspeptin-10 identical to those used in
men failed to stimulate reproductive hor-
mone release in healthy female volun-
teers during the follicular phase of the
menstrual cyclewhen administered as an
iv bolus injection. It is possible that the
lack of effect of iv administration of kiss-
peptin-10 to stimulate reproductive hor-
mone release in women in the follicular
phase of their menstrual cycle was due
to the short period of time that circu-
lating kisspeptin-10 levels were ele-
vated after iv bolus administration.
Subcutaneous bolus administration of
kisspeptin-10 is likely to result in a lon-
ger period of elevated circulating levels
of kisspeptin-10 than iv bolus admin-
istration (22, 23). Furthermore, we
have previously determined that sc bolus injection of kiss-
peptin-54 at doses as low as 0.4 nmol/kg potently stimu-
lates serum LH in healthy women during the follicular
phase of the menstrual cycle (23). However, serum go-
nadotropin levels were not elevated by sc bolus injection
of kisspeptin-10 in healthy women in the follicular phase
of the menstrual cycle, despite elevations in plasma kiss-
peptin IR for up to 90 min after injection.
The lack of effect of sc bolus administration of kiss-
peptin-10 to stimulate reproductive hormone release in
women in the follicular phase of theirmenstrual cyclemay
FIG. 2. Plasma kisspeptin IR and serum reproductive hormone levels after iv bolus injection of
kisspeptin-10 to healthy female volunteers. A–D, Time profiles for plasma kisspeptin IR (A)
and changes in serum LH (B), FSH (C), and estradiol (D) during 4 h after iv bolus injection of
saline, kisspeptin-10 (KP10), or kisspeptin-54 (KP54) to healthy female volunteers. For 10
nmol/kg KP10 vs. saline: , P  0.05; , P  0.01; , P  0.001. For 3 nmol/kg KP10 vs.
saline: , P  0.001. For 1 nmol/kg KP54 vs. saline: , P  0.05; , P  0.01; , P 
0.001. For 10 nmol/kg KP10 (Preov) vs. saline: *, P  0.05; **, P  0.01; ***, P  0.001.
E–H, AUC for plasma kisspeptin IR (E) and changes in serum LH (F), FSH (G), and estradiol (H)
during 4 h after iv bolus injection of saline or kisspeptin-10 to healthy female volunteers.
*, P  0.05; **, P  0.01; ***, P  0.001. Data are shown as mean  SEM. E2, Estradiol;
Preov, preovulatory phase of the menstrual cycle.
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have been due to breakdown of kisspeptin-10 in the sc
tissue. Intravenous infusion of peptides delivers the pep-
tide directly into the circulation, avoiding possible degra-
dation in sc tissue, and results in a sustained increase in
circulating levels of the administered peptide. However,
serum gonadotropin levels were not elevated during iv
infusion of kisspeptin-10 to healthy female volunteers in
the follicular phase of the menstrual
cycle, despite markedly raised plasma
levels of kisspeptin IR up to concen-
trations of 2000 pmol/liter. Our data
therefore suggest thatwomen in the fol-
licular phase of the menstrual cycle are
markedly less responsive to kisspep-
tin-10 administration than men. The
underlying mechanism for this obser-
vation is unclear. However, sexual di-
morphism of hypothalamic kisspeptin
signaling pathways has been demon-
strated in rodents (28–30).
It is important to consider whether
the contrasting effects of kisspeptin-10
in men and women may have been at-
tributable to factors other than differ-
ential sensitivity to the peptide. We ob-
served that levels of plasma kisspeptin
IR appeared slightly lower in women
when compared with men when iden-
tical weight-adjusted doses of kisspep-
tin-10 were administered. It is possible
that levels of kisspeptin-10 may have
been modified by factors known to dif-
fer between the sexes, such as body fat
contentor clearanceofpeptide fromthe
circulation (19). However, it is note-
worthy that only a marginal elevation
ofplasmakisspeptin IR (approximately
10 hpmol/liter) was necessary to stim-
ulate significant LH secretion in men
after injection of kisspeptin-10 (0.3
nmol/kg iv bolus); by contrast, a 200-
fold greater elevation in plasma kiss-
peptin IR failed to stimulate LH release
in women during the follicular phase of
the menstrual cycle. Furthermore, we
observed no significant differences in
the plasma half-lives of kisspeptin-10
betweenmenandwomen. It is therefore
unlikely that the striking contrast be-
tween male and female responsiveness
tokisspeptin-10administration reflects
differences in metabolism of kisspep-
tin-10. We observed nonsignificant re-
ductions in serumLH (P 0.19) and FSH (P 0.91) after
saline injection in men when compared with saline injec-
tion in women. Although both men and women under-
went identical study protocols, it is possible that minor
differences in factors inhibiting reproductive function
such as stress may be greater in the male group. However,
FIG. 3. Plasma kisspeptin IR and serum reproductive hormone levels after sc bolus injection
of kisspeptin-10 to healthy female volunteers in the follicular phase of the menstrual cycle.
A–D, Time profiles for plasma kisspeptin IR (A) and changes in serum LH (B), FSH (C), and
estradiol (D) during 4 h after sc bolus injection of kisspeptin-10 to healthy female volunteers
in the follicular phase of the menstrual cycle (n  4–5 per group). For 32 vs. 2 nmol/kg:
*, P  0.05; ***, P  0.001. For 16 vs. 2 nmol/kg: ƒƒƒ, P  0.001. For 8 vs. 2 nmol/kg: ,
P  0.001. For 4 vs. 2 nmol/kg: , P  0.05. E–H, AUC for plasma kisspeptin IR (E) and
changes in serum LH (F), FSH (G), and testosterone (H) during 4 h after sc bolus injection of
kisspeptin-10 to healthy female volunteers in the follicular phase of the menstrual cycle (n 
4–5 per group). *, P  0.05; **, P  0.01; ***, P  0.001. E2, Estradiol. Data are shown as
mean  SEM.
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such a difference would not explain why men are more
responsive to kisspeptin-10 than women in the follicular
phase of the menstrual cycle.
In the current study, we observed that exogenous kiss-
peptin-54 stimulated significant gonadotropin secretion
in women during the follicular phase of the menstrual
cycle, despite a failure of exogenous kisspeptin-10 to stim-
ulate gonadotropin secretion at a 10-fold higher molar
dose. Furthermore, kisspeptin-54 injection stimulated LH
in female mice more potently when compared with kiss-
peptin-10, and it has been previously observed that kiss-
peptin-52 (31) and kisspeptin-54 (21) stimulate LH more
potently when compared with kisspeptin-10 in male rats.
Collectively, these data suggest that the greater potency of
kisspeptin-54 when compared with
kisspeptin-10 may explain why exoge-
nous kisspeptin-54 injection (but not
exogenous kisspeptin-10) stimulates re-
productive hormone release in women
during the follicular phase of themen-
strual cycle. The differences between
kisspeptin-10 and kisspeptin-54 may
be a consequence of the rapid break-
down of kisspeptin-10 in the circula-
tion. The in vivo plasma half-life of iv
kisspeptin-10 in this study was calcu-
lated to approximately 4 min, which is
7-fold shorter than the calculated in vivo
plasma half-life of kisspeptin-54 (22).
It is interesting to consider whether
men and women have differential re-
sponses to kisspeptin-54 (as they ap-
pear to be to kisspeptin-10) based on
previous studies. Intravenous infusion
of kisspeptin-54 at doses as low as 1.2
nmol (0.25 pmol/kg/min) stimulate LH
secretion in healthy men (22). By com-
parison, sc bolus injection of kisspep-
tin-54 at doses of 28 nmol (0.4 nmol/
kg) or more stimulate LH secretion in
healthy women during the follicular
phase of the menstrual cycle (23); fur-
thermore, this study suggests that iv bo-
lus injection of approximately 60 nmol
(1 nmol/kg) kisspeptin-54 stimulatessig-
nificant LH secretion in these women.
These data demonstrate that, unlike
kisspeptin-10, kisspeptin-54 can stim-
ulate reproductive hormone release in
women in the follicular phase of their
menstrual cycle.
In the current study, gonadotropin
responses during kisspeptin-10 infu-
sion appeared more variable than after iv or sc bolus in-
jections. These alterations in gonadotropin secretion did
not appear to be related to either the dose or to the onset
of kisspeptin infusion; however, it is possible that subtle
effects of kisspeptin-10 infusion on gonadotropin release
were not detected in the current study protocol.
We have previously demonstrated that women in the
preovulatory phase of themenstrual cycle are significantly
more sensitive to the effects of kisspeptin-54 on gonado-
tropin release when compared with women in the follic-
ular phase of the menstrual cycle (23). In keeping with
these observations, iv bolus injection of kisspeptin-10 sig-
nificantly stimulated LH and FSH release in women dur-
FIG. 4. Plasma kisspeptin IR and serum reproductive hormone levels during iv infusion of
kisspeptin-10 to healthy female volunteers in the follicular phase of the menstrual cycle. A–D,
Time profiles for plasma kisspeptin IR (A) and changes in serum LH (B), FSH (C), and estrogen
(D) during 4 h after commencement of a 90-min iv infusion of kisspeptin-10 to healthy female
volunteers in the follicular phase of the menstrual cycle (n  4–5 per group). For 720 vs. 20
pmol/kg  min: ***, P  0.001. For 360 vs. 20 pmol/kg  min: ƒƒƒ, P  0.001. For 180 vs. 20
pmol/kg  min: , P  0.05; , P  0.001. For 50 vs. 20 pmol/kg  min: , P  0.05. E–H,
AUC for plasma kisspeptin IR (E) and changes in serum LH (F), FSH (G), and testosterone (H)
during 4 h after commencement of a 90-min iv infusion of kisspeptin-10 to healthy female
volunteers in the follicular phase of the menstrual cycle (n  4–5 per group). **, P  0.01;
***, P  0.001. E2, Estradiol. Data are shown as mean  SEM.
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ing the preovulatory phase of the menstrual cycle in the
current study. Becausewe observed that kisspeptin-10 has
a similar pharmacokinetic profile in both follicular and
preovulatory phases of the menstrual cycle, our results
suggest that women have heightened sensitivity to kiss-
peptin-10 during the preovulatory phase of the menstrual
cycle. In female rodents, c-fos expressionwithinkisspeptin
neurons and levels ofkiss1 expressionare increasedwithin
the anteroventral periventricular nucleus of the hypothal-
amus immediately before ovulation (35). Furthermore,
levels of kiss1r expression are increased in rat hypotha-
lamic fragments atdiestruswhencomparedwithproestrus
(36). It is therefore possible that women in the preovula-
tory phase of the menstrual cycle have heightened respon-
siveness to kisspeptin-10 administration when compared
with women during the follicular phase of the menstrual
cycle.
In the current study, we observed that kisspeptin-10
stimulated LH secretion more potently than FSH. This is
consistent with our previous studies of kisspeptin-54 ad-
ministration in healthy men and women. After iv bolus
kisspeptin-10 injection, peak FSH secretion was observed
45–150min after injection, whichwas later than peak LH
secretion (30 min after injection); this
phenomenonwas also observed after sc
bolus injection of kisspeptin-54 in
healthy women (23). Our results there-
fore suggest that both kisspeptin-10
and -54 stimulate LH secretion more
potently and more rapidly than FSH.
It is interesting to consider why we
did not observe any consistent stimula-
tion of testosterone secretion after iv
bolus kisspeptin-10 injection in healthy
men when compared with the robust
increases in serum LH and FSH ob-
served at all tested doses. Significant in-
creases in serum testosterone were ob-
served only at 0.3 and 1.0 nmol/kg iv
bolus kisspeptin-10, but these rises were
marginal (no more than 10 hnmol/liter
above baseline). Furthermore, iv bolus
injection of kisspeptin-10 stimulated go-
nadotropin release in women during
the follicular phase of themenstrual cy-
cle but did not increase serum estradiol
during 3 h after injection. Our previous
data suggest that at least 4 h are re-
quired for serum levels of sex steroids
to peak after a sc bolus injection of
kisspeptin-54 (23–25). A longer pe-
riod of blood sampling after injection
may have revealed more pronounced
alterations in sex steroid secretion in subjects after injec-
tion of kisspeptin-10. We observed that serum gonado-
tropins almost returned to baseline levels within 3 h after
iv bolus injection of kisspeptin-10; it is possible that iv
bolus injection of kisspeptin-10 has a duration of action
inadequate to stimulate significant gonadal sex steroid
release.
In the current study, all tested iv bolus doses of kiss-
peptin-10 (0.3–10 nmol/kg) were associated with similar
degrees of gonadotropin secretion in healthy male sub-
jects. A recent study by George et al. (27) suggests that
kisspeptin-10 stimulates serum LH secretion at doses as
low as 0.01 g/kg (equivalent to 0.008 nmol/kg), with a
maximal response seen at 1 g/kg (0.8 nmol/kg) in men.
Taking these data into consideration, all doses of kisspep-
tin-10 selectedduringour studymayhave stimulatednear-
maximal levels of gonadotropin secretion in healthy male
volunteers. Interestingly, George et al. (27) observed that
the increase in serum LH at 3 g/kg (2.4 nmol/kg) was
lower than the increase in serumLHat1g/kg,which they
speculated was attributable to tachyphylaxis, a phenom-
enon that we have previously observed after chronic kiss-
FIG. 5. Detailed time profiles of plasma kisspeptin IR after iv infusion of kisspeptin-10 to
healthy male and female volunteers. A–D, Blood sampling was performed for measurement
of plasma kisspeptin IR during 4 h after commencement of a 90-min iv infusion of kisspeptin-
10 (360 pmol/kg  min) to healthy male volunteers (A and D) and female volunteers during the
follicular (B and D) and preovulatory (C and D) phases of the menstrual cycle (n  4–5 per
group). For men vs. women during follicular phase: , P  0.001; , P  0.05. For men vs.
women during preovulatory phase: ***, P  0.001; *, P  0.05. E, Blood sampling was
performed at 1-min intervals immediately after stopping infusion of kisspeptin-10. Linear
curve fits of natural log plasma kisspeptin IR (dotted lines) were similar for all three groups
(P  0.91). Data are shown as mean  SEM.
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peptin-54 injections (24, 25, 27). We therefore cannot
exclude that the similarity between LH responses at doses
between 0.3 and 10 nmol/kg kisspeptin-10 in men might
be explained in part by tachyphylaxis to kisspeptin-10 at
the higher tested doses. Additional studies are required to
investigate these observations.
In summary, this is the first clinical study to report the
effects of kisspeptin-10 administration on gonadotropin
release in women and to compare the effects of kisspep-
tin-10 between men and women. Kisspeptin-10 robustly
stimulates gonadotropin release in men but fails to stim-
ulate gonadotropin release in healthy female volunteers in
the follicular phase of the menstrual cycle when adminis-
tered by iv bolus injection, sc bolus injection, or iv infu-
sion. These experiments reveal sexual dimorphism in the
responsiveness of healthy human volunteers to kisspep-
tin-10 administration.These findings have important clin-
ical implications for the potential therapeutic use of kiss-
peptin-10 to treat disorders of reproduction.
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